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Summary  
 
‘From microRNA biogenesis to post-translational modifications of TNRC6 complexes’ summarizes 
the two main projects, beginning with the influence of specific RNA binding proteins on miRNA 
biogenesis processes. The fate of the mature miRNA is determined by the incorporation into 
Argonaute proteins followed by a complex formation with TNRC6 proteins as core molecules of 
gene silencing complexes. 
miRNAs are transcribed as stem-loop structured primary transcripts (pri-miRNA) by Pol II. The 
further nuclear processing is carried out by the microprocessor complex containing the RNase III 
enzyme Drosha, which cleaves the pri-miRNA to precursor-miRNA (pre-miRNA). After Exportin-5 
mediated transport of the pre-miRNA to the cytoplasm, the RNase III enzyme Dicer cleaves off the 
terminal loop resulting in a 21-24 nt long double-stranded RNA. One of the strands is incorporated 
in the RNA-induced silencing complex (RISC), where it directly interacts with a member of the 
Argonaute protein family. The miRNA guides the mature RISC complex to partially complementary 
target sites on mRNAs leading to gene silencing. During this process TNRC6 proteins interact with 
Argonaute and recruit additional factors to mediate translational repression and target mRNA 
destabilization through deadenylation and decapping leading to mRNA decay. 
 
Viral miRNA Biogenesis. Surprisingly, miRNAs were identified in human herpes, papilloma and 
polyoma viruses. These miRNAs regulate viral and host gene expression and influence infection 
efficiency. The miRNA biogenesis is strictly regulated and by northern blotting different expression 
profiles of infected cell lines were detected.  
To identify RNA-binding-proteins involved in post-transcriptional regulation of miRNA biogenesis, 
a mass spectrometric pull down assay with in-vitro transcribed pre-miRNA was established. The 
obtained data generated together with bioinformatical analyses a valuable set of potential 
regulatory candidates. The interaction of a subset of potential regulators was verified by repeating 
the pull-down with overexpressed Flag-/Ha-tagged proteins. For further functional 
characterization, the influence of RBPs on pre-miRNA processing was analyzed in knockout cell 
lines in which candidate RBPs have been depleted. Overexpression of the potential candidates 
further confirms a strong impact on the miRNA biogenesis. 
Taken together, mass spectrometric approaches identified RNA-binding-Proteins involved in viral 
miRNA biogenesis. 
 
Post-translational modifications of TNRC6 proteins. TNRC6 and Ago proteins play a central role 
in the gene silencing mechanism. The Interaction of both proteins is based on two Tryptophan’s 
binding into two specific pockets in the PIWI domain of Ago proteins. TNRC6 proteins (also 
referred to as GW proteins) contain Gly/Trp-repeats and serve as binding platform for many 
components of the gene silencing machinery. 
To assess whether gene silencing is regulated by post-translational modifications, TNRC6 proteins 
were analyzed by mass spectrometry. To analyze endogenous proteins, we established 
monoclonal antibodies against TNRC6A-C for immunopurificaiton of TNRC6 proteins from cell 
lysates. The validity and specificity of the antibodies was further verified by mass spectrometric 
selected reaction monitoring analyses. Followed by a detailed mass spectrometric analysis, 
multiple endogenous phosphorylation sites on TNRC6 proteins were detected. The obtained data 
identified conserved phosphorylation sites both among the TNRC6 paralogs and within different 
species. Functional analyses of phospho-mimicking and non-phospho mutants showed low effects 
on the downstream gene silencing processes. Localization studies and Ago-binding assays also 
indicate no effects of the phospho-sites on TNRC6 function.  
Taken together, post-translational modifications on TNRC6 proteins with potential, but so far 
unknown function in gene silencing were identified.  
Zusammmenfassung    
 
 
"From microRNA biogenesis to post-translational modifications of TNRC6 complexes" fasst die 
beiden Hauptprojekte dieser Doktorarbeit zusammen.  
miRNAs werden als primäre transkripte (pri-miRNA) von der RNA Polymerase II transkribiert. Die 
weitere Verarbeitung erfolgt durch den Mikroprozessor-Komplex, der das katalytisch aktive 
Enzym Drosha enthält, welches die pri-miRNA zu Vorläufer-miRNAs (pre-miRNA) spaltet. Nach 
dem Exportin-5-vermittelten Transport der pre-miRNA in das Zytoplasma, spaltet das RNase III-
Enzym Dicer die terminale Schleife der pre-miRNA ab, was zu einer 21-24 nt langen 
doppelsträngigen RNA führt. Einer der beiden Stränge wird in den RNA-induzierten Silencing-
Komplex (RISC) eingebaut, wo er direkt mit einem Mitglied der Argonaute-Proteinfamilie 
wechselwirkt. Der reife RISC-Komplex bildet durch komplementäre Basenpaarung der miRNA zur 
mRNA den Gene-silencing Komplexe. Während dieses Prozesses interagiert ein TNRC6-Protein mit 
Argonaut und durch Rekrutierung von zusätzlichen Faktoren wird die Translation reprimiert und 
die Ziel-mRNA destabilisiert und abgebaut.  
 
Virale miRNA Biogenese. Überraschenderweise wurden miRNAs bei humanen Herpes-, Papillom- 
und Polyomaviren identifiziert. Diese miRNAs regulieren die Virus- und Wirtsgenexpression und 
beeinflussen den viralen Lebenszyklus. 
Die miRNA-Biogenese ist streng reguliert und durch Nothern Blotting wurden verschiedene miRNA 
Expressionsprofile von infizierten Zelllinien nachgewiesen. Zur Identifizierung von RNA-bindenden 
Proteinen, die an der post-transkriptionelen Regulation der miRNA-Biogenese beteiligt sind, 
wurde eine massen-spektrometrische Pull-Down-Anwendung mit in vitro transkribierter Pre-
miRNA etabliert. Die gewonnenen Daten, die zusammen mit bioinformatischen Analysen erzeugt 
wurden, sind ein wertvoller Datensatz von potenziellen regulatorischen Proteinen. Die 
Wechselwirkung einer Teilmenge von potentiellen Regulatoren wurde durch Wiederholen des 
Pull-downs mit überexprimierten Flag-/ Ha-markierten Proteinen verifiziert. Für eine weitere 
funktionelle Charakterisierung wurde der Einfluss von RNA-bindenden Proteinen (RBP) auf die 
pre-miRNA-Verarbeitung in Knockout-Zelllinien analysiert.  
Zusammenfasst, wurden in massenspektrometrischen Analysen RNA-bindende Proteine 
identifiziert, die an der viralen miRNA-Biogenese beteiligt waren. 
 
Posttranslationale Modifikationen von TNRC6-Proteinen. TNRC6- und Ago-Proteine spielen eine 
zentrale Rolle im Gen-Silencing-Mechanismus. Die Interaktion beider Proteine basiert auf zwei 
Tryptophan Bindungen, die in zwei spezifische Taschen in der PIWI-Domäne von Ago-Proteinen 
binden. TNRC6-Proteine (auch GW-Proteine genannt) enthalten repetitive Glycin/ Tryptophan-
Aminosäureabschnitte und dienen als Bindeplattform für viele Komponenten der Gen-Silencing-
Maschinerie. 
Um zu beurteilen, ob Gen-Silencing durch posttranslationale Modifikationen reguliert wird, 
wurden TNRC6-Proteine durch Massenspektrometrie analysiert. Um endogene Proteine zu 
analysieren, wurden monoklonale Antikörper gegen TNRC6A-C für Immuno-Aufreinigungen von 
TNRC6-Proteinen aus Zelllysaten etabliert. Die Gültigkeit und Spezifität der Antikörper wurde 
durch massenspektrometrische ausgewählte Analysen weiter verifiziert. Nach einer detaillierten 
Analyse wurden mehrere endogene Phosphorylierungsstellen in TNRC6-Proteinen nachgewiesen. 
Die erhaltenen Daten identifizierten konservierte Phosphorylierungsstellen sowohl unter den 
humanen TNRC6-Paralogen als auch innerhalb verschiedener TNRC6 proteine anderer Tiere. 
Funktionsanalysen von Phospho-Mimik- und Nicht-Phosphorylierbaren-Mutanten zeigten geringe 
Auswirkungen auf die nachgeschalteten Gen-Silencing-Prozesse. Lokalisierungsstudien und Ago-
Bindungsversuche zeigen auch keine Wirkungen der phosphorylierten Aminosäuren auf die 
TNRC6-Funktion an. 
Zusammengefasst wurden posttranslationale Modifikationen an TNRC6-Proteinen identifiziert 
und charakterisiert.
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2 Introduction 
1.1 Mammalian microRNA biogenesis 
 
miRNAs are the core molecule for selective regulation of gene expression by initiating translational 
repression and mRNA decay. 
miRNAs can be multiply located within the genome and they are organized as individual single 
unit or as cluster (V. N. Kim, Han, and Siomi 2009; Chaulk et al. 2011; Libri et al. 2013; Y.-K. Kim, 
Kim, and Kim 2016). Most of the miRNA genes are organized within different genomic organization 
patterns, mainly in intronic regions of mRNAs (Monteys et al. 2010), non-coding RNAs (nc-RNAs) 
(Libri et al. 2013) or independent intergenic transcription units (P. Ramalingam et al. 2014). 
miRNAs can be derived from other non-coding RNAs like snoRNAs, lncRNAs (Röther and Meister 
2011) or tRNAs (Hasler et al. 2016), from splicing (mirtron pathway) or out of short hairpins (Y.-K. 
Kim, Kim, and Kim 2016). 
Transcriptional regulation of pri-miRNA. The initial biogenesis and simultaneously a highly 
regulated step is the transcription of primary miRNA (pri-miRNA) transcripts. pri-miRNA 
transcripts are mainly RNA Polymerase II generated and hence contain 5' caps with 7-methyl 
guanosine and a 3' poly (A) tail (Cai, Hagedorn, and Cullen 2004; Y Lee et al. 2004; He et al. 2007; 
Raver-Shapira et al. 2007; Tarasov et al. 2007). At a co-transcriptional level, transcription factors 
like p53, MYC, ZEB1/2 or MYOD are known to promote or block transcription by Pol II (Pol III). For 
instance, p53, MYC and MYOD1 promote transcription of the miR-234-cluster, miR-17-cluster and 
miR-1cluster. In contrary MYC and ZEB1/ 2 inhibit transcription of mir-15a-cluster and mir-200-
cluster (Rnas et al. 2008; V. N. Kim, Han, and Siomi 2009; Krol, Loedige, and Filipowicz 2010; Ha 
and Kim 2014; Louloupi et al. 2017).  
 
1.1.1 Processing of primary miRNAs by the microprocessor complex 
 
Primary miRNA processing is the first catalytic cleavage step of the canonical biogenesis pathway. 
The pri-miRNA transcript is incorporated into the microprocessor complex. This complex consists 
of the minimal components RNAse III enzyme Drosha and a dimer of DGCR8 (Figure 1) (Gregory 
et al. 2004; Denli et al. 2004; Han et al. 2004; Landthaler, Abdullah Yalcin and Tuschl 2004; Kwon 
et al. 2016). The pri-miRNA transcript forms a double-stranded RNA (dsRNA) stem-loop-structured 
hairpin with a stem length of usually 35 base pairs (bp) and ssRNA bulges. A single-stranded (ss) 
loop raises as apical structure and an adjacent ssRNA basal junction marks the end of the stem 
(Han et al. 2006; Nguyen et al. 2015). DGCR8 contains two double-stranded RNA-binding domains 
(dsRBDs) (Roth, Ishimaru, and Hennig 2013; Quick-cleveland et al. 2015; Nguyen et al. 2015; Kwon 
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et al. 2016). Drosha is structurally very similar to Dicer (low sequence conservation), but exhibits 
unique compartments like a zinc-finger motif (Figure 1) (Nguyen et al. 2015).  
Drosha and DGCR8 function together as distance measuring system for specific hairpin structured 
RNAs (Kwon et al. 2016). Therefore, the DGCR8 dimer positions at the upper part of the stem and 
Drosha at the lower part of the stem. Catalytic Drosha cleavage occurs after positioning of the 
microprocessor at the height of 11 bp of the stem (Han et al. 2006; Nguyen et al. 2015). This aims 
in a typical stem-loop-structured 60-70 bp long hairpin known as precursor miRNA (pre-miRNA) 
with a 2 nucleotide 3' overhang (Morlando et al. 2008). Drosha deletions result in the loss of 
canonical processed miRNAs (Y.-K. Kim, Kim, and Kim 2016). Because of the main intronic origin 
of the pri-miRNA transcripts, splicing and microprocessor cleavage are interconnected and 
influence each other's efficiency (Y.-K. Kim and Kim 2007; Kataoka, Fujita, and Ohno 2009).  
 
Figure 1 Cleavage of pri-miRNA 
transcript by Drosha and export 
by Exportin 5. 
A stem loop structured primary-
miRNA transcript with a 5‘ cap 
and a 3‘ poly-A-tail is transcribed 
by Pol II and recognized by the 
microprocessor complex 
consisting of Drosha and two 
DGCR8 proteins. Drosha cleaves 
the transcript resulting in a 70-
100 bp long hairpin, called pre-
miRNA. This small RNA is 
recognized by the nuclear export 
receptor Exp5 and transported 
into the cytoplasm and further 
processed by Dicer. (B) 
Indication of structural 
composition of DGCR8/ Drosha. 
 
 
The pre-miRNA hairpin-structure is then exported to the cytoplasm with a canonical RNA export 
mechanism with Exportin-5 (Exp5) in a Ran-GTP depended manner (Yi et al. 2003; Bohnsack, 
Czaplinski, and Gorlich 2004; Y.-K. Kim, Kim, and Kim 2016). The loading of the pre-miRNA into 
Exp5-RanGTP remains unclear, but additional factors of the microprocessor complex like ILF-3 
could have a major role (Libri et al. 2013).The structural mannerism of the pre-miRNA results in a 
specific recognition of Exp5-RanGTP (Okada et al. 2009). After nuclear exporting, the complex 
decomposes and the released pre-miRNA is bound by a multi-protein complex containing Dicer 
(K. Miyoshi et al. 2009). Interestingly, after knockout of Exp5 cytoplasmic transport still occurs 
suggesting redundant or alternative mechanisms (Y.-K. Kim, Kim, and Kim 2016).  
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Figure 2 Examples of regulatory RBPs/RNAs. 
(A) Schematic overview of a representative pri-miRNA structure containing a mature miRNA indicated in red. Interaction 
sites for potential regulators as well as conserved sequence motifs are highlighted. Regulatory RBPs/ miRNAs influencing 
the miRNA biogenesis by direct binding to the hairpin structured pri-miRNA are indicated in red by inhibiting or in green 
by promoting the process. (B) Regulatory RBPs/ miRNAs influencing the miRNA biogenesis are indicated in red by 
inhibiting or in green by promoting the process. 
 
Regulatory mechanisms. As already suggested, the miRNA biogenesis is not only tightly regulated 
at a transcriptional level, but even more at the following biogenesis steps (Libri et al. 2013; Ha and 
Kim 2014; S. Li, Wang, Fu, and Dorf 2014). The efficiency of pri-miRNA and pre-miRNA processing 
underlies the sequence and/ or resulting structural characteristics of the hairpin (Auyeung et al. 
2013). These specific RNA compositions are recognized by hairpin-interacting RNA-binding 
proteins (RBPs) which promote or block the processing steps (Han Wu et al. 2010; Trabucchi et al. 
2009; Gu et al. 2011; X. Zhang et al. 2011; Connerty, Ahadi, and Hutvagner 2015; Du et al. 2015). 
Recently a large proteomics-based hairpin-pull-down screen identified several hundred potential 
interactors which regulate Drosha processing (Treiber et al. 2017). In the following part few 
regulatory RBPs which influence processing are briefly described.  
Regulation of processing by proteins that interact with the pri-miRNA. The pri-miRNA transcript 
contains several conserved sequence elements that are important for processing. The loop 
contains a UGUG motif and at the basal flanking sites an UG and a CNNC motif (Ha and Kim 2014; 
Roden et al. 2017). The splicing factor Srp20 (Ajiro et al. 2015) and the DEAD-box RNA helicase 
p72 (DDX17) interact with the CNNC motif and promote Drosha processing (Figure 2 A) (Sabin et 
al. 2009; Guil and Cáceres 2007).  
The RBP TAR DNA-binding protein 43 (TDP43) positively interferes with Drosha processing by 
binding to the terminal loop sequence of pre-miR-143 and pre-miR-547 (Kawahara and Mieda-
Sato 2012; Ha and Kim 2014). Interestingly the serine/ arginine-rich SR protein (SF2/ASF) promotes 
processing by altering the structure of pri-miR-7. The mature miR-7 regulates the mRNA transcript 
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of SF2 down by gene silencing, suggesting an negative feedback loop for steady-state production 
of miR-7 (Han Wu et al. 2010). The RBP Rbfox3 regulates both inhibition and improvement of 
processing depending on the pri-miRNAs. It was suggested that many pri-miRNAs are regulated 
and particularly shown that interaction of Rbfox3 with the loop region of pri-miR-15a resulted in 
processing. In contrary binding to the stem of pri-miR-485 resulted in an inhibition of the 
microprocessor recruitment (K. K. Kim et al. 2014). The RBPs hnRNPA1 and KSRP (KH-type splicing 
regulatory protein) interact with the terminal loop of several pri-miRNAs e.g. pri-miR18a, pri-miR-
16, pri-miR-21 and promote their processing (Figure 2 A) (Michlewski et al. 2008; Michlewski and 
Cáceres 2010; Guil and Cáceres 2007; X. Zhang et al. 2011; Briata et al. 2012) In contrary hnRNPA1 
negatively regulates pri-let-7a processing while competing with KSRP for the stem binding site. 
The nuclear factors 45 and 90 inhibit processing by interaction to pri-let-7a or pri-miR-21 
(Sakamoto et al. 2009). The RNA editing enzymes ADAR1 and ADAR2 are known to transform an 
adenosine to an inosine within specific pri-miRNAs, which inhibits Microporocessor hairpin 
interaction (Figure 2 A)(Cho, Myung, and Chang 2017). 
Regulation of pri-miRNA processing by proteins that interact with the microprocessor complex. 
The RBP p68 (DDX5) together with p72 (DDX17) are recruited to Drosha by interaction to the 
hairpin and promote pri-miRNA processing (Figure 2 B). It is known that several additional factors 
interact with p68/p72 and further block or promote the processing. For Instance, promoting 
interactors are BRCA1 (breast cancer susceptibility gene 1), SNIP1 (SMAD nuclear interacting 
protein), ARS2 (arsenite resistance protein 2) or the TGF-β induced transcription factors SMAD1-
3 and 5 (Figure 2 B). In contrary, the estrogen receptor alpha inhibits processing by an interfering 
interaction to p68/p72 (Davis et al. 2008; Sabin et al. 2009; Kawai and Amano 2012; Vos et al. 
2015; Thillainadesan et al. 2012; Suzuki et al. 2009; Fukuda et al. 2007). Interestingly, the helicases 
p68/p72 are involved in the processing of nearly one-third of the known pri-miRNAs, according to 
studies within knock-out mice (Fukuda et al. 2007) 
Regulation of pri-miRNA processing by miRNAs. Several examples where miRNAs are transported 
back to the nucleus for the regulation of pri-miRNA processing are known. The interaction to the 
pri-miRNA is formed by complementary base pairing within the flanking regions of the primary 
transcript. For example, in C. elegans the processing of pri-let-7 is promoted by an auto-regulatory 
mechanism of let-7 which interacts with the pri-let-7 3’ flanking region. The mechanism of how 
the miRNA-Alg-1 complex promotes processing is not fully understood (Figure 2 A) (R. Tang et al. 
2012; Zisoulis et al. 2012). 
Drosha/ DGCR8 regulatory modifications. The functionality of the microprocessor complex is 
additional regulated by PTMs. Drosha localization in the nucleus is regulated by phosphorylation 
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of S300 and S302 by GSK3. DGCR8 exhibits higher stability when phosphorylated by ERK. 
Sumoylation at K707 by SUMO1 stabilizes DGCR8 by inhibiting ubiquitination (C. Zhu et al. 2015; 
Fletcher et al. 2017). Further Drosha is stabilized by acetylation which inhibits ubiquitination. In 
contrary the affinity to pri-miRNAs and hence processing is increased by deacetylation of DGCR8 
by HDAC1 (histone deacetylated by histone deacetylase1) (X. Tang et al. 2010; X. Tang et al. 2011; 
X. Tang et al. 2013; Casseb et al. 2016).  
 
1.1.2 Dicer cleavage of pre-miRNAs and RISC loading 
 
In the cytoplasm the pre-miRNA is released from the Exp5-RanGTP complex and immediately 
incorporated into Dicer. Dicer is structurally similar to Drosha a RNase III enzyme. It contains also 
two RNase III catalytic cleavage sites. For proper positioning and function, additional co-factors 
are needed. The cofactor TAR RNA binding protein 2 (TRBP) and the protein activator of PKR 
(PACT) contain both double-stranded-RBDs and additionally promote the substrate interaction 
(Gregory et al. 2005; Chendrimada et al. 2010; Yoontae Lee et al. 2006; H. Y. Lee et al. 2013). TRBP 
functions as a pre-miRNA length determining compartment through a defined positioning of the 
hairpin by interaction with the helicase domain of Dicer (Fukunaga 2005). The function of PACT 
remains elusive and is still unclear (Figure 3) (H. Y. Lee et al. 2013; Y. Kim et al. 2014; Ha and Kim 
2014). TRBP mainly interacts with the apical loop and the upper part of the stem. After the pre-
miRNA is positioned, Dicer interacts with the precursor and cleaves off the terminal loop. This 
occurs within the catalytically active centre of the RIIId domains. The cleavage product is a 21-24 
nt long double-stranded RNA with 2 nucleotides 3’-overhangs, a 5’-phosphate and a 3’-hydroxyl 
group (H. Zhang et al. 2004; MacRae et al. 2006; Taylor et al. 2013; Wilson et al. 2015; Fareh et a 
l. 2016; Song and Rossi 2017). The ssRNA terminal loop as additional cleavage product is degraded. 
After cleavage occurred, the RISC loading complex is assembled. Therefore, Dicer interacts with 
Ago via the Piwi and the RNase III domain. Additionally Ago recruits co-chaparones with the 
components heat shock protein 90/70 (Hsp90) and FK506-binding immunophilins Fkbp4/5. The 
HSP70/HSP90 complex loads the RNA duplex into Ago in an ATP dependent manner (Iwasaki et al. 
2010). During the loading process one strand of the miRNA heteroduplex is selected and imparted 
to Ago while the chaperones stabilize the opening and incorporation process into Ago (Figure 3).  
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Figure 3 Dicer cleavage of the pre-miRNA and RISC complex loading. 
This small RNA is recognized by the nuclear export receptor Exp5 and transported to the cytoplasm and further 
processed within the catalytic domains of the Dicer/TRBP complex. Dicer/TRBP form a multi-subunit complex where 
TRBP is responsible for positioning of the pre-miRNA. This results in a double-stranded RNA with 22 nt length. The 
mature strand is incorporated into Ago during RISC loading and leads to the mature RISC complex assembly. 
 
An unwinding of the dsRNA strand is mediated by the N domain of Ago and the selection of one 
strand which is maybe supported by TRBP has to be performed (Kwak and Tomari 2012). However, 
statistical and thermodynamically rules suggest that the strand with a stable 5' end is 
preferentially loaded (Dueck and Meister 2014; T. Miyoshi et al. 2010; Natalia J Martinez et al. 
2013; Iwasaki et al. 2010; Nakanishi et al. 2016). After loading Dicer and the co-chaperones 
dissociate which leads to the mature RISC complex (Kawamata and Tomari 2010; Dueck and 
Meister 2014; K. Miyoshi et al. 2009). 
 
Regulation of processing by proteins that interact with the pre-miRNA. Rbfox2 another RBP is 
suggested to be important for cancer and neurodegeneration induced by the mis-regulation of 
miR-107 and miR-20b. This miRNAs are suppressed by the interaction with Rbfox2 under certain 
conditions. This leads to a inhibition of Dicer cleavage and hence processing (Yu Chen et al. 2016). 
At the Dicer cleavage stage, several RBPs seem to compete for the binding to the terminal loop of 
the pre-miRNAs. For instance MBNL1 competes with Lin28 and hence U tailing and degradation is 
blocked (Androsavich and Chau 2014; Rau et al. 2011). 
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Surprisingly also base modifications of pre-miRNAs regulate Dicer interaction. For Instance Dicer 
recognition of the 5' monophosphate is blocked by methylation of the 5’ end of the pre-miR-145 
by the human RNA-methyltransferase BCDIN3D (Xhemalce, Robson, and Kouzarides 2012; Park et 
al. 2011). 
Regulatory mechanisms during Dicer cleavage. As already suggested the miRNA biogenesis is not 
only tightly regulated at transcriptional level, but even more at the pre-miRNA biogenesis step by 
many RBPs which interact with the pre-miRNA and the Dicer/TRBP complex (Figure 4) (Libri et al. 
2013; Ha and Kim 2014; S. Li, Wang, Fu, and Dorf 2014). Here, few examples which influence Dicer 
cleavage are presented. The most prominent example of negative influence on pre-miRNA 
processing is the stem cell factor lin28 that interacts with the members of the let-7 family (also 
observed for miR-107, miR143, etc.). The RBP lin28 consisting of a Cold shock and a CCHC-type 
Zincfinger domain interacts with the GGAG motif of the terminal loop of the pre-let-7 members 
except let-7a-3/c-2. Through the interaction the enzymes terminal uridyltransferases TUT4 
(ZCCHC11) or TUT7 which uridylates the pre-miRNAs are recruited (Figure 4) (L. Wang et al. 2017; 
Triboulet, Pirouz, and Gregory 2015). This short poly (U) tail at the 3’ end of the pre-miRNAs 
interferes negatively with Dicer cleavage and leads to 3’ to 5’ degradation of the pre-miRNA by 
DIS3L2. The inhibition of pre-let-7 biogenesis blocks important developmental processes, causing 
the cells to stay at a stem cell level (Newman, Thomson, and Hammond 2008; Rybak et al. 2008; 
Heo et al. 2008; Heo et al. 2009; Viswanathan, Daley, and Gregory 2008; Thornton et al. 2014; 
Shyh-Chang and Daley 2013; Triboulet, Pirouz, and Gregory 2015; Hao-ming Chang et al. 2013). 
Interestingly, lin28 is a phospho-protein which is modified by ERK/MAPK at several residues and 
hence stabilized in pluripotent stem cells (Tsanov et al. 2017; Xiangyuan Liu et al. 2017). In 
contrary of inhibition, TUT4, TUT2 and TUT 7 are reported to monouridylate a specific set of pre-
miRNAs including pre-let-7 at the 3’. This additional uridylation promotes Dicer cleavage in non-
stem cells which lack Lin28 (Heo et al. 2012). 
Regulation of pre-miRNA processing by other RNAs. Other RNAs can block dicer pre-miRNA 
interaction and recognition. For instance the adenoviral RNA VA1 competes with the pre-miRNAs 
for Dicer interaction and hence inhibits the processing (Libri et al. 2013). 
A recent study reports a dysregulation of miR-7 and miR-671 induced by a downregulation of 
circRNA Cdr1as that interacts with the named miRNAs. Interestingly, the data illustrates the 
downregulation of the miR-7 by the loss of the circRNA, hence an influence on pre-miRNA 
processing is suggested (Figure 4) (Piwecka et al. 2017).  
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Figure 4 Regulation of Dicer cleavage.  
This small RNA is recognized by the nuclear export receptor Exp5 and transported to the cytoplasm and further 
processed by Dicer. This results in a double-stranded RNA with 22 nt length. The mature strand is incorporated into Ago 
during RISC loading and leads to the mature RISC complex. During this stepwise process many RBPs positively (green 
arrows) or negatively (red arrows) influence this process. Regulatory RNAs influencing the miRNA biogenesis are 
indicated in red by inhibiting the process. 
 
Regulation of pre-miRNA export. The export mechanism is known to be blocked by few RNAs that 
bind to Exportin-5. For instance the adenoviral non-coding RNA VA1 inhibits miRNA export to the 
cytoplasm by competing with the endogenous pre-miRNAs for binding to Exportin- 5. Hence less 
pre-miRNAs are transported to the cytoplasm (Figure 4) (Y.-K. Kim, Kim, and Kim 2016; Libri et al. 
2013; Lu and Cullen 2004; Grimm et al. 2006).  
Dicer/ TRBP modifications and further functions. The Dicer/ TRBP complex is stabilized by TRBP 
phosphorylation by the MKK1/Erk pathway which causes selectively enhanced miRNA processing 
for growth-promoting miRNAs (Paroo et al. 2009). An additional phosphorylation occurs at 
S283/286 by S6 kinase which leads also to enhanced miRNA processing and links the miRNA 
biogenesis machinery to the mTOR pathway (C. Xu et al. 2016). A recent study reports the 
phosphorylation of TRBP by MAPK, which stabilizes the complex to Lin28a. This interaction leads 
to reduced let-7 levels and hence to an induced neuronal dendritic spine growth (Amen et al. 
2017). 
Further sumoylation of TRBP at K52 inhibits ubiquitination at K48, stabilizes the complex and 
promotes RISC loading (C. Chen et al. 2015). In C. elegans oocytes it was observed that Dicer is 
phosphorylated by ERK which causes inhibition of Dicer activity. This inhibition is reactivated 
before fertilization starts in the oocytes (Drake et al. 2014). Of note, Dicer seems to have a certain 
nuclear role in double-stranded DNA repair when phosphorylation is induced by DNA damage at 
S1016, S1728 and S1852 (Burger et al. 2017). 
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1.2 Gene silencing and translational repression 
 
The mature RISC complex contains a miRNA incorporated in Ago. It finds its mRNA target during a 
less understood scanning mechanism through complementary base pairing of the seed sequence 
with the 3’ untranslated region (3’UTR) of the targets. The state of Ago during scanning in terms 
of protein interactors and regulatory modifications remains speculative. The minimal RISC is 
supposed to interact with mRNA and/or the TNRC6 proteins. However, it is still unclear whether 
interactions are at the same time, sequential or simultaneous. Further, it is assumed that the 
target scanning process and also translational repression and /or storage takes place or is next to 
structured protein networks of various size called p-bodies (Patel, Barbee, and Blankenship 2016; 
Zipprich et al. 2009; J. Liu et al. 2005; Wilczynska and Bushell 2015; S. Lee and Vasudevan 2013; 
Kamenska et al. 2016). As a consequence of Ago-miRNA-mRNA-TNRC6 complex assembly, 
translational repression and mRNA decay are initiated. These processes are mainly induced by 
proteins and enzymes that are recruited sequentially or in parallel by TNRC6. Ago functions 
conclusively as initial target finding enzyme and mediates through binding to TNRC6 gene silencing 
(Jonas and Izaurralde 2015; Dueck and Meister 2014).  
 
1.2.1 Interplay of TNRC6 and Ago 
 
1.2.1.1 TNRC6 functions as core binding platform of the gene silencing 
process 
 
TNRC6 proteins belong to the family of GW proteins. The best known member is GW182 found in 
D. melanogaster (human homolog TNRC6A). Mammals express two additional paralogs TNRC6B, 
C and many uncharacterized isoforms. In general, TNRC6 proteins are structurally and functionally 
conserved from an evolutionary point of view. They may have evolved by the development of 
multicellularity and whole genome duplication to three paralogs within the vertebrates 
(Zielezinski and Karlowski 2015; Mauri et al. 2017). TNRC6 proteins consists of two main regions, 
the N-terminal Ago binding domain (ABD) and the C-terminal silencing domain (SD). Glycine-
Tryptophan (GW, W, GWG, WG) repeats are randomly distributed over the whole proteins, 
especially in the ABD and the SD. Ago proteins interact through specific binding of two binding 
pockets located in the PIWI domain with two Ws located in the TNRC6 ABD (see Figure 6 and Table 
1) (Braun et al. 2011; Jonas and Izaurralde 2015; Huntzinger and Izaurralde 2011; Pfaff et al. 2013). 
This specific interaction is conserved within the mammalian Ago 1-4 proteins. Interestingly, there 
are very limited regions within this various GW repeats in the ABD where Ago proteins interact. 
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However, the specificity or selectivity of this process is not understood. It is suggested that a 
specific distance of 10 amino acids combined with a specific amino acid pattern determines the 
binding process (Pfaff et al. 2013; Hauptmann et al. 2015). Altogether, three binding hot spots on 
TNRC6A are known. These hotspots may interact also with Agos at the same time (Elkayam et al. 
2017). It is further known that the TNRC6 paralogs may contain a different number of Ago 
interaction sites. They are partly conserved, e.g. TNRC6B possesses two and TNRC6A has three 
interaction sites (Takimoto, Wakiyama, and Yokoyama 2009; Nishi et al. 2013; Pfaff et al. 2013; 
Hauptmann et al. 2015a; Baillat and Shiekhattar 2009). TNRC6 proteins are suggested to function 
redundantly and to interact with all Ago1-4 proteins without preferential combinations. 
 
Table 1 Domain organization of mammalian TNRC6 paralogs (adapted from Uniprot database). 
 
Paralog  Domain Position [aa] Length Function   
 
TNRC6A  ABD 1-932  932 Interaction with Argonaute family proteins 
RRM 1781-1853 73 Function unknown 
  PAM2 1604-1622 19 PABPC1-interacting motif-2 
  Gln-rich  93-127  35 Function unknown, p-body localization? 
  Ser-rich  192-365  174 Function unknown 
 
TNRC6B  ABD 1-994  994 Interaction with Argonaute family proteins 
RRM 1648-1720 73 Function unknown 
  PAM2 1472-1490 19 PABPC1-interacting motif-2 
  SD 1218-1723 506 Interaction with CNOT1 and PAN3 
Pro-rich   825-880  56 Function unknown 
  Gln-rich   1150-1220 71 Function unknown, p-body localization? 
 
TNRC6C  ABD 1-926  926 Interaction with Argonaute family proteins 
RRM 1565-1632 68 Function unknown 
  PAM2 1381-1399 19 PABPC1-interacting motif-2 
  SD 1260-1690 431 Interaction with CNOT1 and PAN3 
n.n. 1596-1690 95 Interaction with the CCR4-NOT 
n.n. 1371-1690 320 Sufficient for translational repression when tethered to  target 
UBA 933-978  46 Ubi interaction site 
Gly-rich   204-430  227 Function unknown 
  Thr-rich   756-777  22 Function unknown 
Pro-rich   1215-1248 34 Function unknown, p-body localization? 
 
 
The central part of TNRC6 contains a number of gene silencing independent domains. A typical 
ubiquitin-associated (UBA)-like domain which is involved in the proteasomal degradation (Figure 
6). The UBA-like domain folds into a trimeric helix bundle with hydrophobic regions for 
ubiquitination probably by the E3 ubiquitin ligase TRIM65 (S. Li, Wang, Fu, Berman, et al. 2014; 
Buchberger 2002; V. S. and A. F. Lau 2009).  
Next to the UBA a nuclear localization signal (NLS) and a nuclear export signal (NES) are located 
within the middle region in TNRC6A (Figure 6). Recently the structural composition of the TNRC6A 
NLS interacting with importin α was solved (Chaston et al. 2017). TNRC6B and C contain just a NES 
at a similar position; the location of the NLS is unknown. The NLS and NES recruit additional 
proteins like importin β which leads to nuclear shuttling (Nishi et al. 2013; Schraivogel et al. 2015). 
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All TNRC6 proteins contain several domains where specific residues are enriched e.g. a glutamine- 
and proline-rich region in TNRC6B. The location of these domains is partly conserved. However, 
their function is unknown, but mechanisms in p-body assembly/location are suggested for the Q-
rich region within TNRC6B (Lazzaretti, Tournier, and Izaurralde 2009). 
The C-terminal SD contains a PAM2 motif, a RRM and many Ws important for the interaction with 
the CCR4-Caf1-NOT and the trimeric Pan2-Pan3 complex (Figure 6. A interaction of TNRC6 with 
the decapping complex is not known. Interestingly, the SD mediates translational repression and 
mRNA decay when proximal mRNA is present (Zipprich et al. 2009; Lazzaretti, Tournier and 
Izaurralde 2009; Eulalio, Tritschler, et al. 2009). While Ago has the target recognition and gene 
silencing initiation function, TNRC6 serves as a binding platform and as mediator for all 
downstream processes (see Figure 6 and Table 1). 
 
 
 
Figure 5 Schematic model based on functional and structural aspects of the miRNA-mediated gene silencing process. 
A functional miRNA-mediated gene silencing complex requires at least one Argonaute protein, one TNRC6 protein, 
several Poly-A-binding proteins (PABPC1), and the PAN2–PAN3 and CCR4–caf1-NOT deadenylase complexes. The 
decapping complex is recruited by DDX6 and consists of the core subunits EDC4, DCP1-2 and others. Translational 
repression and destabilization of the target mRNA leads to 5’-to-3’ decay through exonucleases like XRN1 which is in 
direct neighbourhood within the p-bodies. 
 
The RRM of D. melanogaster GW182 (human homolog TNRC6A) lacks the ability to bind RNA. 
Nevertheless, it is required for the full function of gene silencing and is therefore suggested to 
may bind additional unknown protein interactors. The atypical RRM and UBA are the only defined 
structured parts of TNRC6 proteins. 
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Figure 6 Schematic model of TNRC6 domain organization based on functional and structural aspects of the miRNA-
mediated gene silencing process. 
(A), (B), (C), (D) domain organization of TNRC6A-C. Vertical black bars represent the relative positions of tryptophan’s. 
Different domains and regions are marked in different colour, abbreviations can be found within the text. (D) Ago 
proteins bind to two Ws in the ABD. Importin beta may bind to the NLS/NES region to transport TNRC6 into the nucleus. 
CRM1 (not shown) interacts in the same region as imp beta.Pan2-Pan3 trimer interacts through Pan3 dimer with a W 
from TNRC6. CCR4-Caf1-NOT complex interacts with TNRC6 with several Ws interactions of cNOT1 and cNOT9. 
Decapping complex is not interacting with TNRC6. 
 
 
14 Introduction 
The PAM2 motif interacts with the first PABPC1 linked to the poly (A) tail and thus leads to an 
indirect mRNA positioning (Jonas and Izaurralde 2015) (Figure 6). The interaction with the CCR4-
Caf1-NOT deadenylation complexes is thought to be similar to the Ago-TNRC6 interaction, 
meaning that the interaction relies on tryptophan insertion into binding pockets to the respective 
protein partner. After recruiting the complex by Ago-TNRC6, deadenylation will be completed and 
the mRNA will be finally degraded. In case of miRNA independency, translational control through 
deadenylation also occurs (Collart, Panasenko, and Nikolaev 2013; Gupta et al. 2016). 
Binding occurs with the main subunit cNOT1 that possesses a similar function as TNRC6. cNOT1 is 
also considered as a scaffold binding platform for the catalytic deadenylases Caf1 and CCR4a and 
other subunits(Figure 6). 
The interaction of cNOT1 with TNRC6 relies on several Ws together with the regions CCR4-
interacting-motif1/ 2 (CIM-1/ CIM-2). Furthermore, NOT9 contacts two Ws of TNRC6 with 
unknown position and interacts with cNOT1. Both interactions are limited to the silencing domain 
which causes the downstream silencing effects (see Figure 6 and Table 1) (Braun et al. 2011; 
Chekulaeva, Filipowicz and Parker 2009; Chekulaeva et al. 2011a; Fabian et al. 2013a; Ying Chen 
et al. 2014). 
The trimeric Pan2-Pan3 deadenylation complex consists of the catalytic deadenylase Pan2 and 
two Pan3 proteins. This complex mediates mRNA association both through PABPC1 interaction 
and by direct binding to the poly(A) tail through a zinc finger domain (see Figure 6 and Figure 6) 
(Wolf et al. 2014; Jonas et al. 2014). It is thought that the Pan3 dimer assembly leads to a 
formation of a W binding pocket which further stabilizes and strengthens the interaction to TNRC6 
(see Figure 6)(Braun et al. 2011; Christie et al. 2013; Jonas et al. 2014; Wolf et al. 2014). 
All three TNRC6 paralogs function redundantly and promote post-translational gene silencing 
(PTGS). Individual K.O.s indicated no reduction in tethering assays. Inhibition of all three paralogs 
leads to a strong de-repression comparable to de-repression assays conducted with the T6B 
peptide (Hauptmann et al. 2015a; Danner et al. 2017). As binding platforms, TNRC6 proteins are 
required to be unstructured to allow a flexible and dynamic change of interaction partners as well 
as to assemble within bigger structured gene silencing compartments (see Figure 6) (Jonas and 
Izaurralde 2015).  
There are many reports in literature that report on additional binding partners of TNRC6 proteins. 
These are not yet fully related to a functional subunit or understood. For instance, recent reports 
suggest additional interactions with LIM1, which binds to the ABD, and is suggested to have a 
regulatory role within the gene silencing mechanism (S. Li, Wang, Fu, Berman, et al. 2014; E. Wu 
et al. 2016; Bridge et al. 2017). 
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1.2.1.2 Subcellular localization of TNRC6-Ago complexes 
 
The mammalian miRNA mediated gene silencing is suggested to occur in the cytoplasm. Therefore, 
the associated functional proteins are also mainly located in the cytoplasm. The function 
determines localization, hence depending on main or auxiliary function, the subcellular position 
of the proteins to other cellular compartments can switch. For instance it is reported that gene 
silencing occurs at terminal axons or that TNRC6 proteins have putative functions in the nucleus 
(Figure 7) (Kalantari, Chiang, and Corey 2016; N. R. Sharma et al. 2016; Schratt et al. 2006). Hence 
many different cell lines and tissues exhibit a particular localization and expression pattern of 
TNRC6 and Ago Proteins (Schraivogel et al., n.d.; Rüdel et al. 2008; Keith T. Gagnon, Liande Li, 
Bethany A. Janowski 2012; Hauptmann et al. 2015b). 
 
 
Figure 7 Subcellular localization of the gene silencing process.  
A dynamic fast switching system triggered by regulatory stimuli determines the intracellular localization of Ago-TNRC6 
complexes from single molecules to highly structured networks. 
 
TNRC6 and Ago proteins seem to shuttle into the nucleus as single molecules or as complex. Ago 
is imported through canonical redundant mechanisms and has potential chromatin associated 
functions (Ameyar-Zazoua et al. 2012). TNRC6 is mainly imported into the nucleus by importin 
alpha/beta and exported by CRM1 dependent mechanisms (Schraivogel et al.,2015). It is 
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suggested that TNRC6 may act as binding platform for different nuclear processes such as splicing 
and transcription. However, this assumption is speculative and relies on proteomic screens which 
were performed lacking conclusive functional assays and necessary controls (Kalantari et al. 2016).  
According to IF stainings, TNRC6 proteins localize within the cytoplasm in small complexes and 
large structured processing-bodies (p-bodies) when bound to Ago. The functional subunit, called 
p-bodies was, extensively studied in the last decades and many mRNA related functions were 
found such as mRNA decay (deadenylation, decapping complexes, exonucleases), translational 
repression (TNRC6-Ago), PTGS (TNRC6-Ago, deadenylase and decapping complexes) and nonsense 
mediated decay (UPF1/2/3 etc.) (Kulkarni, Ozgur, and Stoecklin 2010; S. Lee and Vasudevan 2013). 
The architecture of p-bodies exhibits a structural binding network and fast, dynamic and flexible 
changing mRNA-complexes (Figure 7). Purification of p-bodies is difficult, therefore, most studies 
use IFs to detect p-bodies in overexpressed conditions (Rüdel et al. 2008). Optical detection of 
small endogenous p-bodies yield unreliable data and estimation of size is difficult. It is suggested 
that the real processing bodies are smaller, dynamic and fast changing/adapting network systems 
which can also store mRNA-RBP complexes. However, this remains speculative (Meister et al. 
2005; Pillai et al. 2005; Leung, Calabrese, and Sharp 2006; Eulalio et al. 2007; Eulalio, Behm-
Ansmant, and Izaurralde 2007; Rajgor et al. 2014; S. Lee and Vasudevan 2013; Pitchiaya et al. 
2017). 
Overexpressed TNRC6 itself co-localizes mainly with p-body markers like Lsm4. Interestingly Ago 
proteins show weaker co-localization with p-bodies (Schraivogel et al. 2015; Nishi et al. 2013). 
Above all in an endogenous manner, it was even shown that p-body location is not required for 
TNRC6-Ago interaction (Lazzaretti, Tournier, and Izaurralde 2009). This findings suggests, that Ago 
proteins and PTGS are located around the p-bodies (N. R. Sharma et al. 2016; Pitchiaya et al. 2017).  
Ago can also be found in other compartments, e.g. in extracellular signalling vesicles (exosomes) 
(McKenzie et al. 2016) and under certain stress conditions in stress granules (Figure 7) (Anderson 
and Kedersha 2008; Detzer et al. 2011; Rieckher and Tavernarakis 2017; Buchan and Parker 2009). 
In general, gene-silencing complexes such as the RISC loading complex are associated with the 
endomembrane system consisting of the ER, Golgi complexes, endosomes and lysosomes (Figure 
7) (Y. J. Kim, Maizel, and Chen 2014; D Gibbings et al. 2012; Derrick Gibbings et al. 2013; N J 
Martinez and Gregory 2013; Barman and Bhattacharyya 2015).  
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1.2.2 Canonical post-transcriptional gene silencing 
 
The initiation of translational repression and mRNA degradation is induced by binding of the 
miRNA seed sequence to the target. Binding occurs through complementarity of the bases 2 - 8 of 
the miRNA with the 3’ UTR of the mRNA or in rare cases in other regions like the 5’ UTR (Hafner 
et al. 2010; Hausser et al. 2013; G. Li et al. 2016; Ørom, Nielsen, and Lund 2008). Thereby, 
repression is triggered while the translational initiation closed loop structure is assembled (Figure 
8). This structure is formed by the poly (A) tail bound to the cytoplasmic poly (A)-binding Protein 
(PABPC1) which interacts with eIF4G within the 5’cap structure (Jackson, Hellen, and Pestova 
2010). 
The target finding process is suggested as highly regulated through internal or external signals 
(Giraldez et al. 2005; van Rooij et al. 2007; Avraham and Yarden 2012). Furthermore, the question 
of target capability of many miRNAs remains unsolved, because a single miRNA can bind many 
mRNAs and the other way round, a mRNA can interact with many miRNAs. The occurrence of 
proper target finding is not well understood, as it also strongly depends on the mRNA/transcript 
expression profile (and turnover) of specific cell and tissue types (Rüegger and Großhans 2012; 
Dueck et al. 2012; Jacobsen et al. 2013; S. Wu et al. 2010). 
To induce mRNA degradation, GW182 (or human paralogs TNRC6A-C) interacts through the 
minimal miRISC with the mRNA. Additionally, PABPC1 binds the PAM2 motif within TNRC6 to form 
a stable structured complex (Figure 8) (in D. melanogaster with additional W interactions) 
(Chekulaeva 2011). The detailed mechanism of the interaction of PABPC1 to TNRC6 is 
controversial discussed. It is assumed that translational repression is independent of this 
interaction because deadenylation through CCR4-Caf1-NOT and Pan2-Pan3 still occurs which 
leads to mRNA decay (Fabian et al. 2009; Braun et al. 2011; Jinek, Coyle, and Doudna 2011; Zekri, 
Kuzuoğlu-Öztürk, and Izaurralde 2013; Fabian et al. 2013b). Nevertheless, the interaction of 
TNRC6 with PABPC1 may decompose the closed loop structure through eIF4G dissociation (Figure 
7) (Zekri et al. 2009; Fabian et al. 2009). 
Nevertheless, within the canonical pathway the translational repression complex is formed, the 
closed loop structure is opened and subsequently the deadenylase complexes consisting of the 
CCR4-Caf1-NOT and Pan2-Pan3 are recruited. Both units interact with several Ws of the C-terminal 
silencing domain of TNRC6 (Makino et al. 2015; Zipprich et al. 2009; Chekulaeva et al. 2011b; 
Lazzaretti, Tournier, and Izaurralde 2009; Eulalio, Huntzinger, et al. 2009; Eulalio, Tritschler, and 
Izaurralde 2009). 
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Figure 8 Small RNA mediated gene silencing by the mature RISC complex. 
Different steps of the miRNA mediated gene silencing process are combined in a schematic chronological multistep 
illustration based on structural and functional information. Briefly, the minimal miRISC mediates gene silencing through 
complementary mRNA target binding together with TNRC6. Binding of RISC to a partially complementary mRNA at the 
seed sequence region results in repression of translation. This subsequently leads to deadenylation through the 
deadenylase complexes CCR4-Caf1-Not and Pan2 –Pan3 that are recruited by their mediator TNRC6. The mRNA is 
further destabilized through 5’decapping initiated by a DDX6 mediated recruitment of the decapping complex consisting 
of EDC1/2. After completing the mRNA destabilization, translational repression complex detaches which leads to 5’ to 
3’ decay through p-body located exonucleases like XRN1. 
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Deadenylation and parallel dissociation of PABPC1 is then thought to be initiated by Pan2-Pan3 as 
first step. Followed by further diminishing of the poly (A) tail by the CCR4-Caf1-NOT complex until 
completing of deadenylation leads to a parallel DDX6 mediated recruitment of the decapping 
complex (Fabian and Sonenberg 2012; Subtelny et al. 2014; Wahle and Winkler 2013; Yamashita 
et al. 2005). Interestingly, only the CCR4-Caf1-NOT complex leads to complete deadenylation and 
subsequent decay (Huntzinger et al. 2013; Piao et al. 2010; Behm-Ansmant et al. 2006; Eulalio, 
Tritschler, and Izaurralde 2009; Yamashita et al. 2005). The Dead-box helicase DDX6 interacts with 
the MIF4G domain of cNOT1 (Ying Chen et al. 2014). Upon interaction it is activated and is 
suggested to recruit the decapping complex through interaction with EDC3 and DCP1-DCP2 after 
its dissociation (Figure 8) (Makino et al. 2015; Tritschler et al. 2009; Mathys et al. 2014; Jonas and 
Izaurralde 2015). Additionally DDX6 mediates, together with the eIF4E transporter protein 4E-T, 
pat1 and the associating Lsm1-7 proteins, the mRNA decay machinery to the 5‘ cap via direct 
interaction to eIF4E (Nishimura et al. 2015; Sharif and Conti 2013; Ozgur et al. 2015; Peter et al. 
2015). 
The decapping complex which is located within the p-bodies consists of DCP1, EDC4, DDX6 and its 
catalytical core subunit DCP2 (Figure 7) (Huntzinger and Izaurralde 2011; Jonas and Izaurralde 
2015). After decapping and deadenylation the stability of the mRNA falls below a critical limit. This 
induces a rapid degradation of the mRNAs by decapping complex associated 5’ to 3’ exonulceases 
such as XRN1. Interestingly, XRN1 depletion results in the accumulation of deadenylated mRNAs 
bound by the RISC and decapping machinery (Nishimura et al. 2015; Sun et al. 2013; Behm-
Ansmant et al. 2006; Nishihara et al. 2013). 
The other components dissociate after decapping and deadenylation and the (minimal) RISC may 
be recycled, degraded or re-initiated in a new gene-silencing round (Quevillon Huberdeau et al. 
2017; Golden et al. 2017).  
 
 
1.2.3 Translational repression and other ways of mRNA decay 
 
Next to direct mRNA decay, translational mRNA repression complexes are stored within p-bodies, 
stress granules or other compartments. The regulation, the possible re-activation, and the reason 
of storage is not well understood (Kulkarni, Ozgur, and Stoecklin 2010; Ayache et al. 2015; Dudek 
et al. 2010; E. Wu et al. 2016). It is suggested that translational repression occurs before mRNA 
destabilization. Hence, a block of decapping and deadenylation is necessary to stabilize 
translational repression complexes. 
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The length of the poly (A) tail may play a role in terms of a sequential degradation process, where 
decapping is initiated after a certain length of the tail is reached (Djuranovic, Nahvi, and Green 
2012; Béthune, Artus-Revel, and Filipowicz 2012; Subtelny et al. 2014). This idea is supported by 
in vitro methods such as constitution assays and Tail-seq. There it was shown that the 
deadenylation rate is influenced by additional RBPs, the sequence/structure of the mRNA itself, 
and the length of the poly (A) tail (Stowell et al. 2016; Hyeshik Chang et al. 2014). 
It is suggested, that the 3’ UTR may modulate the fate of its mRNA, through length, additional 
secondary structures and RNA modifications that allow binding of regulatory RBPs which further 
modify, inhibit or promote translational repression (Mishima and Tomari 2016).  
 
 
1.2.4 Regulation of miRNA mediated gene silencing by post-
translational modifications and interacting modifying 
enzymes 
 
The regulation of miRNA expression and activity can occur at every level at the biogenesis and the 
gene silencing pathway, including transcription, miRNA processing, target site binding and the 
formation of the gene silencing complex (Dueck and Meister 2014; Huntzinger and Izaurralde 
2011; Jonas and Izaurralde 2015). In the following part the regulatory post-translational 
modifications of different steps of the gene silencing pathway, especially TNRC6 and Ago will be 
introduced.  
TNRC6 proteins were identified as autoimmune phospho-proteins. Unfortunately their role as 
phospho-protein is still unclear (Eystathioy T, Chan EK, Tenenbaum SA, Keene JD, Griffith K 2002). 
As large protein(s), they contain numerous serines, threonines and tyrosines, interestingly often 
directly next to the GW repeats. According to the database phosphosite.org, many residues seem 
to be phosphorylated (30-50). Few of them are reported with high numbers of records. Many of 
these records are whole phospho-proteome studies, but they point out few sites to appear more 
often. 
It was further shown that multi dephosphorylated phospho-sites surrounding the PAM2 motif 
which interacts with the MLLE domain of the PABPC1 strengthens the interaction. Thus, it is 
suggested that the multi-phosphorylation of this sites regulate/inhibits the interaction to PABPC1. 
This would be then important in the first steps of Ago-TNRC6-miRNA-mRNA complex assembly 
and maybe for the release of the mRNA (Figure 9) (Huang et al. 2013). PABPC1 exhibits several 
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residues which may also be modified and thus be of importance for typical interaction to PAM2 
motifs (Brook et al. 2012; Brook and Gray 2012). 
The function of all this phospho-sites remains unknown maybe they have importance for nuclear 
shuttling, recycling, complex stabilization and assembly, degradation or even p-body formation. 
However, it was shown that highly phosphorylated Ago proteins interact with TNRC6 proteins in 
the “normal” way (Golden et al. 2017; Quevillon Huberdeau et al. 2017), leaving the question if 
also TNRC6 is highly phosphorylated or in addition to PABPC1 interaction non-phosphorylated.  
The degradation of TNRC6 proteins by ubiquitin dependent pathways and instant influence on 
miRNA mediated PTGS seems to be regulated by tripartite motif 65 (TRIM65) which is a E3 
ubiquitin ligase (S. Li, Wang, Fu, Berman, et al. 2014; S. Li, Wang, Fu, and Dorf 2014). 
TNRC6 expression is regulated at a transcriptional stage through PI3-Akt-mTOR and JAK-stat-Pim 
that act at a cap-dependent way on the transcripts levels and influence the ribosomal output. 
Consequently, the miRNA pathway is influenced. This regulation of the transcript levels occurs 
during the transition from a stimulated/active to an non-stimulated/quiescent state. This leads 
Ago into an inactive state and TNRC6 seems to be degraded over time (Olejniczak et al. 2013; 
Olejniczak et al. 2016; La Rocca et al. 2015). 
Argonaute proteins are shown to be differentially modified with modifications such as 
phosphorylation, sumoylation, ADP-ribosylation and hydroxylation. In Table 2 the best known 
modifications from the last years of intensive research are listed. Many of the modifications are 
exclusively detected in particular conditions like hypoxia or increased stress while others like the 
pS387 may be stable in different cellular states and standard growth conditions. 
The conserved S824-834 phosphorylation cluster is up to five times phosphorylated. It seems to 
have reduced binding ability to target mRNAs through this heavy negatively charged flexible loop. 
An interference with the negatively charged mRNA through proximity to the binding cleft is 
suggested. This modification may be regulated through the kinases CK1/GSK3 and the 
phosphatase 6 complex (Golden et al. 2017; Quevillon Huberdeau et al. 2017). 
Another report suggests LIMD1 and WTIP as modification dependent RISC complex interactors. 
Thereby the AB motif of LIMD1 directly binds to the linker 2 between PAZ and MID domain of 
AGO2 when the Akt3 dependent S387 is phosphorylated (Bridge et al. 2017; James et al. 2010). 
Other groups suggest a role of KRAS to be important for the localization of Ago2 in multi-vesicular 
endosomes which is prevented by the stable pS387 (McKenzie et al., 2016).  
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Table 2 Overview of reported Ago2 modifications (adapted from Wilczynska and Bushell 2015). 
 
Modification [aa] Function      pred. Mod. Enzyme Reference 
 
Phosphorylation  
S[387]  p-body localization of Ago2;    MAPKAPK2 (Zeng et al. 2008) 
  enhancement of miRNA -mediated repression  kinase Akt3 (Horman et al. 2013)
          (Rüdel et al. 2011) 
 
Y[393]  Induced in hypoxia; decreased interaction to Dicer EGFR  (Shen et al. 2013) 
  inhibition of miRNA maturation 
 
Y[529]      Reduced p-body localization; impaired miRNA binding  ?  (Rüdel et al. 2011) 
transient loss of miRNA binding by Ago2;  
reduced interaction to TNRC6 proteins 
S [824-834]  Cluster-phos.; reduced target binding   GSK3?, CK1?            Huberdeau et al. 
2017 
        Phosphatase 6 (Golden et al. 2017) 
 
Sumoylation Increase in protein stability    Sumo1/2/3 Sahin et al. 2014;  
K[402]           Josa-Prado, Henley, 
 and Wilkinson 2015 
Sahin et al.2014 
Hydroxylation Stabilization of Ago2 and enhancement   [C-P4H(I)] (H. H. Qi et al. 2008) 
P[700]  of miRISC function in hypoxia;     
           
  Increase in miRNA abundance      
 
ADP-ribosylation  Enhancement of stress granule formation;  poly(ADP-ribose) (Leung et al. 2011) 
  relief of miRNA repression 
 
Ubiquitination  Specific degradation of Ago2 ,   Trim71  (Rybak et al. 2009) 
degradation during T-cell activation (J. Chen, Lai, and 
Niswander 2012; 
 Loedige et al.2013 
 
 
Recycling mechanisms. The sequential pathway of gene silencing is upon regulation quiet well 
understood. However, it is completely unknown if there are recycling mechanisms after mRNA 
destabilization which return Ago-miRNA and TNRC6 back to certain pools for a new cycle after 
complex decomposition (Figure 9). It is unclear if Ago-miRNA is degraded, stored or unloaded/re-
loaded with a new miRNA. The same is true for TNRC6, which interacts with Ago, the 
deadenylation, decapping complexes and other proteins. For TNRC6 as binding platform there 
would be even the possibility that a core complex of TNRC6 and deadenylation complex stays for 
direct and fast action when an Ago protein together with an mRNA target arrives. Further different 
complex states depending on the fate of TNRC6 including all steps of gene silencing are thinkable. 
Certain hypothesis is addressed for Ago proteins and suggests an recycling of the minimal miRISC 
depending on the state of phosphorylation (Figure 9) (Quevillon Huberdeau et al. 2017; Golden et 
al. 2017; La Rocca et al. 2015). Another report suggest that phospho-regulation of Ago2 through 
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Akt3 seems to be important for interaction to GW182 and p-body localization (Horman et al. 
2013). 
 
 
 
 
 
Figure 9 Recycling mechanism of gene silencing and translational repression. 
After Ago-miRNA-TNRC6-Ago complex is formed, mRNA is destabilized and released from a hyper-phosphorylated Ago 
for decay. The phosphorylation pattern of TNRC6 proteins may change during gene silencing according to the sequential 
function. 
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1.3 RNA binding proteins  
 
All classes of RNAs are associated with RNA-binding proteins. Together they form 
Ribonucleoprotein complexes (RNPs) with diverse functions. These complexes contain at least one 
RBP that interacts with RNA. All different RBPs share the common feature of binding specifically 
RNAs through RNA-binding-domains (RBDs) (Lunde, Moore, and Varani 2007; Gerstberger, Hafner, 
and Tuschl 2014). A RBP can include one class of the same or a combination of different classes of 
RBDs. Typical structural conserved RBDs are the RRM domain (RNA recognition motif), KH domain 
(K homology), DEAD and DEAH box helicase, or dsRBDs (double-stranded RBD) (Lunde, Moore, 
and Varani 2007). In the following part KH domains and RRMs are introduced in detail. 
KH domain. The protein human heterogeneous nuclear ribonucleoprotein K (hnRNP K) was the 
first example of a KH domain containing protein. Within hnRNP K the domain was characterized 
as ssRNA binding domain. In hnRNP K three copies of the KH domain are forming together the 
interacting RBD (Musco et al. 1996; Grishin 2001). KH domains can be modular assembled within 
the proteins as di-, tetra- or multimers. Two different classes of KH domains (I and II) are existent. 
KH domain I is typically found in eukaryotes and KH II in prokaryotes. The two classes are not 
sequence conserved and the typical KH minimal domain consisting of two beta-strands and two 
alpha-helices (β1-α1-α2 β2) are also not structurally conserved (Ostareck-Lederer, Ostareck, and 
Hentze 1998; Valverde, Edwards, and Regan 2008). The KH domain I contains altogether three 
beta strands which are antiparallel arranged as beta-sheet. The three alpha-helices are adjacent 
to the beta sheet. A RNA interaction cleft is assembled by the α1-helix, a GXXG-connection loop, 
α2-helix and the β2-strand. Four nucleic acids can associate with the hydrophobic binding pockets 
and residues within the cleft. Additional structural elements form an expanded KH domain and 
allow the interaction with more than four nucleic acids (Baber et al. 1999; Garc??a-Mayoral et al. 
2007; Nicastro, Taylor, and Ramos 2015). 
KH domains are found in many RBDs with various different functions (e.g. hnRNP proteins, KSRP 
or FMR1). The interaction and hence the function depends on the modular and functional 
architecture of the KH domains. They can act cooperatively together at one interaction site on the 
RNA or as completely independent domains which interact with different parts of the RNA 
(Nicastro, Taylor, and Ramos 2015; Lunde, Moore, and Varani 2007).  
 
RNA Recognition Motif. The RRM is the most prominent RBD within the RBPs and they are often 
organized in multiple copies within the RBPs. This class of RBDs was first identified in hnRNP A1, 
 
25 Introduction 
spliceosomal protein  U1A, PABP, sex-lethal and La (Adam et al. 1986; Swanson et al. 1987; Handa 
et al. 1999; Deo et al. 1999; Ding et al. 1999; Avis et al. 1996; Pérez Cañadillas and Varani 2003). 
This domain is structurally conserved within the species and usually composed of 80-90 amino 
acids. It contains several α-helix and β-sheet sandwich units which form a α1β1β2β3α2β4 
topology. Within different RBPs the structural composition varies according to the function of the 
protein and the interacting nucleic acids. For binding of ssRNA several conserved interactions on 
the surface of the β-sheet are necessary (Avis et al. 1996; Deo et al. 1999; Handa et al. 1999). A 
salt bridge is formed between specific residues (usually Arg/Lys) and the sugar-phosphate 
backbone. Another important hydrophobic interaction is accomplished by aromatic residues and 
the nucleobases. This interactions result in a stable complex formation (Maris, Dominguez, and 
Allain 2005; Lunde, Moore, and Varani 2007).  
There are also reports that the RRM domain interacts specifically with proteins. For instance the 
α1-helix of U2AF is three times longer as usual and then the interaction to a nearby β-sheet is 
solvent which leads to protein interaction with SF1 (Kielkopf et al. 2001; Kadlec, Izaurralde, and 
Cusack 2004; R.-M. Xu et al. 1997). 
 
The class of RBPs contain a huge bandwidth of different identified protein types and many 
unknown candidates, binding domains and dynamic networks which all determine the fate of RNA 
from transcription until decay (Gerstberger, Hafner, and Tuschl 2014). The classes of RNA binding 
domains are growing and many unusual domains are discovered to associate with different classes 
of RNA (Rammelt et al. 2011; Glisovic et al. 2008; McKee et al. 2005; Anantharaman 2002; Baltz 
et al. 2012; Castello et al. 2012). For instance the NHL domain of D. melanogaster protein brain 
tumor (BRAT) was identified as new RBD. BRAT forms together with Pumillio and Nanos a complex 
which interacts with the hunchback mRNA and hence its translation is repressed. The NHL domain 
assembles as a six-bladed beta propeller recognizing ssRNA at its positively charged top surface 
(Loedige et al. 2014; Loedige et al. 2015).  
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1.4 miRNA containing viruses 
 
1.4.1 Viral life cycle 
 
Viruses are non-reproductive genetic systems. In general, all viruses have a similar architecture. 
They consist of a coat and viral genes encoded with nucleic acids. Hence, the virus needs a system 
for reproduction. Due to this reason, viruses have to invade other living cells and use the cells 
replication systems for reproduction. Therefore, the viruses undergo the lytic life cycle, in which 
the host cell is often destroyed by virus production and excretion. There are several stages of the 
lytic cycle that are classified by the genes that are expressed. For instance, in CMV three phases 
during the lytic infection can be distinguished: Immediate-earl, very early and late phase. 
In general, the virus life cycle is similar within all classes of viruses. This means the virus forces the 
host to produce viral proteins and the viral the genome. Afterwards the virus is assembled and 
leaves the cell to invade new hosts. In the following chapter, the lytic life cycle of CMV and the 
latent phase of EBV is briefly described as an example. 
Lytic life cycle. The virus attaches to the cell, enters into the cell and enters through specific 
mechanisms involving target molecules and receptors. Once inside the cell, the genomic DNA is 
transported immediately into the nucleus, where the viral genomic program is initiated by strong 
promotors (Beltran and Cristea 2015; Herbert and Nag 2016). Subsequently the virus takes over 
the entire genetic program of the host, the viral genome is replicated, and viral coat proteins for 
particle assembly are produced in large amounts by the host. The genome is packed into the 
assembled coat and the viruses destroys the host when leaving the cell (Beltran and Cristea 2015).  
 
Figure 10 Schematic representation of the latent 
and lytic virus life cycle (CMV served as example). 
(A) Virus particles attach specifically to cell surface 
receptors and enters into the cell cytoplasm 
through endocytosis. (B), (C), After uncoating, 
capsid-DNA complex is delivered into the nucleus 
(D). In the nucleus the immediate-early genes are 
transcribed, followed by the early genes and 
subsequently the late genes. Viral genome is 
replicated and capsid proteins were expressed. Late 
phase initiates the nuclear capsid assembly, export 
and cytoplasmic tegument formation in the 
assembly complex. (E) Virus is released into the 
intracellular space. (F) Shuttling to latent viral phase 
without active virus production. Persistent virus can 
be reactivated and switch again to the lytic phase 
(modified after Handke et al. 2012; Beltran & 
Cristea 2015). 
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Latent life cycle. Under distinct conditions, viruses can switch into a latent cycle for a persistent 
remaining in the nucleus of the host cell (Speck and Ganem 2010; Cobbs et al. 2002; Sissons et al. 
2002; J. H. Sinclair and Reeves 2013; J. Sinclair and Reeves 2014; Arcangeletti et al. 2016). In this 
process the virus is replicated when the cellular genomic DNA replicates. During cell division, the 
viral genome copies are attached to the chromosomes by specific proteins. This insures that a 
genome copy is taken into the new cells during segregation. Typically, the virus suppresses its own 
gene expression to a certain limit and mimics additionally specific signalling pathways. Hence, the 
host cell is not detecting the virus and an immune response can be avoided. For instance in EBV 
the Epstein-Barr nuclear antigen 1 (EBNA1) is the only protein expressed in latency. Among many 
functions the tethering of the viral genome to the chromosomes is executed by EBNA1 (Hong Wu, 
Kapoor, and Frappier 2002; Yates, Warren, and Sugden 1985; Frappier 2012). The EBV proteins 
LMP1 and LMP2A mimic CD40 and a B-cell receptor (Uchida 1999; Miller et al. 1994). This leads to 
reduced signalling of certain immune response pathways. EBV is reactivated when stimuli like 
normoxia, hypoxia or DNA damage occur. Also some cellular signalling pathways that are required 
for differentiation as well as extracellular mediated signals like TGF-β1 cause reactivation and 
subsequent a switch to the lytic life cycle. The stimuli lead to an activation of the transcription 
factors Zp and Rp. These factors promote the switch to the lytic cycle by massive activation of the 
lytic genetic program (Luftig 2016; Kenney and Mertz 2014).  
 
1.4.2 Function of miRNAs in human herpes viruses 
 
In mammals and higher eukaryotes, thousands of different miRNAs have been identified, 
characterized and extensively studied. However, miRNAs are also present in some specific DNA 
viruses (Pfeffer et al. 2005; Sewer et al. 2007; Sullivan et al. 2005). Here, several of the herpes, 
papilloma and polyoma viruses containing miRNAs are introduced (Table 1). Also viral miRNAs are 
intensively studied and it was observed that most of them are transcribed by RNA Pol III (Diebel, 
Smith, and van Dyk 2010). Drosha and Dicer process the viral miRNAs in a similar way as the host 
miRNAs. Finally, they are incorporated in Ago proteins and gene silencing occurs. 
It is further suggested that the viral miRNAs target host as well as viral genes and the other way 
round host miRNAs regulate host and viral genes ( 
Figure 11)(Carl, Trgovcich, and Hannenhalli 2013). Viral microRNAs are suggested to function 
redundantly together with the host miRNAs, meaning that they act within regulatory networks 
and share the same targets, especially genetic defence systems are potential targets (D. 
Ramalingam and Ziegelbauer 2017; Dölken, Malterer, et al. 2010). Further host defensive miRNAs 
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are downregulated and conducive ones are upregulated, this suggests drastic changes within the 
miRNA pattern of the host (Motsch et al. 2012). Especially during a fast dynamic lytic cycle viral 
miRNAs in contrary to the host, miRNAs may have a minor role, but they could be more important 
by inducing and maintenance of the persistent latent virus life. 
 
Table 3 Classification of virus families and their viral microRNAs (adapted from Grundhoff and Sullivan 2012). 
 
name    virus strain, family  pri/ pre -miRNAs        mature miRNAs  
 
Epstein-Bar-virus   Gamma-Herpesviridae  25  44 
Cytomegalo-virus   Beta-Herpesviridae   15  26 
Herpes-Simplex-Virus 1 Alpha-Herpesviridae   18  27 
 
BK polyomavirus  Polyomaviridae   1  2 
Merkel-Cell-polyomavirus Polyomaviridae   1  2 
Human Papilloma V. 41  Papillomaviridae   1  ? 
 
For instance the expression of viral miRNAs in EBV during the latent persistent phase is very high 
and it seems that they target antiviral genes (Kang, Skalsky, and Cullen 2015; Hooykaas et al. 
2016). The viral expression levels in the latent and lytic phase were intensively studied and reports 
suggest that many miRNAs are highly expressed and processed in both lytic and latent phase. 
Some are blocked at a particular processing step in either the latent or lytic phase and some seem 
to be not present at all (Stern-Ginossar et al. 2009; Forte and Luftig 2011; Jurak et al. 2010; Murphy 
et al. 2008; Flores et al. 2013).  
 
                     
 
Figure 11 The influence of viral and host miRNAs on viral and host targets for controlling viral latent and lytic life cycles. 
 
This differential expression occurs because also the viral miRNAs are organized in either clusters 
(EBV) or individual at intronic regions of pre-mRNAs. Interestingly, also within viruses clustered 
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miRNAs, although transcribed together as one primary transcript, are frequently differentially 
expressed and processed which suggests regulatory networks like for mammalian miRNAs that 
function also in viral miRNA biogenesis. In the following part, an overview of CMV, HSV1 and EBV 
microRNAs and their summarized functions is listed in appendix Table 16).  
 
CMV. The miRNAs of CMV are mainly individual organized in intronic regions of immediate-early 
or early genes and highly expressed during infection of primary cells suggesting a role in the lytic 
life cycle (Pfeffer et al. 2005; Grey and Nelson 2008; Dhuruvasan, Sivasubramanian, and Pellett 
2011; Fruci, Rota, and Gallo 2017).  
HSV1. miRNAs are partly conserved to HSV2 and they are organized in small clusters or individual. 
They locate within overall within the whole genome; just few are in the latency associated 
transcripts (LAT) region. In the latency phase, only LAT miRNAs are expressed. This means that 
only 9 of the 17 HSV1 miRNAs are expressed, processed and loaded into RISC (B. R. Cullen 2004; 
Flores et al. 2013; Jurak et al. 2010; R. L. S. and B. R. Cullen 2013; Kramer et al. 2011; Jennifer Lin 
Umbach et al. 2009; Jennifer L Umbach et al. 2010). During lytic infection just few of the miRNAs 
are expressed, most of them seem to be blocked during miRNA biogenesis (Kramer et al. 2011). 
EBV. 25 EBV pre-miRNAs and 44 mature miRNAs were identified in EBV positive B cells (Jijoye, 
C666-1,SNU-719, etc). The BHRF1 miRNAs are generated by splicing of the bhrf1 gene and only 
expressed in latency phase III. The BART miRNAs are organized in 2 large clusters and mainly 
expressed in latency I/II. Interestingly, a depletion of all EBV miRNAs in the EBV-B95-8 strain, still 
immortalized B cells in cell culture, suggesting a minor role of EBV miRNAs during latency in B cells 
(Cai, Hagedorn, and Cullen 2004; Grundhoff, Sullivan, and Ganem 2006; Xing and Kieff 2007; J. Y. 
Zhu et al. 2009; Hooykaas et al. 2016; Haar et al. 2015). The targets of the viral miRNAs are genes 
involved in apoptotic and immune defense mechanisms (listed in appendix table 16).  
 
 
1.4.3 Polyoma and Papilloma viruses 
 
Papilloma and polyoma viruses belong to the class of human oncogenic viruses like many of the 
prior described herpes viruses, they have also cancerous potential and cause e.g. Merkel cell 
carcinoma tumours (Toker C., 1972; Stamatiou et al. 2016). 
Briefly, Polyoma viruses belong to the family of the polyomaviridae and are classified as ortho-
polyomaviruses with typical members such as MCV, SV40, JC and BK human polyomavirus. The 
genome size of this dsDNA virus clade usually is around 5 kb and contains a small amount of genes 
like the early genes large T antigen (LT), alternative T antigen open reading frame (ALTO), 
 
30 Introduction 
microRNA (miRNA) or the late capsid and coating protein genes (VP1-3) (Stakaityte et al. 2014; 
Richards et al. 2015). 
Interestingly, within MCV (similar in SV40, BKV and others) the viral miRNA that is located 
antisense to the LT coding region regulates early viral genes. This results in a decrease of early 
genes, especially the LT antigen (base complementarity induces cleavage of the transcript) and 
may support the switch to the late phase of the viral life cycle (Sullivan et al. 2005; Gil Ju Seo, 
Chen, and Sullivan 2009; Xi Liu et al. 2011; G J Seo et al. 2008; Richards et al. 2015; Stakaityte et 
al. 2014; C. J. Chen et al. 2016). 
 
Table 4   Viral miRNAs of BKV, MCV, HPV41. 
 
  
mature miRNAs  target/ function     publication 
 
BKV-mir-B1, SV-miR1  binds to Lt-Ag complementary and cleaves target,     Sullivan et al. 2005; Seo et al. 2009; 
MCV-mir-M1, JCV-miR-1 reduced cytotoxic T cell– mediated lysis of infected cells Liu et al. 2011; Seo et al. 2008; 
Richards et al. 2015 
 
HPV41-miR-H1  miRNA was identified by the lab of Prof. Dr. Adam Grundhoff and was not yet published 
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2.1 Part I: Identification of RBPs that regulate the viral 
miRNA biogenesis 
 
2.1.1 Aims of part I 
 
The general biogenesis from primary transcripts to mature microRNAs that is a two-step process 
is well understood in many species. It involves either the differential expression of precursors and 
mature miRNAs, or the differential expression of miRNAs originating from primary transcripts. This 
regulation is thought to be especially important under conditions where transcriptional and 
translational profile changes occur that are for example triggered by viruses. It is likely that RBPs 
can contribute to such a regulation process on posttranscriptional levels. In this project, we 
studied the influence of RBPs on the viral miRNA biogenesis of herpes, papilloma and polyoma 
viruses. 
To identify proteins involved in post-transcriptional regulation of miRNA biogenesis, a large mass 
spectrometric screen with pri/pre-miRNA pull-down assays was set up in a viral background. In 
the following studies, the interaction of the potential regulators was validated, verified and 
further characterized.  
 
Brief overview of planned workflow: 
1. Viral pre-miRNA binding proteins were identified 
2. Results were analyzed in silico 
3. Binding proteins were validated by in vitro assays 
4. Characterization of specific RNA binding proteins 
 
 
2.1.2 Viral miRNA expression profile of EBV, CMV and HSV1 
 
 
As initial starting point, the miRNA expression profiles of the different viruses were observed to 
determine differences that may be caused by regulatory processes. 
The amount of mature and pre/pri-miRNAs was analyzed by northern blotting in the EBV positive 
cell lines Raji and Jijoye. Deep sequencing experiments conducted by a former lab member 
(Michaela Beitzinger) showed high variety in the expression levels of miRNAs. For northern 
blotting 20 µg of total RNA from EBV positive cell lines Raji and Jijoye was separated by RNA-UREA-
PAGE, blotted onto nitrocellulose membranes and viral miRNAs were detected with radioactive 
labelled DNA oligos complementary to the 3p or 5p mature miRNAs. The selected northern blots 
in Figure 12 A-C suggest positive or negative influence during the crucial steps of processing. 
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Blocking or promoting of miRNA biogenesis leads to different levels and hence, stronger or weaker 
signals of pre-miRNA and mature miRNA. The ebv-miR-BHRF1-1 is located within a miRNA cluster 
next to the gene BHRF1 (Cai, Hagedorn, and Cullen 2004; Grundhoff, Sullivan, and Ganem 2006; 
Xing and Kieff 2007; J. Y. Zhu et al. 2009; Hooykaas et al. 2016; Haar et al. 2015) and the levels of 
the processed miRNAs and pre-miRNAs differ from ebv-miR-BHRF1-2 or BHRF1-3 (Figure 12 A). 
This suggests that the co-transcribed cluster is regulated during miRNA processing and thus, the 
levels of pre-miRNAs and miRNAs differ from each other. 
 
 
 
Figure 12 Detection of viral miRNAs by northern blot. 
(A) Detection of EBV-miRNAs and pre-miRNAs by northern blots crosslinked with 20 µg of total RNA extracted from the 
EBV positive cell line Raji. Binding of DNA probe is depicted next to the blots. (B) Comparison of pre-miRNA expression 
in Raji and Jijoye cells with in vitro transcribed RNA probes for pre-miR detection only. Binding of the RNA probes is 
depicted next to the blots. (C) Expression profile of miRNAs detected by northern blot from EBV positive Jijoye cells. 
 
For the ebv-miR-BART6-3p processing stops at the pre-miRNA level, no mature miRNA could be 
observed. For detection of pre-miRNAs, in vitro transcribed RNA probes were used with a 
hybridization temperature of 65 °C. Probes were designed to interact with both, the mature and 
the pre-miRNA, or to interact only with the pre-miRNA (Figure 12 B). In Figure 12 C a subset of 
EBV miRNAs was detected by northern blotting to observe the expression levels. The illustrated 
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signals within the northern blots suggest a differential expression of the detected mature EBV 
miRNAs in Jijoye cells.  
 
            
 
Figure 13 miRNA expression levels during viral infection. 
(A) Detection of viral miRNAs after infection of primary MRC5 cells with CMV strain AD169 with MOI = 5. RNA was 
extracted after different time points and standard northern blots were performed. The miRNA expression levels were 
quantified according to U6 loading control.  (B), (C), (D) Detection of viral miRNAs after infection of primary MRC5 cells 
with HSV1 strain KOS with moi = 5. RNA was extracted after different time points and standard northern blots were 
performed. The miRNA/ pre-miRNA/ pri-miRNA expression levels were quantified according to U6 loading control.   
 
Furthermore, expression levels of some viral miRNAs during infection with human CMV and HSV1 
was assessed at different time points after infection. An equal amount of RNA was extracted of 
every time point and was loaded onto a 12 % PA-gel and miRNAs were detected by northern 
blotting with using DNA oligos (Figure 13 A-D). Selected CMV-miRNA expression increases from 0 
to 96 hours post infection (hpi) (levels were quantified by normalization to U6 loading control; 
Figure  13 A). Clear detection of miRNAs and a lack of signals for pre-miRNAs (not shown) suggest 
a strong transcription and an efficient processing of mature miRNAs after 24 to 48 hpi. 
Surprisingly, infection with HSV1 leads to more divergent viral miRNA profiles compared to CMV 
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(Figure 13 B - D). The expression of the pre-miRNA of hsv1-miR-H1 can be detected already after 
12 hpi, whereas the mature miRNA is not yet processed. The expression of pre-miRNA decreases 
at later time points, while the levels of mature miRNA increase with a distant time shift (Figure 13 
B). hsv1-miR-H2 is similar to the CMV miRNA analyzed. Levels of both pre-miRNA and mature 
miRNA increase during progression of viral infection (see Figure 13). In contrast, hsv1-miR-H3 
biogenesis might be blocked at the pri/pre-miRNA processing step and no mature form can be 
detected (Figure 13 D). Taken together, these different miRNA biogenesis profiles suggest not only 
a transcriptional regulation but also a regulation at the different viral miRNA processing steps. 
 
2.1.3 Identification of pre-miRNA binding proteins by mass 
spectrometric approaches  
 
RNA binding proteins that block or promote the different processing steps cause the differential 
miRNA biogenesis. For identification of specific hairpin binding proteins that are potential 
regulators of the miRNA biogenesis, a mass spectrometric screening approach with pre-miRNA 
pull-downs for the investigation of protein-interactors was first established for ebv-miR-BHRF1-1, 
ebv-miR-BART10 and ebv-miR-BART18 (data not shown). For the pull-down, in vitro transcribed 
pri/pre-miRNAs with a 5’ T7 promotor extension complementary bound to a 2’O-methyl-RNA 
linker (Figure 14) was incubated with cell lysates. That lysates were either actively infected or the 
virus was persistent within the used cell lines. 
After pull-down, magnetic beads were washed and associated proteins were loaded onto a 4 - 12 
% gradient SDS-gel, separated and analyzed by mass spectrometry (Figure 14). pri/pre-miRNA pull-
downs were generated in biological replicates and preclearing pull-downs which were generated 
during the preclearing of the lysates by magnetic beads coupled without pre-miRNA. The 
preclearing samples served as background binding control because of a lack of standardized pre-
miRNA that is not interacting with RBPs as negative control. The mass spectrometric obtained data 
is presented as heatmap with clear delineation of potential protein-RNA binding proteins. The 
heatmap included many different data-sets of every different excised gel part which was analyzed. 
After combination of the single data-sets, a raw heatmap containing all information was created. 
For further protein selection, specific hits had to appear as duplicate with high probability scores. 
Afterwards specific hits were compared to the background and the preclearing and were 
rearranged as heatmap for specific binders. For normalization, probability scores were 
summarized as "lane counts" for one protein lane and all hits were normalized to the lane counts. 
The pull-downs with the different viruses result in four different tables that are presented in the 
following chapters. 
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A first data analysis allows the grouping of interactors into the following categories. First, specific 
binding actions in which one RBP interacts with one pre-miRNA. Second, one hairpin may interact 
with different proteins. Third, one protein interacts with different pri- and pre-miRNAs. Fourth, a 
few hairpins interact with a few proteins and fifth, one part of a whole protein complex interacts 
with one or more pre-miRNAs. 
 
Figure 14 Schematic representation of the pri/pre-miRNA pull-down. 
Experimental set-up of the pre/pri-miNRA pull-down with magnetic streptavidin beads coupled to in vitro transcribed 
pre/pri-miRNAs through a 2'O-methyl RNA biotin linker. Prepared beads were incubated with cell lysates of EBV positive 
or CMV/ HSV1 infected cells. Proteins were separated by a 4-12 % gradient SDS-gel, coomassie stained and tryptic 
digested for mass spectrometric analysis. Obtained data was analyzed with MS excel.  
 
2.1.3.1 RBPs associated with CMV pre-miRNAs 
 
CMV encodes 15 different pre-miRNAs. To identify functional relevant regulators, RNP candidates 
were further grouped and analyzed. The heatmap shows that the mass spectrometric identified 
proteins of the hairpin pull-down are assigned to specific pre-miRNAs. Proteins with high 
background binding or weak binding were rejected. The pull-downs were performed in biological 
duplicates and only duplicate hits were counted. After all criteria were considered, the heatmap 
summarized around 100 specific proteins, clustered on the y-axis according to their interacting 
pre-miRNAs that are listed at the x-axis. There are potential regulators with one specific hit like 
SART3 or Rbfox2, without any or weak background. Other factors seem to bind two hairpins like 
CPSF5 or Zincfinger 346. Weak binding actions or even no obvious or distinct binding by potential 
candidates can be explained by low or no protein expression in the used cell lines. To get a first 
functional glimpse and to support specific binding, GO term analysis associates the potential RBPs 
to different cellular pathways such as RNA processing or mRNA processing with high p-values 
(Figure 16 A). 13 candidates can be linked to viral processes or viral life cycle which are listed on 
the right side of the table in Figure 16 A (original data obtained with go.princeton.edu). 
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Figure 15 Heatmap of specific CMV hairpin RBPs. 
Heatmap of proteins identified by mass spectrometry. Uniprot gene symbols are listed on the y-axis and pre-miRNAs 
are listed on the x-axis. Annotated protein hits were defined by score (obtained with Mascot and proteinscape) and 
normalized to the summarized counts of one protein. Pull-downs were performed in replicates and were averaged 
afterwards. The probability of specific binding is indicated in blue shades (from white = 0 to blue = 20).  
 
Subcellular localization annotations illustrate that many candidates are located within the nucleus 
suggesting interactions on the pri-miRNA level. Others are exclusively cytoplasmic or within 
distinct cellular locations, which implements a role within pre-miRNA processing (Figure 16 B). 
Many candidates contain one or more known RNA binding domains. The dominant RBD class with 
a frequency of about 40 % is the RRM (Figure 16 C). Around 25 % of the listed candidates are not 
known to be associated with RNA or related mechanisms like RNA processing.  
Furthermore, a subset of potential CMV proteins binding to hairpin-structured RNAs was 
identified which are early expressed during viral infection and have potential or known functions 
in the viral life cycle (shown in appendix Figure 39). The identified factors have not yet been 
associated with RNA binding and related processes. These factors probably resemble unspecific 
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binders due to high background levels and many unspecific binding actions. Therefore, the focus 
was shifted to the associated human candidates. Taken together, the statistical analysis suggests 
the specific identified RBPs as RNA associated proteins of the cmv-pre-miRNAs.  
 
Figure 16 Functional analysis of identified RBPs. 
(A) GO term analysis classifications with high p-values and cluster frequency. (B) Subcellular localization of identified 
proteins (classified with Uniprot database). (C) Distribution of RNA binding domains within the identified proteins. 
 
 
2.1.3.2 RBPs associated with EBV and HSV1 pre-miRNAs 
 
EBV encodes 22 different pre-miRNAs. To identify functional relevant regulators, a pre-miRNA 
hairpin pull-down was performed. RNP candidates that specifically bound to the exposed ebv-pre-
miRNA were further grouped and analyzed. The heatmap is illustrated in appendix Figure 40. 
HSV1 encodes 18 pre-miRNAs. A mass spectrometric screen of hsv1-pre-miRNA pull-downs 
identified potential regulators of miRNA biogenesis. The potential hairpin interactors are 
illustrated in appendix  
Figure 41. The hsv1-miR-11 was excluded from the experiments as sequence and structure specific 
characteristics of the hairpin resulted in methodical problems.  
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2.1.3.3 RBPs associated with BKV, MCV, HPV41 pre-miRNAs 
 
The Merkel-cell-polyoma, the BK polyoma and the human papilloma virus 41 each express one 
specific miRNA, which is not conserved in other viruses. To identify how these miRNAs are 
processed, a pri/pre-miRNA pull-down was performed using their pre-miRNAs as described above. 
However, in contrary to the experiments performed in chapter 2.1.3.1, MRC5 cells could not be 
actively infected with the viruses because of methodical and technical issues. 
 
 
Figure 17 Heatmap of specific BKV/MCV/HPV41 hairpin RBPs and in silico analysis. 
(A) Heatmap of proteins identified by mass spectrometry. Uniprot gene symbols are listed on the y-axis and pre-miRNAs 
are listed on the x-axis. Annotated protein hits were defined by score (obtained with Mascot and proteinscape) and 
normalized to the summarized counts of one protein. Pull-downs were performed in replicates and averaged 
afterwards. The probability of specific binding is indicated in blue shades (from white = 0 to blue = 30). Correlation of 
CMV pull-down results with r = 0.84 to the repeated results of cmv-miR-US5-2 indicates high reproducibility of the pull-
down approach. (B) GO term analysis classifications with high p-values and cluster frequency. (C) Subcellular localization 
of identified proteins (classified with Uniprot database). (D) Distribution of RNA binding domains within the identified 
proteins. 
 
Preclearing samples as well as an additional pull-down with cmv-miR-5-2 served as controls. The 
cmv-miR-5-2 pull-down was used as positive control. The additional pull-down with a pre-miRNA 
of CMV was necessary to compare and correlate the small data set of the papilloma and polyoma 
virus pull-down with the CMV data set because a negative control of the pri/pre-miRNA is not 
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defined and hence was missing. Thus an additional pull-down with the cmv-miR-5-2 was 
performed together with the BKV, MCV and HPV41 pull-downs to compare the data sets and to 
obtain a marker for the reproducibility of the pull-down experiments. The correlation between 
the different cmv-miR-5-2 pull-downs of r = 0.84 suggests a significant overlap of both data sets 
(Figure 17 A).The heatmap depicts specific single hits for most of the annotated proteins like 
GRSF1, NOP14, Sync or PTBP1. 
GO term analysis links the found proteins to different RNA based regulatory functions (Figure 17 
B, also included in appendix Figure 42) and Uniprot analyses reveal that most of the proteins 
contain RNA binding domains and that they are located mainly within the nucleus (Figure 17 C). 
Taken together, the statistical analysis suggests the specifically identified RBPs as RNA associated 
proteins.  
 
2.1.4 pri-miRNAs sequence alignments with RBP consensus motifs 
 
RBPs interact with RNAs via RBDs that recognize and bind RNA sequence motifs. To identify such 
sequences, bioinformatical sequence alignments were performed using sequences of the different 
RBP interacting pri/pre-miRNAs. In Table 5 examples of sequence motifs are summarized.  
The proteins GRSF1 (G-rich sequence factors 1) and Pum2 (Pumilio homolog 2) contain RNA 
binding domains with a well-known consensus sequence. GRSF1 interacts with viral, cytoplasmic 
and mitochondrial ssRNAs within G-rich elements of the 5’UTR with a consensus motif of 
AGGGA/U/G (Antonicka et al. 2013; Jourdain et al. 2013; Noh et al. 2016; Ufer et al. 2008). MSAs 
were performed and analyzed according to the location of the consensus sequences. Within the 
pri-miRNAs (bkv-miR-B1, hsv-miR-H3, hsv1-miR-H6 and hsv1-miR7) bound to GRSF1 the MSA 
depicts several motifs highlighted in yellow within the sequence which may be conserved through 
pri/pre-miRNAs (Figure 18 A). The predicted binding sites are located in the double stranded stem 
and the single stranded loop of the hairpin structure (Figure 18 B, highlighted in yellow).This 
suggests that the known binding motif which is located within the ssRNA terminal loop is 
specifically recognized by RBDs within GRSF1. However, the sequence motif is also found in the 
stem of the hairpin and thus, specific binding has to be biochemically confirmed. 
Pum2 binds to a consensus motif with the sequence UGUA(N)AUA (Loedige et al. 2013). The MSA 
shows a perfectly conserved sequence within ebv-miR-3/4/10 (Figure 18 C, highlighted in yellow) 
and the location within the hairpins is exclusively in the loop region (Figure 18 D). This suggests 
that Pum2 interacts with the ssRNA region within the terminal loop that exhibits the binding motif. 
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For additional multiple sequence alignments and hairpin alignments of PURA, NOL11, PTBP1 and 
PLOD3 see appendix Figure 44. 
 
A  
  hsv1-miR-H3      CCGCGGGCGCGCUCCUGACCGCGGGUUCCGAGUUGGGCGUGGAGGUUACCUGGGACUG--  
  bkv-miR-B1       -------GGGAAUCUUCAGCA-------------GGGGCUGAA-G-UAUCUGAGACU---  
  hsv1-miR-H6      -------------------CG-------------GGGGGC---CGGAGGGUGGAAGGCAG  
  hsv1-miR-H7      ---------------GAAGAG-------------GGGGGAGAAAGGGGUCUGCAACCAAA  
                                                     ***       *     **  *      
 
  hsv1-miR-H3      -------------UGCGGUUGGGACGGCG----CCCGUGG----------------------------------- 
  bkv-miR-B1       -UGGGAAGAGCAUUGUGAUUGGGAUUCAGUGC-----UUGAUCCAUGUCCAGAGUCUUCAGUUUCUGAAUCCU-- 
  hsv1-miR-H6      GGGGGUGUAGGAUGGGUAUCAGGACUUCCACUUCCCGUCCUUCCAUCCCCCG----UUC----------CCCUCG 
  hsv1-miR-H7      GGUGGUCUGGGUCCGUCCUUUGGAUCCCGACCCCUC-UUCUUCCCU-----C----UUC----------UC----  
                                 *   *  ***             *                       
 
B  
bkv-miR-B1 
 
  aucuucag   gg       ua    a   u    aa        u   u  
 a        cag  gcugaag  ucug gac uggg  gagcauug gau g 
 |        |||  |||||||  |||| ||| ||||  |||||||| |||   
 u        guc  ugacuuc  agac cug accu  uucgugac uua g 
  ------aa   uu       ug    -   u    ag        -   g  
 
 
  hsv1-miR-H3  
       
           gc   ug      -      g  u   g g  
 ccgcgggcgc  ucc  accgcg gguucc ag ugg c u 
 ||||||||||  |||  |||||| |||||| || ||| | g 
 ggugcccgcg  agg  uggcgu ucaggg uc auu g g 
           gc   gu      g      -  c   g a       
 
  hsv1-miR-H6 
 
       -c   a          ca        u   --a  g  
cgggggg  cgg ggguggaagg  ggggggug agg   ug g 
|||||||  ||| ||||||||||  |||||||| |||   || u 
gcucccc  gcc ccuaccuucc  cccuucac uuc   ac a 
       uu   c          ug        c   agg  u 
 
 
  hsv1-miR-H7   
 
--             aa       u caa       -   uc  
  gaagaggggggag  agggguc g   ccaaagg ugg  u 
  |||||||||||||  ||||||| |   ||||||| |||  g 
  cuucucccuucuu  uccccag c   gguuucc gcc  g 
cu             -c       c cua       u   ug  
 
C  
  ebv-miR-BART10      -CAGAGG-AGUGUCCCGGG--GCCA---CCUCUUUGGUUCUGUACAUAUUUUGUUAU-UG 52 
  ebv-miR-BART3       CCUUUGGUGG--AACCUAGU---GU-UAGU-GUU-GU-GCUGUAAAUA------AGU--G 43 
  ebv-miR-BART4       --UUUGGUGG--GACCUGAU---GCU--GCUGGU-GU-GCUGUAAAUA------AGU--G 41 
                            * .*   ..* ..                *    ****.***       .   * 
 
D  
  ebv-miR-BART3  
          ga    a   -      u       uaaau  
 ccuuuggug  accu gug uuagug ugugcug     a 
 |||||||||  |||| ||| |||||| |||||||       
 ggaggccac  ugga cac gaucac acgcgac     a 
          ug    c   u      c       cugug  
 
  ebv-miR-BART4  
 u       g     a   -   -         --   aa  
  uuggugg accug ugc ugc uggugugcu  gua  u 
  ||||||| ||||| ||| ||| |||||||||  |||    
  gaccacu uggac acg aug acuacacga  cgu  a 
 g       g     c   g   c         uc   ga  
 
  ebv-miR-BART10  
    -      uc   g     c    u     c      uauu  
caga ggagug  ccg ggcca cucu ugguu uguaca    u 
|||| ||||||  ||| ||||| |||| ||||| ||||||    u 
gucu ccucac  ggu ucggu gagg accaa acaugu    g 
    a      gu   g     u    u     u      uauu  
 
 
Figure 18 Multiple sequence alignments (MSA) from pri-miRNAs interacting with one particular candidate. 
(A) MSA of pri-miRNA sequence of hsv1-miR-H3/-H4/-H7 and bkv-miR-B1 performed with Clustal Omega from EMBL-
ebi-tools. (B). Location of the consensus sequence within the pri-miRNA hairpins marked in yellow, sequence of mature 
miRNAs are highlighted in red. Complementary base pairing is illustrated with lines between the corresponding bases. 
Hairpin structures were taken from the miRBase database (C) MSA of the pri-miRNA sequence of ebv-miR-3/4/10 
performed with Clustal Omega from EMBL-ebi-tools. (D) Location of consensus sequence within the pri-miRNA hairpins 
marked with yellow, sequence of mature miRNAs are shown in red. Complementary base pairing is illustrated with lines 
between the corresponding bases. Hairpin structures were taken from the miRBase database. 
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Table 5   In silico characterization of pri/pre-miRNA binding candidates (with Uniprot, Genecard, NCBI CDD, EMBL InterPro/SMART 
and other references). 
 
protein  bound miRNAs    consensus seq.        RNA bin. domain  
 
GRSF1  hsv1-miR-H3/-H4/-H7   AGGGA/U/G  RRM   
  bkv-miR-B1         
PUM2  ebv-miR-3/4/10   UGUA(N)AUA  Pumilio rpts./PUM-HD  
PURA  hsv1-miR-H3   GGN   PUR   
  cmv-miR-70/148 
NOL11  cmv-miR-112   not known  WD-40 
  bkv-miR-B1 
PTBP1  hsv1-mir-H8   not known  RRM 
  cmv-miR-59 
  hpv41-miR-1 
PLOD3  hsv1-miR-H3/H6   not known  not known 
  cmv-miR-70 
 
 
 
2.1.5 Validation of specific pre-miRNA-RBP interactions 
 
The identified potential hairpin interacting proteins have to be validated, because methodical and 
technical performance may promote unspecific binding of false positives. As a first validation step, 
the DNA-sequence of a subset of candidates was amplified and cloned into human expression 
vectors with an N-terminal Flag/HA-tag. Proteins were transiently overexpressed in HEK 293T cells 
and the pri/pre-miRNA pull-down approach (as described in 2.1.3) was repeated and confirmed 
by western blotting using antibodies against the HA-Tag (Figure 19 A). Several candidates were 
tested for EBV, CMV and BKV/ HPV41 (Figure 19 B-D). For EBV, the candidates show a specific 
interaction to NOL8, TRIM25, PUM2 and c9orf114. In contrast, SK2L2 also bind to the control pull-
down with an unrelated pri/pre-miRNA. In case of CPSF5 and CPSF7, which exist as complex only 
CPSF5 shows weak bidning to the hairpin. 
The interaction validation for the papilloma and polyoma virus hairpins shows a specific and clear 
binding pattern for the selected candidates GRSF1, ARMX1, PTBP1 and Zincfinger 7b compared to 
the control pull-down (this experiments were partly done by my bachelor student Barbara Ritter; 
Figure 19 C). 
For cytomegalovirus, human as well as viral potential interactors were tested. The data depicted 
in Figure 19 D confirms specific binding of Rbfox2, UNG, SDOS and PTBP1. The viral Factors UNG, 
UL97, UL77 and PP65 show weak or unspecific binding in this experimental set-up (data not shown 
expect for UNG). Taken together many of the identified potential hairpin interacting candidates 
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seem to bind specifically to the exposed viral pri/pre-miRNAs. Others could not be validated as 
specific binders in this experimental set-up. 
 
 
Figure 19 Validation of the specific pri/pre-miRNA protein interactions. 
(A) Validation of the identified protein pri-miRNA interactions by repeating the pri-miRNA pull-down workflow with 
Flag/HA-tagged overexpressed constructs and detection by western blots. After preclearing of the lysate, pull-downs 
were performed with specific pri-miRNAs and on unrelated control. For overexpression, 5 to 15 µg of VP5-constructs 
were used per 15 cm2 dish. (B), (C), (D) Pull-down of Flag/HA-tagged potential interactors using different miRNA hairpins. 
5 % of the lysates were loaded as input. 
 
 
2.1.6 Influence of RBP candidates on viral miRNA processing 
 
To examine potential effects of the identified RBP candidates on processing of pri/pre-miRNAs, 
Flag/HA-candidate RBPs were overexpressed in HEK293T cells at different time points. As viral 
miRNAs are not present in HEK 293T cells, effects of overexpressed regulators may change the 
levels of the different miRNA processing species (Figure 20 A - D).  
These effects can be caused by inhibition or activation of Drosha or Dicer cleavage by a specific 
interaction of the RBP with the hairpin that could block or stabilize the recruitment of the 
processing complexes. Western blotting using specific antibodies against the HA-tag controlled 
overexpression of proteins. Cells were harvested 15 or 30 hours after transfection and changes of 
 
45 Results 
mature and pre-miRNA levels were detected using northern blotting probes against the mature 
miRNAs. Signals were quantified using a Phosphoimager (PMI) and normalized to the U6 loading 
control. The candidate Nol8 was validated as specific interactor of ebv-pri/pre-miR-BART5 (Figure 
19 B). In Figure 20 A and B the signal intensities of the ebv-pre-miRNA-BART5 are decreased 
compared to the samples without Nol8 overexpression at both time points. Although the 
overexpression of Nol8 slightly decreases the level of pre-miRNAs, the mature miRNA levels of the 
ebv-miR-BART5 seem to be unaffected at both time points represented by an equal signal intensity 
(Figure 20 A and B). This suggests that Nol8 may block processing of ebv-miR-BART5. 
 
Figure 20 Influence of potential regulators on miRNA levels. 
(A) Schematic overviews of myc-Drosha-IP. (B) Overexpression was performed with standard CaPi-transfection using 5 
µg of plasmid for proteins and 10 µg of plasmid for miRNA in HEK293T cells. 5 % of lysate was taken as input control. IP 
was performed with 50 µl Protein Sepharose G beads coupled with 3 µg of myc antibody. The whole IP was loaded onto 
a 10 % SDS-PA-gel. (C), (D) For overexpression of proteins and miRNAs, HEK 293T cells were transfected using CaPi 
method. Protein overexpression was controlled by western blot using HA-antibody. 20 µg of total RNA was loaded for 
standard northern blotting. Signal quantification was performed using PMI software and normalized to U6 loading 
control levels. 
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The RBP Rbfox2 inhibits microprocessor processing by interacting with the terminal loop of 
different pri-miRNAs and reduces Dicer levels by downregulation of miR-20b and miR-107 (Yu 
Chen et al. 2016). The suggested consensus sequence GCAUG is also present in the terminal loop 
of cmv-miR-US22 (data not shown). Rbfox2 specifically interacts with the cmv-miR-US22 (Figure 
19 C) and may also influence viral miRNA processing steps. The signal intensities of both, the 
overexpressed mature miRNA and overexpressed pre-miRNA of cmv-miR-US22 are clearly 
reduced compared to the control with normal expression of Rbfox2 (Figure 20 C and D).  
This suggests that Rbfox2 inhibits miRNA processing by blocking of microprocessor processing of 
cmv-miR-US22.  
 
 
Figure 21 Influence of potential regulators on miRNA levels. 
(A), (C) HEK293T K.O. cell lines were produced using the CRISPR/Cas9 method. Cells were cultured in 6-wells and 
transfected with 0.5 µg of each miRNA expression and control plasmid with unrelated miRNA cmv-miR-US5-2. For 
northern blotting, 20 µg of total RNA was loaded and separated on a 12 % PA-gel. For detection of miRNAs and pre-
miRNAs, complementary DNA probes were used. (B), (D) Signals were quantified using PMI software and normalized to 
both U6 loading control and the unrelated transfection control. 
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In addition, GRSF1 and Rbfox2 HEK293T K.O. cell lines (produced by Dr. Thomas Treiber and Dr. 
Nora Treiber, partly published in Treiber et al. 2017) were transfected with miRNA expression 
vectors to further analyze the effects on miRNA biogenesis. Unrelated miRNAs were co-expressed 
as transfection control (Figure 21 A - D). For quantification, data was normalized to the U6 loading 
control and to the transfection control. Northern blots in Figure 25 A and B depict higher signal 
intensities for mature miRNAs in the K.O. cells and further much stronger levels of pre-miRNAs. 
The ratios of miRNAs to pre-miRNAs in Figure 25 B suggest that the efficiency of processing is low. 
Thus, the cytoplasmic GRSF1 isoform may bind to the hairpin loop and influence pre-miRNA 
cleavage. This suggests that GRSF1 is promoting the miRNA processing of the bkv-miR-B1. 
Rbfox2 K.O. clearly leads to higher pre-miRNAs levels and to a very slight increase of the mature 
miRNA when compared to WT control (Figure 25 C and D). This result suggests that Rbfox is a 
negative regulator of miRNA biogenesis of the cmv-miR-US22. 
Taken together, a few examples were presented in this chapter where RBPs influence viral miRNA 
processing.  
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2.2 Part II: Post-translational modifications of TNRC6 
proteins 
 
2.2.1 Aims of part II  
 
As described in the introduction the importance and the functional principles behind gene 
silencing are reasonable well understood and our knowledge about miRNA-guided gene 
regulation during embryonic development, homeostasis and disease is increasing every day. 
However, less is known about post-translational modifications of the RISC complexes and dynamic 
signalling pathways.  
The aim of this part of the thesis was to establish a strategy to analyze protein modifications of 
TNRC6 proteins and to functionally characterize these potential modifications.  
 
Brief overview of planned workflow: 
1. Specific antibodies against TNRC6 proteins will be established and functionally 
characterized 
2. Purification strategies for TNRC6 and Ago will be optimized 
3. Mass spectrometric analysis of modifications of TNRC6 and Ago complexes  
4. Functional validation and characterization of TNRC6 phosphorylation sites  
 
2.2.2 Purification and characterization of TNRC6 containing 
complexes 
 
2.2.2.1 Characterization of monoclonal antibodies against TNRC6 proteins  
 
For the production of monoclonal antibodies against TNRC6 proteins, several different 
overexpressed fragments of TNRC6A-C, such as the RRMs or the C-terminal parts of the three 
paralogs were used to immunize rats and mice (listed in material and methods, Table 14). 
Immunization was performed by the group of Dr. med. Elisabeth Kremmer and Dr. Regina Feederle 
in the monoclonal antibody core facility (MAB) at the Helmholtz center in Munich. Monoclonal 
antibody hybridoma supernatants were received from our collaborators and tested in western 
blotting, immunopurification and partly in immunofluorescence experiments. Antibody screening 
was performed with input samples of HEK 293T cell lysates and overexpressed Flag/HA-TNRC6A-
C proteins that served as positive control. Gel-separated proteins were blotted on nitrocellulose 
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membranes and incubated with the appropriate TNRC6A-C antibodies. Detected signals were 
confirmed as TNRC6 proteins with HA-antibody against the tag. Positive candidates were further 
analyzed regarding their subtype specificity (IgG1, IgG2a, IgG2b, IgG2c with secondary antibodies 
linked to HRP; data not shown) and were afterwards purified in a large scale set-up from Robert 
Hett (colleague in the lab).  
Enrichment of TNRC6 proteins was further tested by using lysates from different human cell lines 
(data shown for HEK293T and Hela cells only) for immunoprecipitation with the antibodies 6G3, 
7A9 and 11C12. Therefore, monoclonal antibodies were coupled to Protein Sepharose G beads, 
incubated with HEK 293T/ HeLa cell lysates, washed and loaded onto a 6 % SDS-PA-gel and 
detected per western blotting with the same antibodies used for IP (Figure 22 A). Monoclonal 
antibodies were further characterized for their specificity in knockdown experiments (performed 
by Daniel Schraivogel and partly published in Schraivogel et al., 2015).  
 
 
Figure 22 Characterization of monoclonal antibodies against TNRC6 proteins. 
(A) Monoclonal antibodies were coupled to Protein Sepharose G beads and incubated with HEK293T and HeLa cell 
lysates. The proteins were detected with the same antibody that was used for immunoprecipitation. (B) For further 
characterization of the antibodies, knockdown assays with siPools against endogenous TNRC6A-C showed particular 
specificity for the proteins compared to control and non-transfected (n.t.) samples. (C) The association of Ago and 
endogenous GW proteins is disrupted by the GW peptide. Co-immunoprecipitations of Ago2 and TNRC6B were 
conducted either in presence or absence of an excess amount of the GW peptide, showing high specificity of the TNRC6B 
antibody.  
 
To confirm antibody specificity, differential knockdowns of TNRC6 proteins using siPools were 
performed and detected by western blotting. The reductions of endogenous protein levels 
illustrate specific antibody detection because in knockdown samples signals should be decreased 
and unspecific detection would remain. Figure 22 B shows that the monoclonal antibody 6G3 is 
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specific for TNRC6B. In case of the 6G3 antibody, co-immunoprecipitations of Ago2 and TNRC6B 
were conducted either in the presence or absence of a recombinantly produced TNRC6 peptide 
that competes for Ago1-4 binding (Figure 22 C, performed and published in Hauptmann et al. 
2015). Both experiments also show that TNRC6 proteins are stable in input samples but seem to 
get degraded quickly in immunoprecipitation experiments which might be generally problematic 
for biochemical investigations. Antibody tests and selectivity are summarized in Table 6. To 
optimize the purification process of TNRC6-Ago complexes, the antibodies were purified 
(performed by Robert Hett, see in 4.2.4.2). 
 
Table 6   Antibody specificity (confirmed by MS analysis). 
 
antibody  specificity   method   
 
C RRM 4D7  TNRC6 A,B,C  WB, IP 
B RRM 6G3  TNRC6 B  WB, IP, IF 
C RRM 7A9  TNRC6 A,B,C  WB, IP, IF 
RRM 7C5  TNRC6 A,B,C  WB, IP 
B RRM 10B1  TNRC6 B  WB, IP 
TC6 C 11C12  TNRC6 A,B, C (mainly C) WB, IP 
 
Figure 23 A illustrates that TNRC6 co-IPs performed with purified antibodies show reduced 
background levels, higher sample purity as well as distinct and clear bands for TNRC6 as well as 
Ago1-4 proteins compared to co-IPs with non-purified hybridoma supernatants. The 
immunoprecipitated TNRC6 and Ago1-4 proteins were analyzed by mass spectrometry. The 
obtained MS data analysis assigns the indicated coomassie bands to the respectiveTNRC6 proteins 
and emphasizes the selectivity of the used antibody 7A9 for all three TNRC6 proteins with high 
probability scores and sequence coverages especially when the purified antibodies were used 
(Figure 23 A and B). Besides immunoprecipitation of endogenous TNRC6A-C, the newly 
established antibodies are capable of co-immunoprecipitating endogenous human Ago1-4 at high 
purity. This allows continuative experiments such as MS-based phospho-analysis. 
Following large-scale purifications from HEK 293T cell lysates with around 100 mg of total protein 
were performed to enrich enough endogenous TNRC6 proteins for a detailed phospho-proteomic 
analysis. Therefore immunopurifications with the ABs 6G3, 7A9 and 11C12 were conducted and 
coomassie-stained SDS-PA-gels confirm a high antibody selectivity for TNRC6 proteins and large 
amounts of purified endogenous proteins (Figure 23 C in the upper part of the gel). Additionally 
to Ago proteins, Pabpc1 which is interacting with TNRC6 and is associated with the target mRNA 
was enriched and identified by mass spectrometry (listed in appendix 5.1.4 Table 18).  
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Figure 23 Further functional characterization of the TNRC6 
antibodies. 
(A) Different monoclonal antibodies against TNRC6 proteins were 
coupled to Protein G Sepharose beads and incubated with 
HEK293T cell lysates. To increase sample purity, the antibodies 
were purified by affinity and size exclusion chromatography. The 
immunoprecipitated TNRC6 and Ago1-4 proteins were identified 
and analyzed by mass spectrometry.  For further characterization 
of the tested antibodies TNRC6A-C and Ago1-4 were identified by 
mass spectrometry. The (co)-immunoprecipitated proteins were 
cut from a coomassie-stained gel and subjected to in-gel tryptic 
digest. (B) The MS data analysis shows a selectivity of the used 
antibody to all TNRC6 paralogs with high scores and sequence 
coverages. The possibility to co-precipitate all human Ago 
proteins will facilitate the analysis of post-translational 
modifications of TNRC6-interacting Ago proteins. (C) Comparison 
of co-IPs with (D) antibody specificity analyzed by western blot 
detection of TNRC6A-C co-IPs illustrates higher selectivity of the 
11C12 AB against TNRC6C. (E) The MS data analysis of a TNRC6A-C 7A9 co-IP indicates selectivity of the used antibody 
for all three TNRC6 proteins with high scores and sequence coverages. The data was obtained after division of the SDS-
gel in an upper and lower part. (F) Confirmation of complex integrity by qRT-PCR. The target p27 was tested upon 
binding to Ago2 enriched in RNA-IP experiments with 7A9 vs. 11A9 antibody from HEK 293T cells. RNA from each IP was 
extracted, cDNA was synthesized and mRNA enrichment was measured by qRT-PCR. Relative enrichment of the target 
mRNA p27 was normalized to GAPDH. Experiment was performed in three technical replicates. 
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Enrichment of TNRC6 and Ago proteins was confirmed by specific signals in western blots using 
10 % of the second elution of the IPs (Figure 23 D). Due to methodical limitations the part of the 
SDS-PA-gels which contain TNRC6 proteins were excised as a lower and upper part. Interestingly, 
this approach leads to the qualitative separation of the TNRC6 paralogs. According to sequence 
coverage and specifically identified peptides, TNRC6A and B are enriched in the upper part while 
TNRC6C is more located in the lower part (Figure 23 E). This qualitative observation is supported 
by protein size as well as by small differences that can be observed within the western blots and 
the coomassie-stained gels. Figure 23 D shows the western blot signal for TNRC6 in the lane of the 
11C12 co-IP that appears after incubation with 11C12 antibody. This suggests a certain selectivity 
of 11C12 for TNRC6C. However, this assumption remains speculative and has to be additionally 
validated by other experiments. TNRC6/Ago complexes associate with target mRNAs. To test 
whether the established antibodies immunoprecipitate such complexes or interrupt mRNA 
interactions, qRT-PCRs were performed on a target. Therefore, RNA-IPs with Ago2 11A9 antibody 
and TNRC6 7A9 antibody were performed and mRNA enrichment of the p27 mRNA target was 
confirmed by qRT-PCR (Figure 23 F). 
 
 
Figure 24 Further analysis and optimization of immunopurifications. 
(A) Comparison of co-IP efficencies of 7A9, 11A9 and cov. coupled 7A9 with/without RNase A treatment of HEK-lysates 
in a coomassie-scaled manner. (B) Western blot was performed with 5 % of the first elution of the IPs as control.  
 
To achieve higher sample purity and larger amounts of enriched TNRC6-Ago complexes for 
phospho-proteomic analysis, IP conditions were optimized by testing different lysis and elution 
conditions (Figure 23 A, B). In the left part of Figure 23 A RNase A was added during cell lysis and 
afterwards TNRC6 and Ago IPs were performed. The treatment resulted an enrichment of 
TNRC6A-C and Ago1-4 in both IPs. This result was additionally confirmed by western blotting 
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(Figure 23 B). This suggests that RNA degradation by RNase A results in a better accessibility to 
TNRC6-Ago complexes.  
Furthermore, antibodies were covalently coupled to the beads and cell lysates were applied. To 
reduce unspecific background within the SDS-gels, a selective elution of the antibody bound 
proteins was performed with glycine adjusted to pH=2.5 (right part in Figure 23 A). The lanes with 
reduced background were excised and analyzed with mass-spectrometry. The analysis identified 
many known interactors of the whole gene silencing pathway (protein list in appendix Table 18). 
Taken together, TNRC6 specific antibodies were established and the characterization underlined 
the power of our antibodies as useful tool for further phospho-proteomic analysis 
 
2.2.2.2 Immunopurification of TNRC6-Ago complexes from mouse tissues 
 
The TNRC6 antibodies are a useful tool to enrich TNRC6-Ago complexes in human cell lines. To 
widen their usage applicability the antibodies were tested for cross reactivity with TNRC6 proteins 
in other species. 
 
Figure 25 Purification of murine TNRC6-Ago complexes. 
(A) Western blot detection of mmAgo2 and TNRC6A-C IPs performed with mmAgo2 6F4 and TNRC6A-C 7A9 antibodies. 
5% of input was loaded and RMC-IP served as IgG control. (B) Coomassie-stained 10% SDS-gels loaded with 
immunoprecipitated 7A9-IPs from N2A mouse brain cells and CMT93 spleen cells. (C) Immunopurified murine TNRC6 
and Ago1-4 from different mouse tissues. IP from N2A lysates served as positive control. 
 
TNRC6 proteins were first aligned in multiple sequence alignments (MSA). The results show a 
relatively weak conservation among the human paralogs (around 0,4-0,45; listed in the appendix 
Figure 44), but a very strong conservation between species (mmTNRC6A : hsTNRC6A =0.9473; 
mmTNRC6B : hsTNRC6B =0.9644; mmTNRC6C : hsTNRC6A =0.9138; listed in the appendix Figure 
44). 
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To test specificity of TNRC6 antibodies for the mouse homologs, IPs were performed with cell 
lysates from N2A nervous mouse cells where Ago1-4 and TNRC6 proteins are highly expressed and 
detected by western blotting. For comparison, an IP with the mmAgo2 specific antibody 6F4 
(Frohn et al. 2012) and an IgG control with the unrelated RMC antibody were performed. This 
illustrated that the 7A9 antibody can enrich Ago as well as the 6F4 with an even better enrichment 
rate of TNRC6 proteins (Figure 25 A). Continuous coomassie-scaled purifications with 7A9-IPs from 
N2A and CMT93 cells were conducted (Figure 25 B). Furthermore, endogenous TNRC6 and Ago1-
4 was purified from different mouse tissues (Figure 25 C). Both coomassie-scaled purifications 
indicate that mouse TNRC6 proteins are immunoprecipitated with high quantity and selectivity by 
the monoclonal TNRC6 antibodies. 
The purification was then used for quantification studies of endogenous TNRC6 expression levels 
(see chapter 2.2.3.2) and phospho-proteomic analysis (see chapter2.2.3.2).  
 
 
2.2.2.3 Quantification of TNRC6 expression levels in cells and mouse tissues 
 
The TNRC6 antibodies can enrich human and mouse TNRC6-Ago complexes. To further 
characterize the antibody specificity, a detailed analysis for the preference of different TNRC6 
paralogs for Ago interaction was performed. Most of the studies analyzing TNRC6 proteins are 
based on qualitative mass-spectrometry or qRT-PCR data sets. Thus the protein expression levels 
and paralog distribution remains speculative. For a complete understanding of the functionality 
of the produced and purified monoclonal antibodies, selected-reaction-monitoring (SRM) 
measurements were executed from different IPs as well as from input samples to examine 
endogenous paralog distribution. The SRM method is used for peptide quantification, therefore 
defined amounts of a stable isotope-labeled peptide is spiked into the sample before tryptic 
digestion. The synthetic and the peptide of interest will be detected at the same time and can still 
be distinguished by their isotopic mass difference. Unique peptides were selected for every 
human and mouse TNRC6 paralog and used for SRM analysis (location within the proteins 
depicted in Figure 26 A).  
To assess the specificity of the antibodies, first the general distribution of TNRC6 paralogs was 
measured in HEK 293T cell lysates. Figure 26 B depicts the averaged distribution of the paralogs. 
Here, TNRC6A is the highest expressed with about 45 %, followed by TNRC6B with 30 % and 
TNRC6C with 25 %. For determination of the AB specificity, IPs with monoclonal TNRC6 and Ago 
antibodies were performed and analyzed with SRM. In Figure 26 C the quantification indicates 
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that the antibody 6G3 exclusively enriches TNRC6B. The monoclonal antibody 7A9 enriched 
TNRC6 B with 50 %, TNRC6A with 35 % and TNRC6C with 15 %. This suggests that the 7A9 enriches 
all three paralogs with a weak preference for TNRC6B compared to the inputs. The antibody 11C12 
enriched in IPs with N2A cell lysates all TNRC6 paralogs with a preference for TNRC6C with 50 % 
(Figure 26 left side). This results suggests the antibodies to enrich TNRC6 proteins with certain 
preferences for different paralogs. 
 
Figure 26 Quantiﬁcation of TNRC6A-C and Ago1–4 levels. 
(A) Schematic representation of unique SRM peptide localization within TNRC6 proteins. (B) Quantitative analysis by 
SRM measurements with stable isotope-labeled peptides of endogenous TNRC6A-C proteins from 50 and 100 µg 
HEK293T cell lysate. The relative amount of one TNRC6 paralogue related to the total TNRC6 pool is shown. Error bars 
represent the standard deviation of identical samples that were quantiﬁed with at least two different paralogue-speciﬁc 
peptides. (C) Enrichment and distribution of TNRC6 proteins by immunoprecipitation with different TNRC6- and Ago-
specific antibodies.  
 
The expression profile for TNRC6 proteins in different cell lines and mousse tissues is completely 
unknown.  
To get a first insight, transcript levels of TNRC6 were assessed by qRT-PCRs. To analyze the 
different human TNRC6 paralogs, cDNA from different cell lines was used. In general, qRT-PCR 
results indicate that the amount of TNRC6B and TNRC6A transcripts is relative high and distributed 
similar between 40-50 %, with a 5-15 % higher expression of TNRC6A compared toTNRC6B, while 
TNRC6C possesses the lowest expression of about 5-10 % (Figure 27 A). In HEK 293T cells the 
expression of TNRC6B is up to 60 % and thus higher than TNRC6A and C. However, the analysis of 
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transcript levels just allows assumptions on the endogenous expressed proteins, because 
differential regulation on TNRC6 mRNAs levels can occur (Olejniczak et al. 2016). 
Due to the small differences between the paralog transcript distributions detected by qRT-PCR, 
the TNRC6 expression profiles of different mouse tissues were analyzed with SRM measurements 
of 7A9-co-IPs. 
 
Figure 27 Transcript levels of TNRC6A-C measured 
by qRT-PCR in different cell lines. 
RNA from each cell line was extracted, cDNA was 
synthesized and mRNA enrichment was measured 
by qRT-PCR. Relative enrichment of the different 
TNRC6 proteins was normalized to GAPDH. The 
experiment was performed in three technical 
replicates. 
 
 
Purified TNRC6-Ago complexes from mouse tissues with 7A9-IPs (Figure 28) show a strong 
enrichment of TNRC6B in brain, heart, liver, kidney (comparable to HEK293T) and lung. 
Unfortunately inputs could not be measured because SRM measurements are technically limited 
and need certain protein amounts for significant measurements. In spleen and testis the TNRC6C 
signal is about 50 % higher compared to the other paralogs. Surprisingly, TNRC6A is expressed to 
a level up to 15 % in all mouse tissue samples compared to the other paralogs and the data 
obtained from HEK 293T lysates (Figure 26 B). This suggests that TNRC6 protein expression 
probably is tissue specific and might be regulated at the transcript level.  
 
Figure 28 Quantiﬁcation of 
TNRC6A-C levels in murine 
tissues. 
Endogenous TNRC6 proteins 
were puriﬁed from different 
murine tissues using a 7A9-
TNRC6-IPs and quantified 
via SRM approach. 
 
 
 
 
 
TNRC6 proteins seem to have particular distributions in different cell lines and tissues. As these 
proteins function redundantly and Ago proteins also have distinct expression distributions, 
interaction preferences of Ago and TNRC6 proteins may be possible. To study the distribution of 
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Ago bound to TNRC6 proteins, 6G3- and 7A9-co-IPs were performed and analyzed by SRM. In  
Figure 29 both immunoprecipitations seem to enrich a similar distribution profile of Ago1-4. 
Compared to Ago-APP and inputs (Hauptmann et al., 2015) the distribution of Ago proteins in the 
two TNRC6-IPs is not significantly different (Ago2 0.6 - 0.7 > Ago1 0.2 - 0.3 >= Ago3 0.2 > Ago4 
0.01). Ago1- and Ago2-co-IPs were performed to examine the distribution of interacting TNRC6 
(Figure 26 C, left part of the graph). Both IPs show a similar distribution of co-immunprecipitated 
TNRC6 paralogs. This suggests that the usage of the ABs produces no preferences during complex 
purification.  
Taken together, the quantification of the input and the IPs suggests that the monoclonal 
antibodies enrich TNRC6 with weak preferences. The 7A9 antibody enriches all three paralogs with 
a light preference for TNRC6B. The 6G3 antibody exclusively recognizes TNRC6B and the 11C12 
antibody has a higher preference for TNRC6C. TNRC6 distribution profiling in mouse tissues 
resulted in tissue specific expression profiles of the different paralogs. The TNRC6 and also Ago 
proteins seem to interact with each other without preferences. Thus, it is suggested that the 
interaction profile depends on the differential cell line and tissue specific expression of the TNRC6 
and Ago proteins. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 29 Quantiﬁcation of co-immunoprecipitated 
Ago proteins 
Ago1-4 protein levels were quantified from a 6G3-
TNRC6B-and a 7A9-TNRC6A-C co-IP and analyzed by 
SRM.  
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2.2.3 Phosphorylation of mammalian TNRC6 proteins 
 
2.2.3.1 Detection of endogenous phosphorylation sites of human TNRC6 
 
Proteins are often regulated by post-translational modifications such as phosphorylation. To 
assess whether TNRC6 proteins are phosphorylated, endogenous TNRC6-Ago complexes were 
enriched using specific antibodies, separated on a SDS-PA-gel. The excised protein bands were 
digested and the peptides were eluted for mass spectrometric detection. Additionally, TNRC6-
phospho-peptides were enriched with the TiO2 FASP method where the TiO2 column matrix 
selectively interacts with phospho-peptides. After washing, the bound phospho-peptides are 
eluted and analyzed by MS (performed by Dr. Astrid Bruckmann) (workflow schematically 
depicted in Figure 30 A). For statistical significance, data was obtained from technical as well as 
biological replicates. Only stable detected and overlapping phospho-sites within the technical 
(Figure 30 B) and the biological (Figure 30 C) replicates were considered in the analysis. 
 
 
D Figure 30  Mass spectrometric detection of potential 
phosphorylation sites in endogenous TNRC6A-C proteins. 
(A) Schematic overview of the mass spectrometric workflow. 
(B) Grey bars represent the different TNRC6 paralogs, 
phosphorylation sites of technical replicates are indicated in 
red. Venn diagrams depict overlapping phosphorylation sites 
of technical replicates. (C) Venn diagrams depict overlapping 
phosphorylation sites of biological human replicates. 
Diagrams were conducted with the browser based software 
Biovenn. (D) Summarized phospho-sites of biological 
replicates. Selected phospho-sites are found in at least two 
replicates. Red: conserved among all paralogs; Green: 
conserved among two paralogs. 
 
 
hsTNRC6A  hsTNRC6B  hsTNRC6C 
  
S[739]  S[385]  S[465] 
S[771]  T[480]  S[568] 
S[943]  S[879]  S[714] 
S[991]  S[1336]  T[777]   
S[1217]  S[1432]  S[1011] 
S[1585]  S[1461]  S[1016]   
S[1599]  S[1512]  S[1674]   
S[1704]  T[1517]   
  S[1816]   
  S[1832]    
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In Figure 30 B the technical replicates (TNRC6_TR1-3) for MS measurements of TNRC6A 
represented as grey bar and detected phospho-sites as red bars are shown at the relative position 
within TNRC6A. The overlapping phospho-sites of all three technical replicates (TNRC6_TR1-3) 
were combined as one biological replicate as illustrated in the Venn diagram (Figure 30 B). 
 
 
Figure 31 Mass spectrometric detection of potential phosphorylation sites in endogenous TNRC6A-C proteins. 
(A), (B), (C) Overview of potential phosphorylation sites according to their individual localization within the TNRC6 
paralogs. Grey bars represent TNRC6 proteins, red bars represent potential phosphorylation sites and black lines 
between the phospho-sites indicate conservation. Hs: Homo sapiens. Schematic TNRC6 illustrations are described in the 
chapter 1.2.1.1. (D) Schematic illustration of the location of phospho-sites conserved between the different paralogs.  
 
Different biological replicates of one TNRC6 paralog were combined and were assumed as existing 
sites when two out of three replicates were overlapping (depicted in Venn diagrams for all 
paralogs, Figure 30 C). The phospho-sites are summarized in the table shown in Figure 30 D. The 
sites marked in red are present in the three paralogs; the green sites are found only in two 
paralogs. Phospho-sites, which fulfill parts of the criteria are listed in the appendix Table 17. 
Finally, the phospho-sites are schematically illustrated at the position within the protein domain 
structure in Figure 31 D. The sites are in a first view randomly distributed within the different 
paralogs. It is likely that this is just an excerpt of the whole phospho-pattern and further analysis 
may increase the number of stable measured sites within the TNRC6 proteins. 
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Some of the identified sites are located in the Ago binding domain but not at an obviously 
important position. Only in case of TNRC6A the S739 is located next to the decisive tryptophans 
for Ago interaction. This site is also conserved in TNRC6C but was not identified in our analysis 
(marked lines between the paralogs illustrate conserved sites; Figure 31 D). The TNRC6A S1217 
(and a weak S1212) is directly located at the well-characterized nuclear export signal (NES). The 
sites located in the silencing domain are conserved in TNRC6B but far away from any particular 
domain (Figure 30 D). Since the current model suggests that TNRC6A-C may execute the same 
function, it may be expected that they exhibit a similar phosphorylation pattern. 
Surprisingly, only one site is conserved among all three paralogs (marked in red in Figure 30 D) 
which is located at a functional undefined part of the proteins next to a proline-rich region. For 
TNRC6B and TNRC6C phospho-site position can be classified analogous to TNRC6A. 
 
2.2.3.2 Detection of endogenous phosphorylation sites of TNRC6 in mice 
 
To study whether the phosphorylation sites identified in human cells are conserved in mouse, the 
TNRC6 enrichment was also performed from mouse cell lysates and mouse tissues (as described 
in Figure 25). The obtained mass spectrometric data from 7A9-IPs of murine CMT93, N2A and 
partly from the mouse tissues were taken together and analyzed in the same way as described 
above using similar replicative and statistical criterias. This resulted in a high confidence set of 
mouse TNRC6 phospho-sites that were identified and selected (analogous to Figure 31 A-D, 
depicted in appendix Figure 46 A-E). The overlapping sites of both data-sets are summarized in 
Table 7 and Figure 32. 
 
Table 7   Comparison of human and murine phospho-sites (red: conserved among all paralogs, green conserved among two paralogs, 
grey conserved amino acid not measured). 
 
hsTNRC6A vs. mmTNRC6A hsTNRC6B vs. mmTNRC6B hsTNRC6C vs. mmTNRC6C  
 
S[739]  S[724]  S[385]  S[421]  S[465]  S[465] 
S[771]    T[480]  S[912]  S[568]  S[568]  
S[943]    S[879]  S[1044]  S[714]  S[714] 
S[991]  S[976]  S[1336]  S[1312]  T[777]  T[776] 
S[1217]  S[1202]  S[1432]  S[1408]  S[1011]  S[1006] 
S[1585]  S[1520]  S[1461]  S[1437]  T[1016]   
S[1599]  S[1534]  S[1512]  S[1314]  T[1674]  T[1674], T[1678] 
S[1704]  S[1639]  T[1517]  S[1488]    S[1358] 
S[1582]  S[1520]  S[1816]  S[1792]     
  S[1540]  S[1832]  S[1808]     
      S[1191]     
      S[90]     
      S[95]     
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In general, the conservation of phospho-sites between mouse and human is very high since 
residues are conserved. Although many conserved Ss, Ts, Ys may not be measured due to technical 
issues. The phospho-pattern between the two species is very similar and there are also similarities 
between the paralogs. These conserved patterns indicate a conserved role or function of the 
phosphorylated sites in mouse and human.  
 
 
 
 
 
Figure 32 Mass spectrometric detection of potential phosphorylation sites in endogenous TNRC6A-C proteins. 
(A) Venn diagrams depict overlapping phosphorylation sites of biological human replicates. Diagrams were conducted 
with the browser based software Biovenn. (B) Overview of potential overlapping phosphorylation sites of 
immunoprecipitated TNRC6 proteins. Human and murine TNRC6A-C is pairwise indicated in grey bars. Unique and 
conserved phosphorylation sites are indicated in red. Black lines indicate conserved phospho-sites among the three 
human and three murine TNRC6 paralogs. All measurements were conducted in replicates on a MAXIS 4G mass 
spectrometer. 
 
 
2.2.3.3 Detection of endogenous phosphorylation sites of nuclear TNRC6  
 
In prior phosphorylation MS measurements, whole cell lysates were used for immunoprecipitation 
of TNRC6 proteins (Figure 24 and Figure 25). Unfortunately, differences between the cytoplasmic 
TNRC6 and Ago proteins and the postulated nuclear versions could not be distinguished in these 
measurements. To address potential differences, TNRC6A alanine mutants (received from Daniel 
Schraivogel) within the nuclear localization signal (∆NLS) and the nuclear export signal (∆NES) 
were used for further analysis of nuclear TNRC6 proteins (Figure 33 A). These mutants have been 
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shown to localize exclusively in the nucleus or the cytoplasm according to their respective 
mutation.  
The NLS/NES of TNRC6B and TNRC6C are less well defined and therefore, only TNRC6A was in the 
focus of interest. First, nuclear/cytoplasmic fractionations were performed from stable and 
inducible HEK 293T Flp/in Trex TNRC6A ∆NLS, ∆NES and HEK 293T cells. Input samples were 
analyzed by western blotting. The western blot signals depict relatively pure biochemical 
fractionations, as evident from the analysis of the nuclear marker Lamin A/C and the cytoplasmic 
marker α-Tubulin (protocol adapted from Gagnon et al. 2014; detailed description in 4.2.4.1.2,  
Figure 33 B). Theoretically, the ∆NES-mutant should enrich in the nucleus after induction and the 
∆NLS mutant should be restricted to the cytoplasm (Schraivogel et al. 2015). Both assumptions 
could not be clearly confirmed in this analysis, although the controls suggest only limited cross 
contamination of the extracts. In the following parts, the ∆NLS mutant was not further analyzed 
because the cytoplasmic TNRC6 was already analyzed without overexpression (Figure 33 B). 
The Quantification of the IPs from the fractionated lysates yield similar results compared to the 
cytoplasmic distribution (as already described in Figure 26 E; Figure 33 C). Coomassie - scaled 
purifications after fractionation lead to a decrease in protein enrichment with 7A9 and myc-IPs, 
because protein amount was sufficient for quantification, but insufficient for phospho-analyses. 
This was caused by a nearly complete loss of nuclear proteins during washing steps (Figure 33 D). 
To solve this problem, a fast fractionation with a higher amount of cytoplasmic cross-
contamination was established and afterwards myc-IPs from this lysates massively enriched the 
overexpressed TNRC6A-∆NES mutant and WT (Figure 33 E). Then gel bands were excised and 
prepared for MS phospho-analysis. The table in Figure 33 F shows high confidence phospho-sites 
exclusively found within the ∆NES mutants. Within these phospho-sites, the S1212 and the S1217 
(also weakly observed in other measurements) were directly located next to the NES amino acid 
signal (Figure 33 G). 
This suggests a potential function in the regulation of nuclear/cytoplasmic transport. 
Furthermore, T644 was the dominant phospho-site, altough its position is located in the Ago 
binding domain at a position with no particular/ unknown function. Additionally, the promising 
phospho-site positions are conserved among mouse and rat and the phospho-sites S1212 and 
S1217 were also detected weakly in measurements with mouse cells (Figure 33 H).  
The analysis of nuclear TNRC6 reveals phosphorylation sites that seem to be specific for nuclear 
enriched TNRC6. 
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Figure 33 Detection of phosphorylation sites of nuclear TNRC6 WT, ∆NLS- and ∆NES-mutants. 
(A) Amino acid sequence of TNRC6A WT, NLS-, NES-mutant and the alanine deletion mutants (as described in Schraivogel 
et al. 2015 and Nishi et al. 2013). (B) Fractionation of HEK293T, TREX-FLP/IN HEK TNRC6A WT and TREX-FLP/IN HEK 
TNRC6A ∆NES cells. Similar amounts of nuclear and cytoplasmic extracts were loaded and detected by western blotting. 
Fractionations were performed in an adapted version of Gagnon et al. 2014. Tubulin and Lamin A/C served as marker 
for lysate purity. (C) Quantification of immunopurified TNRC6 levels from nuclear and cytoplasmic lysates. (D) 
Immunopurification of overexpressed and endogenous TNRC6 and Ago proteins after nuclear/cytoplasmic 
fractionation. Proteins were separated on a 10 % SDS-PA-gel and coomassie-stained. (E) Enrichment of overexpressed 
and endogenous TNRC6 from HEK 293T cell lysates and preparation for mass spectrometric phospho-analysis. (F) Table 
showing unique phospho-sites of overexpressed TNRC6A WT and mutant. (G) Aa sequence of the phosphorylation sites 
directly located at the NES of TNRC6A. (H) Schematic overview of the location of measured phospho-sites within TNRC6A 
colored in red and conservation within other species (not measured; Hs: Homo sapiens, Mm: mus musculus, Rn: rattus 
norvegicus.). 
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2.2.3.4 Detailed computational and experimental analysis of the TNRC6 
phosphorylation sites regarding localization, conservation and 
accessibility 
 
For the obtained conserved phosphorylation sites, kinase prediction tools were used to search for 
potential kinases. Therefore, the browser based program NET phos 3.1 (Blom et al. 2004) was used 
to generate a probability list for different kinases (data shown in the appendix Table 19). The 
conserved sites share the same predicted kinases. However many prediction probability values 
are low and often the amino acid sequence information maps to none of the kinases. The kinases 
NEK9, BAZ1B and SHIP2 can be found in our MS analysis of a 7A9-IP suggesting a possible role in 
RISC phosphorylation. However, the co-IP data and the predictions yield no overlapping 
candidates. This data suggests that many kinases could have potential roles in the phosphorylation 
of TNRC6 proteins and that further analysis needs to be performed. 
 
 
Figure 34 De-phosphorylation assay of enriched TNRC6-Ago-complexes. 
(A) Large-scale 7A9-IPs were performed with HEK293T cell lysates. After washing, enriched proteins were incubated for 
30 min either at 4°C/PBS or 37°C/ PBS or 37°C/FastAP (Alkaline phosphatase) and MS measurements were performed 
(B) Summary of different treatment conditions of the measured peptides and resulting sequence coverages (SQ). (C) 
Graph shows decreasing amounts of measured phosphorylation sites.  
 
A de-phosphorylation assay was established to study the accessibility and stability of the 
phosphorylated sites on TNRC6 proteins and to hypothesise structural, conformational and 
stability changes within the gene silencing complexes after de-phosphorylation. In Figure 34 A 
coomassie-stains of the 7A9-IPs illustrate that de-phosphorylation has minor effects on TNRC6-
Ago complex stability under this experimental conditions. In the MS measurements high sequence 
coverages and peptide amounts postulate again a high stability of the complex within all three 
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TNRC6 paralogs under different reaction conditions (Figure 34 B). The de-phosphorylation assay 
itself drastically decreases the amount of phosphorylated-sites and just a few sites remain 
phosphorylated due to reaction conditions (Figure 34 C). In appendix Table 20 the decrease of the 
particular residues which are de-phosphorylated are listed together with the corresponding p-
values which depict the statistical significance. For TNRC6C the 4 °C and 37 °C controls contain 
similar phospho-sites and p-values < 0.05 (Figure 34 C and appendix Table 20). The sample treated 
with FastAP includes just one remaining site, although TNRC6C peptides were comparable 
detected according to SQ and amount of peptides (Figure 34 B). The same is true for TNRC6A and 
B. Some sites seem to be more stable than others. For example, the S739 in TNRC6A that is located 
directly next to the Ago binding site is detectable in all different approaches. The same is true for 
some other residues like the conserved TNRC6A S991 and TNRC6B S879 (appendix Table 20). 
However, the assay has to be repeated due to statistical and technical issues for further 
conclusions regarding the stability and the accessibility of certain phosphorylation sites.  
 
 
2.2.4 Characterization of TNRC6 phospho-mutants 
 
As a first functional analysis, tethering assays were performed to investigate the downstream 
effects of potential phospho-sites on gene silencing after the TNRC6-Ago-miRNA-mRNA 
complexes were formed. Tethering assays mimic effects on translation independent from Ago-
miRNA complexes. To show effects on translation the protein of interest is tethered by the 
interaction of the λ-N-peptide to a 5box-B Renilla fusion mRNA which leads to the recruitment of 
mRNA destabilization factors and hence, to the decay and the loss of the Renilla signal. Therefore, 
cells were transfected with NHA and λNHA WT-, alanine- and glutamate-phospho-mutants of 
TNRC6 with appropriate controls. The signals of the ratio of affected Renilla and unaffected Firefly 
was calculated from different replicates and normalized to the NHA transfection control. In 
general, all phospho-mutants (with weak variations) are fully functional and the signal of the 
Renilla-target RNA is as strong as the WT TNRC6 control (Figure 35 A). To screen upstream effects 
on the interaction of TNRC6 with Ago, co-IPs with Flag-tagged TNRC6A phospho-mutants were 
performed. Figure 35 B indicates no effect of the phospho-site mutation on the TNRC6-Ago 
interaction. IF co-localization studies were performed to detect changes of the subcellular 
localization of TNRC6 phospho-mutants. IFs showed a perfect match of the Lsm-4 p-body-marker 
and the HA-tagged TNRC6 phospho-mutants (Figure 36). Compared to the overexpressed TNRC6A 
WT also no differences could be observed in localization or number of p-bodies. This first phospho-
 
66 Introduction 
site characterization experiments suggest minor effects of single phosphorylation sites on the 
functionality of TNRC6 to recruit Ago and the downstream decapping and deadenylation 
complexes.  
 
Figure 35 Characterization of TNRC6 phosphorylation sites. 
(A) Tethering assays with Flag-/HA-tagged WT TNRC6 and several phospho-mimicking and non-phosphorylatable-
mutants. Renilla luciferase (RNL) activity was detected in extracts of HeLa cells co-transfected with constructs expressing 
the RNL-5BoxB reporter, Firefly luciferase (FF) and λNTNRC6, phospho-mutants and WT Ago2.WT λNTNRC6 and Ago2 
served as positive control. The expression levels of Renilla luciferase were normalized to co-transfected Firefly luciferase 
signals. (B) Co-immunoprecipitation of Ago1-4 with TNRC6 mutants. Flag-/HA-TNRC6 WT and phospho-mutants were 
overexpressed in HEK 293T cells, immunopurified by anti- FLAG-IP, separated on a SDS-PAGE, and analyzed by Western 
Blotting. Co-immunoprecipitated TNRC6 proteins were detected by using anti-HA antibody, Ago2 was detected by 11A9 
antibody. 
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Figure 36 Characterization of 
TNRC6 phosphorylation sites with 
IFs. 
Immunofluorescence of over-
expressed TNRC6 mutants. TNRC6 
WT and mutants were detected in 
immunofluorescence with anti-HA 
antibody staining (shown in green). 
For co-localization studies, Lsm4, a 
p-body marker, was stained with a 
specific antibody (shown in red). 
DAPI staining (blue) indicates the 
nucleus.   
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3.1 Part I: Dissection of viral miRNA biogenesis 
 
This part of the discussion chapter dedicates the identified interactors of hairpin structured pri-
/pre-miRNAs of the different herpes papilloma and polyoma viruses. The validation and possible 
regulatory effects on the miRNA biogenesis are discussed. Additionally an outlook based on results 
of this project will be given. 
 
3.1.1 Viral miRNA expression profile of EBV, CMV and HSV1  
 
To assess an overview of the expressed miRNAs in the different model systems used for the pull-
downs, northern blots were performed with different DNA and RNA probes. The detection of 
nearly all mature viral miRNAs was possible within the EBV positive suspension cell line Jijoye. 
Within the Raji cell line just few could be detected. Therefore, all follow-up experiments were 
achieved with Jijoye cells. 
The other herpes virus miRNAs were detected at different time points while an active and massive 
infection with a moi = 5 to reach an infection efficiency of up to 100 %. For CMV exclusively mature 
miRNAs were detected after 24 to 48 hours during the transition from the early to the late phase 
of the virus life cycle. This suggests an important role of the CMV miRNAs during infection. Indeed 
it is known that highly expressed CMV miRNAs have certain regulatory functions in immune 
evasion and viral replication (compare appendix Table 16). 
In contrast, HSV1 exhibits a differential pattern of the chosen miRNAs and pre-miRNAs, suggesting 
particular specific regulatory mechanisms to block or inhibit the processing of the mature miRNA 
during the infection (B. R. Cullen 2004; Flores et al. 2013; Jurak et al. 2010; R. L. S. and B. R. Cullen 
2013; Kramer et al. 2011; Jennifer Lin Umbach et al. 2009; Jennifer L Umbach et al. 2010). 
The miRNAs of BKV, MCV and HPV41 could not be detected by northern blotting because a good 
model system where sufficient amounts of total RNA could be extracted was not available. 
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3.1.2 Identification of miRNA hairpin binding  
 
Technical and methodical challenges. The hairpin pull-down work-flow contains critical parts at 
distinct steps. For instance the pull-down was performed overnight and RNA or proteins as well 
as complexes could have been lost because of degradation. In contrary non-physiological 
interactions and hence new structures and complexes may have been assembled due to the used 
incubation conditions. Additionally unspecific binding events may be caused by mild washing 
conditions and thus background binding increases and may covers weak specific binders. To be 
further critical, the in vitro RNA-pull-down approach with high concentrations of the bait system, 
favouring buffer conditions, lacking subcellular compartments and lacking cellular regulation may 
produce also non-physiological, unspecific binding actions with many false positive candidates. 
Concerning other methodical issues the virus (CMV and HSV1) infected cell lysates of different 
time points had to be mixed. This had the consequence that the highly expressed viral coat and 
particle proteins were massively and unspecific bound by the experimental pull-down set up and 
the possibility that weak binders were covered by these strong binders is high. In addition, the 
pull-downs with the BKV, MVC and HPV41 miRNAs were performed in MRC5 cells, but without an 
active infection. Thereby factors that are specifically expressed during a viral invading or the 
cellular immune response are lacking. 
To minimize side effects, biological replicates were performed and unspecific binding actions were 
analyzed with the "bead-proteome" of the magnetic beads of the preclearing controls.  
 
MS challenges. Further technical challenges concerning the MS sample preparation, 
measurements and data analysis will be just briefly reviewed. For standardized and equal 
conditions, precast gels were used and samples were prepared with the same work-flow. The 
obtained data and further processing is based on the probability score as qualitative value. To 
present semi quantitative results, emPAI-values (Ishihama et al. 2005) were generated and are 
used for future directions and illustrations, unfortunately no emPAI values were considered for 
this thesis. However, the main output generated by scores and emPAI values constantly stays 
comparable. 
 
Potential binders. The protein-hairpin interaction pull-down identified proteins with different 
types of binding patterns, first one RBP interacts specific to one hairpin, second, one hairpin 
interacts with different proteins. Third, one protein interacts with different pri/pre-miRNAs. 
Fourth few hairpins interact with few proteins and fifth one part of a whole protein complex 
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interacts with one or more pre-miRNAs. In all of these different binding classes many unusual 
binders were identified. These ones often lack known RBDs or are known to function in completely 
unrelated metabolic processes. 
In addition, the whole obtained data reflects a difference between very specific interactions based 
on structure, consensus sequences and binders which can be classified as sequence unspecific 
RNA interactors. Many of these belong to different classes of interactors like spliceosomal or 
metabolic proteins (Lunde, Moore, and Varani 2007; Gerstberger, Hafner, and Tuschl 2014).  
However, compared to other large protein-RNA interaction studies, the data-set contains many 
known factors and RBPs which specifically interact with RNA (Castello et al. 2012; Treiber et al. 
2017).  
 
Bioinformatical analysis reveals a first conclusion without any validation experiments. First, the 
link to RNA can be made with GO term analysis, as expected many RNA associated functional 
mechanisms and pathways with typical housekeeping functions are present. The potential of the 
proteins to interact with RNA (compulsive required) was analyzed and many contain RBDs, but 
also many are not classified or the data bases are incomplete or obsolescent. 
The hints of the subcellular localization have minor relevance, because many data bases of the 
subcellular localization of many proteins are again incomplete, obsolescent, unknown or critically 
discussed in the scientific field. For a more distinct analysis, subcellular co-localization with Drosha 
and Dicer should have been checked. 
 
MSA. The analysis based on consensus sequences with MSAs gained insights in potential 
conserved binding sites, but also revealed that lacking data on different candidate consensus 
sequences makes the analysis nearly impossible. For many cases the MSAs showed no overlapping 
sequences, but a single analysis of the structural hairpin elements would be necessary. But a 
sequence based analysis without considering structural information (or just predicted ones) shows 
the weakness of this analysis and simultaneously strengthens the aspect that also secondary 
structure is important for selectivity. 
 
To summarize this part, it is not possible to avoid unspecific binding and false positives. Therefore 
the screening data was validated and further characterized by biochemical assays. 
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3.1.3 Validation and influence of specific pre-miRNA protein 
interactions 
 
The first validation step was mo the repetition of the hairpin pull-down with overexpressed Flag-
/HA-interactor proteins in an unrelated cellular system without a viral infection. Basically, just the 
binding reaction was repeated. The different proteins varied in their expression level and few 
candidates did not express at all. Unfortunately the strong expressed proteins lead to strong 
unspecific binding to the beads and to the unrelated hairpin control. When possible, the approach 
was adjusted to more optimal conditions, but in many cases the overshooting expression resulted 
in unspecific bindings. However, many candidates could be shown to be specific interactors of the 
according pri/pre-miRNA, although background binding occurred. To proof the interaction from 
both sides, a RNA-IP with the hairpin-interacting protein should be performed and detected by 
northern blotting and highly sensitive qRT-PCRs. 
In a next step viral miRNAs were overexpressed together with the potential regulator in a viral 
free background to force the processing pathway through high accessibility of RNA and potential 
regulator. The effects on the processing efficiency are rather mild, but give hints for the potential 
regulatory function. The mild results are caused from the endogenous background and the lack of 
controls. 
A better assay in terms of sensitivity and without background was established in a cellular hairpin 
interactor knockout background. The idea was, to force the effect of blocking or promoting the 
processing without endogenous proteins. The cells were produced within the publication of 
Treiber et al. 2017. The unaffected hairpin can of course be influenced by present endogenous 
factors, but this would be equal in all used cell lines, thus this side effect on the control was 
neglected. The results that were detected reveal an effect on the processing activity of the 
regulators on the miRNA biogenesis. Unfortunately, effects are again mild. This can be caused by 
massive overshooting overexpression of the hairpins and thus clear effects remain weak. Also just 
one candidate RBP was depleted and still others could influence the miRNA processing and then 
no effects would be visible. Such effects are conceivable when RBPs compete for the same binding 
site and one competitor is missing. 
Also a viral background which may have supported the effects is missing and thus regulatory 
pathways which may activate additional functions of RBPs are not present.  
From a methodical sight, endpoint assays by northern blotting were performed and maybe cover 
weak effects. For a better visualization, different time points after infections or transfections 
should have been studied. Additionally the effects should be confirmed by other methods such as 
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qRT-PCRs or small RNA deep sequencing. The variances in this assay and clear results could be 
optimized by further biological and technical replicates. 
For the RBP Rbfox2 as the best example, the results in Figure 20 and Figure 21 strongly together 
with the reports from the literature (Yu Chen et al. 2016) support that it is a negative regulator for 
cmv-miR-US22 biogenesis. This nice example clearly shows further extensive research will reveal 
the effects of the identified RBPs on miRNA biogenesis. 
 
3.1.4 Future perspectives and a model for the viral miRNA 
biogenesis 
 
The identified candidates together with the known fates of the miRNAs provide insights in the 
biogenesis of viral miRNAs and lead to the following working model Figure 37. This model 
illustrates that the viruses through a distinct regulation of the miRNA biogenesis influence many 
cellular processes. By blocking or promoting miRNA biogenesis a particular miRNA profile is 
generated which helps the virus to establish the lytic or the latent life cycle. 
For further RBP characterization, consensus sequences within the pre-miRNAs will be studied with 
bind and seq. assays and hairpin binding mutants. Afterwards, RNA-binding domains will be 
analyzed with truncated protein versions in EMSAs and co-IPs. This will be studied in detail by Dr. 
Nora Treiber and Dr. Thomas Treiber. The MS data based on scores will be re-analyzed by 
considering the semi quantitative emPAI values. 
To maintain a full picture viral infection assays will be investigate and elucidate whether our RBP 
candidates are important for individual steps of viral infection (lytic cycle) or long term viral 
persistence (latent cycle). This will be performed together with Prof. Michael Nevels and Dr. 
Christina Paulus for CMV. Knock out cell lines will be infected and virus production and maturation 
will be analyzed at different steps of the viral life cycle (very early, immediate early, early and late 
phase). Furthermore, infection rescue assays with mutated consensus sequences within the pre-
miRNAs will confirm the crucial role of the RBPs on the virus. 
For papilloma and polyoma viruses, where miRNAs play a pivotal role in switching from early to 
late infection stages, the identified RBPs which associate with the BKV, MCV and HPV41 pri/pre-
miRNAs will also be tested in a similar infection system as for CMV. Strikingly, first hints for drastic 
effects during in vivo infection studies with BKV in GRSF1 HEK 293T knock out cells were detected 
for the virus replication and particle formation (data not shown). The viral work has been and will 
be further performed in close collaboration with Prof. Adam Grundhoff (Heinrich-Pette Institut 
Hamburg). 
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Figure 37 Schematic model of the effect of viral miRNAs on the host and the virus. 
Inhibition or promotion of certain miRNAs by regulatory RBPs during biogenesis may influence the latent or lytic cycle 
of the virus. Thereby several important functions such as cell cycle control, apoptosis and cellular immune response 
are affected. The virus influences with its own and host miRNAs the expression of regulatory RBPs to influence 
miRNAs. Hence the virus produces optimal homeostatic conditions to survive. 
 
Future perspectives will elucidate the effect of miRNAs and their regulation on the viral life cycle. 
Within the virus field a strong role of the viral (and host) miRNAs in the initiation of the latent viral 
stage is suggested. Furthermore, a distinct and highly regulated equal level of miRNAs is needed 
which controls a light promoting system of many different pathways and cellular growth 
regulation for the viral persistence (like suggested in the introduction 1.4.2). This can be kept with 
a regulation network of a redundant human and viral gene regulation system influencing the 
cellular processes to maintain long-term (life-long) persistence within the host. 
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3.2 Part II: Post-translational modifications of TNRC6 
proteins 
 
The second part of the discussion dedicates the established antibodies, their characterization and 
the usage for immunopurification of TNRC6-complexes from different species. Furthermore, 
newly identified TNRC6 phospho-sites are summarized, obtained functional data is discussed and 
reviewed with regard to the current literature. Additionally, an outlook based on future directions 
will be illustrated. 
 
3.2.1 Immunopurification and enrichment of TNRC6-Ago-
complexes from different species with monoclonal TNRC6 
antibodies 
 
Antibodies. The novel established and characterized monoclonal TNRC6 antibodies demonstrate 
a valuable tool for the characterization of the human TNRC6-Ago-miRNA-mRNA complexes. The 
advantages of these antibodies compared to other approaches are a high selectivity and the ability 
to purify stoichiometric amounts of Ago and TNRC6 proteins. The presented data, in particular 
selectivity tests, competing assays (see in 2.2.2.1) and MS interaction studies as well as IFs 
presented in Schraivogel et al. 2015 lead to the development of new enrichment strategies for 
TNRC6 proteins. The purification of the antibodies clearly increased the quality of the 
immunopurifications and made the TNRC6 proteins visible as stable proteins when bound to Ago. 
Even the target RNAs were successfully enriched with high yield and comparable to Ago IPs. 
Compared to literature (Meister et al. 2005; Hock et al. 2007) also many known interactors and 
maybe also unknown ones were co-immunoprecipitated A potential disadvantage is the 
recognition of the monoclonal antibodies of the RRM domain. This interaction could lead to a loss 
of interaction partners within the RRM domain or even within the whole SD domain. 
 
For large scale purifications, the lysates were treated before clearing with RNase A (Kalantari, 
Chiang, and Corey 2016; Kalantari et al. 2016). This leads to a higher accessibility of the TNRC6-
Ago complexes, but maybe the functional integrity of the gene silencing network is lost. Degrading 
the mRNA could have favoured the decomposition of the silencing complexes resulting in a 
breakdown of larger p-body structures. Thus, the proteins are in a free state and the lysate 
conditions lead them again together to reunification. As PAPBC1 is still detectable with high yield, 
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a break down to smaller structures could be also assumed. However, this remains speculative and 
cannot be proofed easily. 
The universal applicability of the TNRC6 antibodies compared to Ago-APP is limited through the 
conservation of the RRM domain between the species. Additionally the very well conserved TNRC6 
proteins can also be purified from mouse and rat tissues with high specificity. The purity and 
quantity was depending on the lysates, total protein amount. In general, the purification and 
detection was efficient when the proteins were highly expressed. However, in full-differentiated 
cell lines where gene silencing action is weak also the purified amounts of TNRC6 proteins were 
low. 
 
3.2.2 Quantification of TNRC6 levels by SRM 
 
The antibodies were subsequently used together with SRM analyses to measure protein 
expression levels of the TNRC6 and partly also from Ago proteins.  
All monoclonal antibodies of which the immunoprecipitated TNRC6 proteins were analyzed 
showed their own specificities. Due to this fact the antibodies can be now used even better, 
depending on the question. 
In general, the binding actions between TNRC6A-C and Ago1-4 indicate an equal distribution 
relative to their expression level as already partly observed in Hauptmann et al. 2015.  
All together the results depict that the antibodies work and that they reflect the cellular spectrum 
of TNRC6 and Ago proteins. Furthermore, different cell lines and tissues may have a specific 
transcription and expression pattern, but this remains speculative and additional experiments 
have to be performed. 
Technical challenges. The SRM measurements are sensitive enough to analyze complex input 
samples. However the data obtained from these measurements are at the lower limit of detection 
and thus the inaccuracy of the analysis had to be considered.  
Additionally high varieties in the properties and the resolution of the different used peptides were 
detected. Because the peptides itself have certain characteristics which may influence the sample 
preparation and the measurement. For instance, TNRC6A was quantified using 4 peptides. All of 
them were single reviewed and would lead to a comparable, but different expression profile. 
Therefore, the measurements were averaged with different calculation methods and compared 
to each other. 
For a full picture many more SRM measurements with more peptides from different cell lines and 
tissues (and replicates) are compulsory necessary.  
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3.2.3 Detection of endogenous phosphorylation sites of 
mammalian TNRC6 proteins 
 
The enrichment of TNRC6 and also Ago proteins was the main focus of the antibody production 
(Hauptmann et al. 2015; Quevillon Huberdeau et al. 2017). The obtained data from many different 
measurements taken from different species and approaches can be summarized in several 
modification sites. Many of these sites were already detected in phospho-proteomic approaches 
(K. Sharma et al. 2014; Mertins et al. 2016; Robles, Humphrey, and Mann 2017) and listed in 
different publications or databases (www.phophosite.org). Previous detection approaches mainly 
focused on other questions or hypothesis than specific phosphorylation sites of few proteins. 
Therefore, many sites could not be observed or reproduced which are publicly listed. A closer look 
on these datasets reveals that nearly all serines, threonines and tyrosines in TNRC6 are 
phosphorylated. 
The mass spectrometric phospho-site detection of the Ago-TNRC6 complexes (focus on TNRC6) in 
technical and biological replicates resulted in several unique and conserved phospho-sites. These 
residues are stably measured and therefore maybe the sites needed for a functional complex. 
Interestingly, the residues which were inconsistent or weak phosphorylated could get more in the 
focus of interest, after more replicates are performed, because weak sites could be regulatory 
sites which lead the complex through the pathway. Besides, the measurements are restricted and 
first we are forced to keep certain standards. However, also “weak” measured sites will stay in the 
focus of interest, not only the stable measured ones. 
The non-conserved phospho-sites itself seem to be randomly located all over the protein paralogs. 
Many phospho-sites were found to locate in random areas with no distinct or known functions, 
suggesting that these proteins need at particular positions a negative charge to function in the 
usual way. 
It remains unclear how flexible this phospho-patterns may change and through the variety of 
isolated complexes it will first stay unclear. TNRC6 is seen as binding platform and could need just 
the negative charge at distinct regions/positions for a micro structural change and a proper 
functionality like suggested for the regulation of PABPC1 binding (Huang et al. 2013). 
Interestingly, many phospho-sites are conserved between the species, which support the idea of 
a conserved function of the detected sites. Also for many sites measured in other species, at least 
the amino acid is conserved, supporting the assumption that this peptide was just not measured 
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with modification, but still could be modified. This conclusion may increase the number of 
predicted phospho-sites.  
The location of the phospho-sites seems first randomly, but different functional interaction parts 
of TNRC6 seem to be non-phosphorylated. For instance, the whole silencing domain seems to be 
nearly non-phosphorylated. 
Interestingly, the three different proteins with the same function have many unique sites that are 
just conserved among the species and not the paralogs. Due to many different and fast changes 
within the complex it could be that there is a stable pattern to keep the system functional. This 
pattern could be specific for every TNRC6 paralog. 
Technical issues. Briefly the technical challenges in measuring a flexible system with inflexible 
approaches had to be overcome but first detection itself in a stable way had to be optimized. The 
first challenging part was to get enough endogenous protein material. After overcoming this, the 
analysis itself had to be optimized, to get a good ionization efficiency and fragmentation patterns. 
But also minor important points like semi tryptic digestions or not digested peptides or too big 
peptides had to be optimized. After obtaining the raw data, the analysis pipeline and its 
restrictions were optimized. Further, the position of a phospho-site within a peptide containing 
many phosphorylate-able residues needed confirmation through additional raw data analysis 
(also for multiple phosphorylated-peptides) (Boersema, Mohammed, and Heck 2009; Palumbo 
and Reid 2008; Steen et al. 2006).  
The question for kinases is unanswered. Unfortunately, the detection of phospho-sites is just the 
starting point for more differential analysis. The first upcoming question about the modifying 
enzymes remains up to this point unsolved. There are different possibilities that would be 
probable in terms of cellular mechanisms. The prediction of kinases with tools are limited to the 
properties of the known kinases and also phosphatases. The tool suggests common and broadly 
involved kinases based on the sequence characteristics, thus K.O.s of these would result in cell 
death. For Ago proteins some kinases are suggested to specifically phosphorylate particular 
residues (Quevillon Huberdeau et al. 2017; Zeng et al. 2008). Hence, it is possible that the 
functional unit of Ago-TNRC6 complexes is modified together. 
This suggests that the close neighbouring systems of gene silencing, translational repression, p-
body formation and translational activity could have the same regulatory machinery, meaning that 
the kinases and phosphatases are always present at the centres of action. Following this 
conclusion the co-immunoprecipitated potential interactors may contain already all modifying 
enzymes to keep this mechanisms running. Many possibilities are imaginable in a fast changing 
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system with limited access. Summarized, predictions give just hints to the known fact that the 
protein needs the phospho-sites to function, but how and why cannot be answered. 
Detection of nuclear phosphorylation sites of TNRC6 proteins. The nuclear/cytoplasmic 
fractionation approach is a qualitative biochemical assay with a high potential for cross-
contaminations. Hence, all unique sites could be contamination side effects. Therefore, follow-up 
experiments with LMB treatment which blocks the nuclear export could help to further confirm 
unique sites of nuclear TNRC6. 
Data of nuclear TNRC6 phospho-sites was mainly obtained from overexpression and without 
replicates. Many sites were overlapping with the endogenous data-set and therefore the 
measurements seemed trustfully and valuable. Few appearing phospho-sites that are measured 
with high yield are not or just weak appearing in the data-set of the mainly cytoplasmic TNRC6. A 
function of the phospho-sites has to be carefully validated, because the function of nuclear TNRC6 
in contrast to the cytoplasmic ones is still unclear and highly debated in the field (Nishi et al. 2013; 
Schraivogel et al., n.d.; Gagnon et al. 2014; Kalantari et al. 2016).  
It can be postulated that phosphorylation sites could have a potential regulatory function for the 
transport into the nucleus. Interestingly S1212 (or/and S1217) are located at the NES and the 
negative charge may influence the binding to the importins or CRM1.  
 
3.2.4 Characterization of selected TNRC6 phospho-mutants 
 
The second upcoming question aims the function of the phosphorylated sites. As basic functional 
assays, tethering, Ago interaction and localization studies per IFs were performed to analyze 
effects on gene silencing (similar to Huberdeau et al. 2017). The tethering assays concentrate the 
functional analysis on all aspects independent from Ago containing miRNAs. Therefore, all 
downstream effects are monitored. Taken together, no downstream effects are influenced by the 
exchange of one particular residue neither by phospho-mimicking glutamate mutants nor by non-
phosphorylateable alanine mutants. Since IFs illustrate a perfect overlap with various visible 
differential structured p-bodies, again no effects on the functionality, can be observed (just a 
subset of IFs is shown. The influence of phospho-sites on the Ago TNRC6 interaction seems also 
not be different. However, these assays rely on overexpression of TNRC6 proteins. Thus effects on 
gene silencing and Ago interaction could be just not detected, because overexpression was 
insufficient. The localization within p-bodies is again just observed during overexpression and 
could conclusively lead to hidden effects that are not detectable with IFs. 
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As one phospho-site seems to have minor effects on the functionality of TNRC6 it is suggested 
that many phospho-sites are required for a proper function. This suggests on the one hand that 
TNRC6 is heavily phosphorylated and that one phospho-site is maybe not crucial for the function. 
On the other hand it can be concluded that TNRC6 needs phosphorylation for proper function. 
This leads to the hypothesis that a pattern of negative charges overall the whole protein is needed 
for proper function and the loss of one phospho-site is not decisive. A monitoring of different 
stages of the gene silencing pathway with TNRC6 truncations combined with phospho-mutants 
could proof certain functions.  
 
De-phosphorylation assay. The de-phosphorylation depending on the stability and abundance of 
the peptides suggests a high variance within the phosphorylation pattern, because it seems that 
only the relative position is important and the negative charge, but not typical conformational 
changes like for many other phospho-proteins. Additionally, it proofs the accessibility of the 
phospho-sites, thus the residues are not protected or hidden by the complex assembly. 
Due to the reason that the different detected phospho-peptides vary in their characteristics and 
hence technical detection as well as statistical analysis differs among the peptides. This leads to 
the effect that some peptides are strongly detected and others not. For further conclusions, the 
de-phosphorylation assay has to be repeated. 
 
3.2.5 Model and Outlook for the PTM project 
 
The universal applicability of the established antibodies opens various possible approaches. The 
detection of phospho-sites was in the main focus. Taken together, there are no clear signs for 
distinct functions of TNRC6 phospho-sites. Maybe, just complex integrity is influenced. At least we 
know that the Ago-TNRC6 protein complex is heavily phosphorylated while acting in the gene 
silencing pathway.  
Apart from all advantages, the limit of the antibodies was in the differential analysis of all the 
different steps of the gene silencing pathway.  
To solve the question of associated kinases or phosphatases a large scale knockdown screen with 
fluorescent Ago and TNRC6 will be performed. Additionally, the mass spectrometric detection of 
associated proteins will be investigated with new approaches. Furthermore, a new purification 
strategy with functional protein truncations and the possibility to distinguish between different 
complexes will be established. The prior mentioned new approaches will be then combined with 
different in vitro phosphorylation assays and structural analysis experiments.  
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Taken together the following model illustrates that in general the gene silencing process from a 
sequential point of view is quiet well understood. But many questions within the field are unsolved 
like the regulatory mechanisms which control the system, if there are recycling systems for both 
Ago and TNRC6 proteins or how all these modifications make the difference in terms of function  
 
 
 
 
Figure 38 Schematic model of gene silencing networks with a focus on TNRC6. 
Within the gene sileincing pathway many different stages are postulated, however none of these steps is understood 
in the way of regulatory mechanisms. It is known that Ago-TNRC6 complexes perform together with many other large 
complexes gene silencing. The state of regulatory modifications as well as involved signaling pathways for TNRC6 is 
completely unknown. Hence many questions have to be solved in the future to understand gene silencing, complex/p-
body formation and translational repression in a distinct way. 
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4.1 Materials 
 
4.1.1 Consumables and chemicals  
 
All Chemicals for buffers and solutions were obtained from Sigma-Aldrich (St. Louis, USA), Merck 
(Whitehouse Station, USA), Roth (Karlsruhe, Germany), AppliChem GmbH (Darmstadt, Germany) 
and Thermo Fisher Scientifc (Waltham, USA). 
Radiolisotope-labeled chemicals were purchased from Hartmann Analytic GmbH (Braunschweig, 
Germany). 
Heavy-isotope-labeled peptides for SRM measurements were purchased from JPT Peptide 
Technologies GmbH (Berlin, Germany). 
Oligonucleotides were synthesized by Metabion GmbH (Planegg, Germany).  
Cell culture reagents were purchased from Sigma-Aldrich (St. Louis, USA). 
All Enzymes, oligonucleotides, and molecular weight markers for molecular biological methods 
were obtained from Thermo Fisher Scientifc (Waltham, USA) or New England Biolabs (Ipswich, 
USA). 
The composition of individual buffers is specified with the respective method they were used for. 
 
 
4.1.2  Instruments and technical equipment  
 
Table 8   Instruments and technical equipment 
 
device        supplier company (location) 
        
SDS-Page, Western blot, Northern blot  
Screen Eraser-K      Bio-Rad (Hercules, USA) 
Trans-Blot SD       Bio-Rad (Hercules, USA) 
Wet-blot      Bio-Rad (Hercules, USA) 
Odyssey Infrared Imaging System     LI-COR Biosciences (Lincoln, USA) 
Power Supply EV233      Consort (Turnhout , Belgium) 
Personal Molecular Imager TM (Phosphoimager)  Bio-Rad Laboratories, Inc. (Hercules, 
USA) 
Film Processor CP 1000      AGFA (Mortsel, Belgium) 
Geiger Counter LB123 EG&G     Berthold (Bad Wildbad, Germany) 
Hybridization oven T 5042     Heraeus (Hanau, Germany) 
PowerPac HC Power Supply     Bio-Rad (Hercules, USA) 
 
Centrifuges 
Centrifuge 5415D      Eppendorf (Hamburg, Germany) 
RT-fuge       Eppendorf (Hamburg, Germany) 
Megafuge 40R      Thermo Scientific (Rockford, USA) 
 
Cell culture equipment  
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HeraCell 240i CO2 Incubator    Thermo Scientific (Rockford, USA) 
 
 
Mass spectrometers    
maXis plus UHR-QTOF     Bruker (Billerica, USA) 
CaptiveSpray nanoBooster Source 
QTRAP®4500 AB SCIEX      AB SCIEX(Framingham, USA) 
NanoSprayIII Ion source AB SCIEX  
 
Chromatography system for both mass spectrometers: 
UltiMate 3000 RSLCnano System Thermo Fisher Scientifc  (Waltham, USA) 
with Acclaim® PepMap100 C18 Nano-Trap column 
and Acclaim® PepMap C18 column 
 
Other equipment 
FastPrep®24 (with Lysing Matrix D) 
 
Thermomixer compact Eppendorf     (Hamburg, Germany) 
Incubator Model B6200 Heraeus     (Hanau, Germany) 
Biofuge pico Thermo Scientific     (Rockford, USA) 
HeraSafe KS Thermo Scientific     (Rockford, USA) 
Branson Sonifier 450 Heinemann     (Schwäbisch Gmünd, Germany) 
Milli-Q PLUS and Reference A+    Millipore (Billerica, USA) 
Ultraspec 3300 pro Amersham Biosciences    (Little Chalfont, UK) 
Avanti J-20 XP Centrifuge Beckman Coulter   (Krefeld, Germany) 
Quantum ST4 PeqLab      (Erlangen, Germany) 
 
 
4.1.3 Bacterial strains, cell lines and viruses 
 
Table 9   Bacterial strains  
 
strain  genotype specifications 
 
XL1-blue F– recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac F’[proABlacI qZ_M15 Tn10 (TetR) 
BL 21  B F- dcm+ Hte ompT hsdS(rB- mB-) gal endA Hte 
 
 
 
Table 10   Viruses  
 
strain   family   genotype specifications   
 
EBV (within +B cells human herpes virus DNA virus 
CMV (AD169)  human herpes virus  DNA virus 
HSV1 (KOS)  human herpes virus  DNA virus 
MCV   human polyoma virus  DNA virus 
BKV   human polyoma virus  DNA virus 
HPV41   human papiloma virus  DNA virus 
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Table 11   Mammalian cells 
 
strain   genotype specifications   lysis conditions  
 
cancer cell lines 
HEK 293T  human embryonic kidney cells  IP lysis buffer 
HeLa    human cervical cancer cells  IP lysis buffer 
LNT-229   human glioma cells   IP lysis buffer 
Ntera2   human metastatic testis cells  IP lysis buffer 
 
mouse cell lines 
MEF Ago2 -/-   mouse embryonic fibroblasts  IP lysis buffer 
MEF Dicer -/-   mouse embryonic fibroblasts  IP lysis buffer 
MEF ADicer +/+   mouse embryonic fibroblasts  IP lysis buffer 
N2A mouse   neuroblastoma cells   IP lysis buffer 
CMT93   colorectal cancer    IP lysis buffer 
 
suspension cell lines 
Raji   T-cell lymphoma    Sonication, Pull-down buffer 
Jijoye   T-cell lymphoma    Sonication, Pull-down buffer 
 
Primary cells 
MRC5   primary lung fibroblasts   Sonication, Pull-down/IP lysis buffer 
 
HEK293T Flp/In T-Rex  human embryonic kidney cells  IP lysis buffer 
 
 
 
4.1.4 DNA oligonucleotides 
 
DNA probes for northern blot listed in the appendix 5.1.5 
DNA oligonucleotides for PCR listed in the appendix 5.1.6 
DNA oligonucleotides for qRT-PCR listed in Hannus et al, 2014  
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4.1.5 Plasmids 
 
Table 12    Plasmids  
 
Plasmid   tag    application 
 
pGEM T easy   no tag   template for PCRs 
 EBV      miRNAs BHRF1-1/1-3; BART1-22 
 CMV      miRNAs US4-1 to UL148D 
 HSV1      miRNAs H1-H8/H11-H17/H26-H27 
 MCV      miRNA M1 
 BKV      miRNA B1 
 HPV41      miRNA H1 
 
psuperior    GFP   overexpression of miRNAs in mammalian 
cells 
 EBV       miRNAs BHRF1-1/1-3; BART1-22 
 CMV       miRNAs US4-1 to UL148D 
 HSV1       miRNAs H1-H8/H11-H17/H26-H27 
 MCV       miRNA M1 
 BKV       miRNA B1 
 HPV41       miRNA H1 
 
PCDNA3 SK2L2   Flag    clones by Franziska Weichmann 
 
VP5 (modified pIRES neo)  Flag-/HA   overexpression of mammalian 
Proteins in cells 
  
 NONO, ZCHC3, PTCD3, Rbfox2, UL97, UNG,   this work 
 UL77, PORTL, PP65, K0020, CPSF5, CPSF7 
 C9orf114, NOL8, TRIM25, PUm1/2,   cloned by Nora Treiber 
 Zincfinger346, SDOS, PTBP1,    used in Treiber et al, 2017 
 PURA, PURB      clones by Hung-Xuan Ho  
  
 
VP5 (modified pIRES neo)  Flag-/HA   overexpression of TNRC6A-phospho-
mutants 
 TTS736/738/739AAA, TTS736/738/739EEE 
 S991A, S991E 
 S1582A, S1582E 
 SSS1582/1585/1599AAA, SSS1582/1585/1599EEE 
 S1548A, S1548E 
 T1549A, T1549E 
 T1844A, T1844E 
 
PCIneo     HA/NHA    TNRC6A-phospho-mutants  
        for tethering assays 
 TTS736/738/739AAA, TTS736/738/739EEE 
 S991A, S991E 
 S1582A, S1582E 
 SSS1582/1585/1599AAA, SSS1582/1585/1599EEE 
 S1548A, S1548E 
 T1549A, T1549E 
 T1844A, T1844E 
 
88 Introduction 
4.1.6 Antibodies  
 
Table 13   Primary and secondary antibodies 
 
antibody origin   application  dilution   supplier 
 
antibodies against endogenous proteins 
Hs Ago1, clone 1BX rat   WB, IP  1:5 
Hs Ago1, clone 1C9 rat   WB, IP  1:5  Dr. E. Kremmer,Dr Regina 
Federle 
Hs Ago2, clone 11A9 [187] rat   WB, IP   1:5  Helmholtz Zentrum München 
Mm Ago2, clone 6F4 rat    WB, IP  1:5  
Hs TNRC6B, clone 6G3 rat    WB, IP  1:5  
Hs TNRC6A–C, clone 7A9 rat    WB, IP  1:5  
Hs TNRC6A–C, clone 11C12 rat  WB, IP  1:5 
Rmc (IgG control) rat    IP  1:5 
 
antibodies against tags 
HA, clone 16B12 mouse    WB   1:1000   Covance Research Products 
FLAG M2 rabbit     WB   1:1000   Sigma-Aldrich 
c-Myc polycl. C3956   WB   1:1000   Sigma-Aldrich 
 
secondary antibodies 
rat IRDye® 800CW goat    WB   1:10.000  LI-COR Biosciences 
mouse IRDye® 800CW goat    WB   1:15.000  LI-COR Biosciences 
rabbit IRDye® 800CW goat    WB   1:10.000  LI-COR Biosciences 
rat IRDye® 680CW goat    WB   1:10.000  LI-COR Biosciences 
mouse IRDye® 680CW goat    WB   1:15.000  LI-COR Biosciences 
rabbit IRDye® 680CW goat    WB   1:10.000  LI-COR Biosciences 
 
 
 
 
Table 14    peptides and proteins for monoclonal antibody production* 
 
label  tag/protein/part 
   
TNRC6B  His-TNRC6B full length 
TNRC6C  His-TNRC6C full length 
Bct  His-TNRC6B C-term (999-1723 aa) 
BmI  His-GST-TNRC6B motif I (597-683 aa) 
BmII  His-GST-TNRC6B motif II (861-911 aa) 
A RRM  GST-TNRC6A RRM (1525-1609 aa) 
B RRM  GST-TNRC6B RRM (1535-1619 aa) 
C RRM  GST-TNRC6C RRM (1511-1595 aa) 
 
 
*peptides and proteins were generated by former lab alumni’s (Simone Harlander, Janina Pfaff, 
Sabine Rüdel) 
 
 
 
 
 
 
89 Materials And Methods 
4.1.7 Heavy peptides for SRM measurements 
 
Peptides were obtained as SpikeTides™ TQL peptides that contain a quantifiable tag that is cleaved 
of during tryptic digest. Amino acid sequences of the proteotypic peptides used in selected 
reaction monitoring experiments are listed in Table 155. 
 
Table 15   Peptides 
 
Uniprot   Protein name  Position [aa]   Peptide  
 
Q8NDV7  TNR6A   151-167    GQHFPVIAANLGSAVK 
Q8NDV7  TNR6A   1196-1206   QEEAWINPFVK 
Q8NDV7  TNR6A   1458-1467   QLDPNLLVK 
Q8NDV7  TNR6A   883-892    SVSGWNELGK 
 
Q9UPQ9  TNR6B   73-85    VAVPNGQPPSAAR 
Q9UPQ9  TNR6B   1209-1225   GLHTPVQPLNSSPSLR 
Q9UPQ9  TNR6B   747-757    NGWGEEVDQTK 
Q9UPQ9  TNR6B   1470-1487   SSNASWPPEFQPGVPWK 
 
Q9HCJ0  TNR6C   456-467    QNTAWEFEESPR 
Q9HCJ0  TNR6C   1323-1337   HGAIPGGLSIGPPGK 
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4.2 Methods 
 
4.2.1 Molecular biological methods 
 
4.2.1.1 Polymerase chain reaction and site-directed mutagenesis 
 
4.2.1.1.1 PCR with Phusion DNA polymerase for cloning 
 
General PCR composition is listed below (Oligonucleotides are listed inappendix 5.1.6). Amplified 
PCR products were purified with an agarose gel (0,7-2 %), cut and extracted using the 
NucleoSpin Gel and PCR Clean-up kit (Macherey-Nagel GmbH). Phusion DNA Polymerase was 
used for cloning of Proteins (and mutants) and site-directed mutagenesis (described in 
4.2.1.1.3). 
 
 
4.2.1.1.2 PCR with Taq DNA polymerase for cloning 
 
General PCR composition is listed below. Amplified PCR products were purified with an agarose 
gel (0,7-2 %), cut and extracted using the NucleoSpin Gel and PCR Clean-up kit (Macherey-Nagel 
GmbH). Taq Polymerase was used for amplification of viral pri-miRNAs.  
Phusion PCR mix   50 µL  20µl 
DNA template  10-100 ng 10 ng 
5x HF/GC Buffer  10 µl  4 µl 
dNTPs   0,2 mM  0,08 mM 
forward Primer  0,5 µM  0,2 µM 
reverse Primer  0,5 µM  0,2 µM 
Phusion   0,5 µl (2U) 0,2 µl (0,8 U) 
 
H2O (bidest.)  ad 50 µl ad 20 µl 
PCR program, phusion   
  
Initial denaturation 98 °C  30 s 
 
Denaturation  98 °C  10 s 
Annealing  50-72 °C 30 s 
Elongation  72 °C  30 s/kb 
 
Terminal elongation 72 °C  7 min 
30-35 cycles 
 
91 Materials And Methods 
 
4.2.1.1.3 Site-directed mutagenesis 
 
Changes of 1 to 7 basepaires of plasmid constructs or amino acid changes were inserted by site-
directed mutagenesis. The whole plasmid was amplified with PCR through mutagenic primers 
forming bulges in case non-complementarity. Template DNA was removed by DpnI digestion. 
Reaction conditions are listed below 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCR mix, 50 µl   
DNA Template   50 ng 
5x HF Buffer   10 µl  
dNTPs    0,2 mM 
forward Primer   0,5 µM 
reverse Primer   0,5 µM 
Phusion DNA Polymerase 0,5 µl (2U) 
 
H2O (bidest.)   ad 50 µl 
PCR programm     
Initial denaturation  98 °C  30 s 
 
Denaturation   98 °C  10 s 
Annealing   50 °C  30 s 
Elongation   72 °C  1 min/kb 
 
Terminal elongation  72 °C  10 min 
18 cycles 
Taq PCR mix, 50 µL   
DNA template   10-100 ng 
10x buffer   5 µl 
MgCl2    4 µl 
dNTPs    0,2 mM 
forward Primer   0,5 µM 
reverse Primer   0,5 µM 
Phusion DNA Polymerase 0,5 µl (2U) 
 
H2O (bidest.)   ad 50 µl 
PCR program, taq     
Initial denaturation  95 °C  30 s 
 
Denaturation   95 °C  10 s 
Annealing   50-72 °C 30 s 
Elongation   72 °C  30 s/kb 
 
Terminal elongation  72 °C  7 min 
30-35 cycles 
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4.2.1.1.4 Scale up PCRs 
 
For amplification of large amounts of DNA templates for In-vitro-transcription a scale-up PCR 
was performed after following conditions. PCR product was gel-purified using the NucleoSpin 
Gel and PCR Clean-up kit (Macherey-Nagel GmbH).  
 
 
4.2.1.1.5 Annealing PCRs 
 
Small DNA fragments were produced through a fill-up PCR reaction with the Phusion DNA 
polymerase after oligonucleotides were annealed in a separate heat gradient from 95 to 30 °C. 
 
4.2.1.2 General restriction and ligation of DNA constructs 
 
PCR fragments were purified from Agarose gels using the Nucleospin Gel and PCR Clean-up Kit 
(Macherey-Nagel GmbH) after manufacturer’s protocol. 1-3 µg of PCR fragments were digested 
with restriction enzymes (FastDigest) after manufacturers protocol (Thermo Fischer Scientific) at 
37 °C, purified by agarose gel and NucleoSpin Gel and PCR Clean-Up Kit. For ligation 50 ng of the 
vector and appropriate amounts of PCR fragments were taken. Ligations were done for 1-2 h at 
22 °C or overnight at 16 °C. 
Alternatively FastAP (Thermo Fisher Scientific) was added to vector restriction reactions for de-
phosphorylation.  
 
4.2.1.3 Transformation of competent E.coli 
 
For (Re-) Transformations 50 µl of chemically competent XL Blue 1 E.coli cells were thawed on ice. 
Approximately 100 ng of Plasmid DNA, 5-10 µl ligation reaction mixtures or the whole DpnI-
resctriction mixture of site-directed-mutagenesis were added and incubated on ice for 10 to 30 
PCR mix, 50 µl   
DNA Template   200 ng 
5x HF/GC Buffer  10 µl  
dNTPs    0,2 mM 
forward Primer   0,5 µM 
reverse Primer   0,5 µM 
Phusion DNA Polymerase 0,5 µl (2U) 
 
H2O (bidest.)   ad 200 µl 
PCR programm     
Initial denaturation  98 °C  2 min 
 
Denaturation   98 °C  30 s 
Annealing   50 °C  30 s 
Elongation   72 °C  10 s 
 
Terminal elongation  72 °C  7 min 
35 cycles 
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min, followed by a heat shock step at 42 °C for 1 min. Afterwards bacteria were chilled on ice for 
2 min and alternatively incubated with 1 ml LB medium at 37 °C for 30 min while shaking.  
Whole transformation mix was plated on LB plates containing appropriate antibiotics and 
incubated overnight at 37 °C. 
 
4.2.1.4 Cloning with pGEM T easy Kit 
 
For subcloning without restriction sites the pGEM T easy Kit (Promega) was used after the 
manufacturer’s protocol. Therefore the PCR fragments were A-tailed by the Taq polymerase and 
afterwards ligated in the pGEM T easy multiple cloning site with T-overhangs at its 3’-and 5’-ends. 
After standard transformation bacteria were plated out on LB Amp plates containing 20µl 1 M 
IPTG and 35 µl X-Gal (50µg/ml). White colonies were picked for plasmid extraction. 
 
4.2.1.5 Plasmid purification and sequencing 
 
Plasmid DNA was extracted for all applications with the NucleoBond® Plasmid and Xtra Midi kits 
(Macherey-Nagel) according to the manufacturer’s protocols. Plasmid sequence was verified by 
sequencing with convenient sequencing primers by GATC (Köln, Germany) or Macrogen 
(Amsterdam, Netherlands).  
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4.2.2 Cell biological methods 
 
4.2.2.1 Cultivation of mammalian cells 
 
Human and murine cells were in general cultured under standard atmosphere conditions of 5 % 
CO2 at 37 °C in a Cell culture incubator. Dulbecco’s modified Eagle’s medium (DMEM, Sigma-
Aldrich) supplemented with 10% FBS (Sigma- Aldrich; Gibco, Thermo Fischer Scientific) and 1 % 
Penicillin/Streptomycin (Sigma-Aldrich).. 
 
4.2.2.2 Cell transfections  
 
4.2.2.2.1 Cell transfection by Lipofectamin 2000  
 
6-wells with 60-80 % confluent cells were transfected with 1µg plasmid DNA using Lipofectamin 
2000 according to the manufacturer’s protocol. Medium was changed after 6-18 h and cells were 
harvested after 24-48 h.  
 
4.2.2.2.2 Cell transfection by calcium phosphate 
 
Per 15 cm2 cell culture plate with 20-50 % confluent cells, 2-20 µg of Plasmid DNA mixed with 123 
µl 2 M CaCl2 and filled up to 1 ml with sterile H2O. 1ml of 2x HEPES buffer was added while shaking 
to the DNA containing mix and incubated for 10-15 min at RT. Afterwards DNA mix was added to 
the adherent cells and incubated for 24-48 h, alternatively medium can be changed after 24 hours 
to remove precipitated DNA. 
   
2x HEPES-buffered saline   274 mM NaCl, 1.5 mM Na2HPO4, 54.6 mM HEPES (pH 7.1) 
 
4.2.2.3 Cultivation and induction of stable HEK T-REx 293 FLP/IN cell lines 
 
Stable cell lines were used as described in Schraivogel et al. 2015. Briefly, cells were cultivated as 
described in 4.2.2.2.1 supplemented with Balstidcidin 15 µg/ml and Hygromycin 200 µg/ml. 
Expression was induced 24 h with 1 µg/ml Doxycycline and 48 h with Tetracycline 1µg/ml. Medium 
was changed 2-4 h before harvesting. 
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4.2.2.4 Tethering assay with Luciferase reporters 
 
HeLa cells were grown to 60 % confluence on 48 well-plates. Per well, 300 ng of HA/NHA-
constructs, 120 ng Renilla-5 boxB luciferase (RNL20) and 80 ng Firefly-Luciferase (FF) were 
transfected using Nanofectin (PAA Laboratories/GE Healthcare) according to the manufacturer’s 
guidelines. Cells were lysed 48 h after transfection with 60-100 μl Passive Lysis Buffer (Promega) 
for 15 min at RT while shaking. Luciferase activity was measured on a Mithras LB 940 luminometer 
(Berthold Technologies). Coelenterazine and DTT were added freshly before use. Data was 
analyzed by calculating the ratio of FF/RNL20 and the normalization of the NHA-tagged plasmid 
sample to the appropriate HA-tagged plasmid sample and compared to empty vector. All samples 
were measured in 3 technical and 3 biological replicates. 
 
4.2.2.5 Immunofluorescence of cells 
 
Immunofluorescence was conducted as described previously in Schraivogel et al. 2015. After 
incubation with the first and secondary antibody, cells which were grown on a glass slide were 
washed once with blocking solution, three times with 1xPBS and mounted using Prolong Gold 
containing DAPI (Thermo Fisher Scientific–Life Technologies). Confocal microscopy was done on a 
TCSSP8 (Leica Microsystems) equipped with acousto-optical beam splitter, 405 nm laser (for 
DAPI), argon laser (488 nm for Alexa 488), and DPSS laser 561 nm.  
 
4.2.2.6 Cultivation of Human Herpes Virus containing cells 
 
The Cultivation of cells and viruses classified as risk group 2 as well as all other molecular 
biochemical work were performed in the S2 laboratory of PD Dr. Hans-Helmut Niller, PD Dr. 
Michael Nevels and Dr. Christina Paulus.  
 
4.2.2.6.1 Generation of virus stocks  
 
Virus stocks were generated through infection of the primary fibroblast cell line MRC5 and 
havesting of the medium supernatant containing the viruses through centrifugation. Afterwards 
the virus titer was estimated with plaque assays. 
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4.2.2.6.2 Infection of confluent cells 
 
For infection of the cells, viruses stock was first gently sonicated, and diluted to a moi of 5. 
Afterwards virus was added to confluent MRC5 cells and incubated for 2 hours, cells were washed 
with DMEM medium and further cultivated until certain time points.  
 
4.2.2.6.3 Cultivation of virus-latent suspension cells 
 
Suspension cells were in general cultivated with RMPI 1640 mediumsupplemented with 10 % FBS 
(Gibco, thermos fischer scientific) and 1 % Pen/Strep (sigma-aldrich) under standard conditions of 
37 °C and 5 % CO2 in 25-, 75,-175 cm2 cell culture flasks.  
 
4.2.3 RNA based methods 
 
4.2.3.1 In vitro Transcription, gel purification by UREA-Page and RNA 
purification 
 
The T7 RNA Polymerase was purified by Dr. Nora Treiber and Dr. Thomas Treiber (both belong to 
the Meister lab, Biochemistry I, University of Regensburg) and used for large scale in vitro 
transcriptions. Reactions were incubated for 4 to 6 h at 37°C with Pyrophosphatase (Fermentas/ 
Thermo Fischer Scientific) and inactivated with DNA sample buffer. Reactions were gel-purified 
using a 15 % UREA-page, monitored under UV light shadowing and eluted with 300 mM NaCl 
followed by a precipitaiton with 0,8 volume Isopropanol and several washing steps with 75 % EtOH 
p.a.. RNA pellet was solved in 300 µl DEPC-H2O.  Reaction composition is listed below. 
 
 
In-vitro-transcription mix, 1 ml   
DNA Template   2 µg 
NTPs (0.2M each)  50 µl  10 mM 
1M Tris pH 8.0    30µl   30 mM 
1M MgCl2 1M   25µl   25 mM 
Triton X-100   10µl   1% 
1M DTT   10 µl   10 mM 
Spermidin   2µl   2mM 
Pyrophosphatase    1µl  
T7 RNA Polymerase (5mg/ml)  20µl  
DEPC-H2O    ad 1ml 
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4.2.3.2 RNA extraction 
 
RNA was extracted from cells, lysates (inputs) and IPs with TRIzol (Thermo Fisher Scientific) 
according to the manufacturer’s guidelines. Additionally a second chloroform purification step 
was added for qRT-PCR experiments.  
 
4.2.3.3 Quantitative real time-PCR  
 
For quantitative real time-PCR (qRT-PCR) for quantitative detection of input RNA and 
immunoprecipitated RNA levels, 1μg of extracted RNA or complete RNA yield from IPs was 
digested with DNaseI (Thermo Fisher Scientific) for 30 min at 37 °C and inactivated by heating at 
72 °C for 10 min and adding 1µl 100 mM EDTA.  
cDNA was synthesized with First Strand cDNA synthesis kit (Thermo Fisher Scientific) using random 
hexamer primer and following the manufacturer’s protocol. cDNA was diluted with 30µl H2O. qRT-
PCR was performed with Sso Fast Eva Green Mix (Bio-Rad Laboratories), 0,4µM forward and 
reverse primer. DNA was amplified using standard PCR programs from the Sso Fast Eva Green Mix 
manual with denaturation and annealing/ extension times of 5 s and 40 cycles. Reaction 
monitoring was performed on a C1000 thermal cycler with CFX96TM real time detection system 
(Bio-Rad Laboratories).  
Data were evaluated using ∆∆Ct method with GAPDH as reference mRNA and normalized to 
control sample. Error bars were calculated based on the standard deviations from three biological 
replicates.. 
 
4.2.3.4 Small RNA detection by UREA-page and northern blotting 
 
Northern blots for small RNA detection were basically performed as described in Pall and 
Hamilton, 2008. RNA was separated on a 12 % UREA-polyacrylamide gel at 400 V with 1x TBE 
buffer after preheating the gel. Gel pockets were flushed and 5-20 µg of RNA mixed with RNA 
sample buffer was loaded. After disassembling of the UREA-gel, RNA quality was verified with 
etidiumbromide staining and blotting was performed onto an Amersham Hybond-N membrane 
(GE Healthcare) for 30 min at 20 V with a semi-dry blotting chamber (Bio-rad Laboratories). 
 
10x TBE      890 mM Tris, 890 mM boric acid, 20 mM EDTA 
2x RNA sample buffer   0,025 % (w/v) Xylencyanol, 0,025 % (w/v) Bromphenolblau in 
Formamide Ethidiumbromide staining solution 1 µg/ml ethidiumbromide in 1x TBE 
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Afterwards the miRNA 5’ ends were subsequently chemically crosslinked for 1 h at 50°C to the 
membrane with a freshly prepared EDC crosslinking solution. Therefore the membrane was placed 
on an EDC-soaked-whatman paper and wrapped with plastic. After gentle washing the membrane 
was prehybridized with Hybridization solution at 50 °C while rolling. Probe was labeled using 20 
pmol DNA oligonucleotide  with 20 µCi of 32P-ATP (Hartmann Analytics) in a T4 PNK reaction 
according to the manufacturer’s protocol (Thermo Fischer Scientific) for 1h at 37°C. Reaction was 
stopped by adding 30µl 30 mM EDTA and probes were purified by Illustra MicroSpin G-25 columns 
(GE Healthcare). Flowtrough was added to the prehybridized membrane after PNK reaction 
verification and incubated overnight while rolling at 50 °C. Membrane was washed on the turning 
wheel first twice with wash buffer I followed by a third time with wash buffer II at 50°C for 10 min. 
Liquid was discarded and plastic was wrapped around membrane and exposed to a imaging 
screen. RNA signals were detected with the Personal Molecular Imager system (Bio-Rad 
laboratories). Alternatively current probe can be stripped off the membrane for re-usage. 
Therefore H2O was boiled, membrane was added and 10 % SDS was added to a final concentration 
of 0,1 %. After 10 min incubation at RT on a shaker this step was repeated followed by a third step 
with boiled water.  
 
 
EDC crosslinking solution 184 mg EDC (1-ethyl-3-(3-dimethyl-aminopropyl)-carbodiimid), 
61.25 µl 1-methylimidazol (12.5 M), 75 µl HCl (1M), adjust to  6 ml 
with H2O 
20x SSC    3 M NaCl, 0.3 M trisodium citrate (pH 7) 
50x Denhardt’s solution 1 % Bovine serum albumin fraction V, 1 % Polyvinylpyrrolidon K30, 
1 % Ficoll 400 
Hybridization solution   1x SSC, 20mM Na2HPO4 pH 7.2, 7 % SDS, 1x Denhardt’s solution 
Wash buffer I   5x SSC, 1 % SDS 
Wash buffer II    1x SSC, 1 % SDS 
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4.2.4 Proteinbiochemical methods 
 
4.2.4.1 Lysate preparation 
 
Total protein concentration of lysates after preparation was determined by Bradford 
measurements with BSA as standard. 
 
4.2.4.1.1 Lysate preparation from cultured cells 
 
Cells were grown under standard conditions on 12-, 6-well, 10 cm2 or 15 cm2 cell culture dishes. 
Cells were harvested after medium was removed, washed with cold PBS and additionally cell pellet 
was weighted after centrifugation (300 g/ 5 min/ 4°C) and removal of PBS supernatant. Pellet was 
either divided into more samples, frozen in liquid nitrogen and stored at -80 °C or lysed directly 
with IP lysis buffer. For lysis 1ml/15cm2 IP lysis buffer was added to the pellet, resolved and 
incubated for 10-30 min. Lysates were cleared by centrifugation (15.000 g/ 20 min/ 4°C). For mass 
spectrometric analyses cells were lysed with IP lysis buffer MS or RNAse/MS followed by 
immunoprecipitation. 
 
IP lysis buffer  150 mM KCl, 25 mM Tris pH 7,5, 2 mM EDTA, 1 mM NaF, 0,5 % NP-40, 1 mM DTT, 1mM 
AEBSF 
 
IP lysis buffer  MS 150 mM KCl, 25 mM Tris pH 7,5, 2 mM EDTA, 5 mM NaF, 0,5 % NP-40, 1 mM DTT, 1mM 
AEBSF, 1x tablet/10ml buffer PhosSTOP phosphatase inhibitor (Roche) 
 
IP lysis buffer  RNase A/MS 150 mM KCl, 25 mM Tris pH 7,5, 2 mM EDTA, 5 mM NaF, 0,5 % NP-40, 1 mM DTT, 1mM 
AEBSF, 1x tablet/10ml buffer PhosSTOP phosphatase inhibitor (Roche),  RNase A 1 µg/ml 
(Thermo Fischer Scientific) 
 
4.2.4.1.2 Nuclear and cytoplasmic fractionation 
 
Nuclear and Cytoplasmic fractionations were performed in general as described in Gagnon et al. 
2014 with slight modifications. Hek 293 T cells were cultured up to 80 % confluency, washed with 
PBS, harvested and washed again with ice-cold PBS. After centrifugation (100 g/ 5 min/ 4°C), cell 
pellet was resuspended by gentle pipetting with ice-cold hypotonic lysis buffer (HLB) with 1ml/ 75 
mg cell pellet or 10 mio. cells and incubated for 10 min and mixed by gentle inversion. Afterwards 
cells were centrifuged (800g/ 4 °C/ 8 min), supernatant (= cytoplasmic fraction) was transferred 
in a new tube and 140 mM NaCl was added to a final concentration of 150 mM for IPs. The nuclei 
pellet was washed gentle for three times with HLB through pipetting and centrifugation (200 g/ 
4°C/ 2 min). Nuclei were resuspended in 0,5 ml/75mg or 10 mio. cells and sonicated on ice three 
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times with 10-20 % power for 15 s with cooling periods between sonication steps. For fraction 
clearance centrifuge (15.000 g/ 15 min/4 °C) 
 
Hypotonic lysis buffer (HLB) 10 mM Tris (pH 7.5), 10 mM NaCl, 3 mM MgCl2, 0.3% (vol/vol) NP-
40 and 10 % (vol/vol) glycerol1 mM DTT, 1mM AEBSF, 1x 
tablet/10ml buffer PhosSTOP phosphatase inhibitor (Roche) 
 
Nuclear lysis buffer (NLB) 20 mM Tris (pH 7.5), 150 mM KCl, 3 mM MgCl2, 0.3% (vol/vol) NP-
40 and 10 % (vol/vol) glycerol1 mM DTT, 1mM AEBSF, 1x 
tablet/10ml buffer PhosSTOP phosphatase inhibitor (Roche) 
 
4.2.4.1.3 Lysate preparation from tissues 
 
Mouse tissue lysates were prepared in 800 µl NET buffer and mechanically disrupted by FastPrep®-
24 with lysing matrix D (45 s at 6.5 m/s) or with a 6 ml douncing homogenizer with a thight 
douncing spatel until suspension was homogeneous. Lysates were spinned down (13,000 g/ 1 min/ 
4 °C) and transferred to a new reaction tube and centrifuged (15.000 g/ 20 min/ 4 °C).  
 
NET buffer 50mM Tris/HCl pH 7.5, 150mM NaCl, 5mM EDTA, 0.5 % NP-40, 10 % Glycerol, 1mM NaF, 
0.5mM DTT, 1mM AEBSF, 1x tablet/10ml buffer PhosSTOP phosphatase inhibitor (Roche),  
RNase A 1 µg/ml (Thermo Fischer Scientific) 
 
4.2.4.1.4 Lysate preparation for protein-pull-down assays 
 
Virus infected cells were harvested on ice and washed twice with ice-cold DMEM. Cell pellet was 
resuspended in pull-down buffer 1ml/ 50 mio. cells and two times sonicated (power: 10 %/ duty 
cycle: 50 %/ 20 pulses) for inactivation. Afterwards lysate was centrifuged (20000 g/ 10 min/4 °C) 
and diluted to 5-10 mg/ml total protein and frozen with liquid nitrogen and stored on -80 °C. 
 
Pull-down buffer for lysate preparation  50mM Tris pH 8, 150mM NaCl, 5% Glycerin, 1 mM DTT, 1mM AEBSF 
 
4.2.4.2 Immunoprecipitation 
 
For immunoprecipitations (IP) of endogenous proteins from cell lysates, monoclonal or polyclonal 
antibodies were coupled after washing twice with PBS to Protein G Sepharose beads (GE 
Healthcare). Depending of the amount of protein material and experimental set up 30 to 200 µl 
of beads were used and coupled overnight at 4 °C while shaking. Afterwards beads were washed 
once with PBS through centrifugation (1000g/ 2 min/ 4 °C) to remove excess antibody.  
For Flag-/HA-tagged overexpressed proteins, IPs were performed with anti-FLAG M2 agarose 
beads (Sigma-Aldrich) for mass spectrometry and RNA experiments and for western blots with the 
monoclonal antibody 6F7 coupled to Protein G Sepharose beads. 
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Covalent coupling of monoclonal antibodies to Protein G Sepharose (GE Healthcare) was 
performed after for selective elution of proteins without co-elution of ABs (Gersten and 
Marchalonis, 1978; Schneider et al. 1982 und Simanis and Lane, 1985). First beads were washed 
with PBS by centrifugation (1000 g/ 2 min/ 4 °C), AB was added and incubated for 1h at RT while 
shaking. Afterwards beads were washed with 10x bead-volume 0,2 M Sodiumborat (pH 9.0, RT) 
and resuspended with 0,2 M Sodiumborat containing 20 mM Dimethylpimelimidate and 
incubated for 30 min at RT while shaking. Coupling reaction was stopped by washing once with 
10x bead-volume of 0,2 M Ethanolamine (pH 8.0) and repetition of this step and further incubation 
for 2 h at RT while shaking. Afterwards beads were washed again with PBS twice and stored in PBS 
supplemented with 0,025 % NaN3 at 4 °C. 
 
Antibody-coupled beads were added to prepared lysates (described in 4.2.4.1) for 1-3 h at 4 °C 
while rotating. After incubation supernatant was removed and alternatively mixed with SDS 
sample buffer. Beads were washed four times with IP wash buffer by centrifugation (1000g/ 2 
min/ 4 °C) and transferred into a new tube. Beads were eluted with 1-,5-2,5 SDS sample buffer 
after a final wash step with PBS.   
For extraction of co-immunoprecipitated RNA TRizol was used as described in 4.2.3.2. 
 
Antibody hybridoma supernatants were partly purified by Robert Hett with a 3-step purification 
protocol. Briefly, an appropriate amount of Ammoniumsulfate was added to the hybridoma 
supernatants. After centrifugation the pellet was resolved in PBS and antibodies were bound by 
an IMAC column with Co-IDA-beads (Fastflow Sepharose). After elution fine polishing was 
performed by a gelfiltration.  
 
IP wash buffer 300 mM NaCl, 50 mM Tris pH 7,5, 1 mM NaF, 0,01 % NP-40, 5 
mM MgCl2, 0,1-1 mM DTT, 0,1-1 mM AEBSF 
IP lysis buffer 150 mM KCl, 25 mM Tris pH 7,5, 2 mM EDTA, 1 mM NaF, 0,5 
% NP-40, 1 mM DTT, 1mM AEBSF 
5x SDS sample buffer 300 mMTris/HCl pH 6.8, 10 % SDS, 62.5 % glycerol, 0.05 % 
bromophenol blue, 10 % β –mercaptoethanol 
 
 
 
4.2.4.3 SDS-Page, Western Blot and coomassie-stainings 
 
For separation and visualization of proteins a 6-15 % SDS polyacrylamide gel was poured 
depending on the molecular weight of the protein of interest. Pockets were loaded with 
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appropriate amounts of denatured and preheated (95 °C/ 5 min) protein lysates mixed with SDS 
sample buffer form input (subsequently taken after lysate preparation) and IP samples for western 
blots and mass spectrometric analysis. Gels were run at 140 V for 30 min, followed by 220 V until 
dye front ran out. 
 
Stacking gel  125 mM Tris/HCl pH 6.8, 0.1 % SDS, 0.15 % TEMED, 5 % Acrylamide/Bis solution (37.5:1), 
0.05 % APS 
Separating gel  380 mM Tris/HCl PH 8.8, 0.1 % SDS, 0.1 % TEMED, 6-10 % Acrylamide/Bis solution 
(37.5:1), 0.05 % APS, 
SDS running buffer  25mM Tris, 192mM glycine, 1 % SDS 
5x SDS sample buffer 300 mMTris/HCl pH 6.8, 10 % SDS, 62.5 % glycerol, 0.05 % bromophenol blue, 10 % β –
mercaptoethanol 
 
For Western Blotting, three Whatman papers soaked with towbin blotting buffer were placed 
under a Hybond ECL membrane (GE Healthcare) onto the positive electrode. SDS gel and another 
three Whatmann papers were exactly applied to the membrane and air bubbles were removed. 
Western blots were performed in a semi-dry blotting chamber (Bio-rad) either at 10 V with a 
blotting time of 3 h or 1 min/ kDa protein and 2 mA/ 1 cm2. Alternatively proteins were blotted at 
30 V by wet-blotting overnight for 16 h at 4°C with wet blot buffer. Afterwards membrane was 
blocked with 5 % milk in TBS-T for at least 1 h and primary antibodies (AB) were diluted in 5 % milk 
in TBS-T and incubated with the blocked membrane for 1 h. To remove unspecific bound AB 
membrane was washed three times with TBST-T for 10 min each and secondary antibody was 
applied for 30-60 min. Signals were detected after washing the membrane three times with TBS-
T through scanning with the Odyssey Infrared Imaging System (Bio-rad). For antibody subtype 
identification specific secondary-HRP (supplied by Elisabeth Kremmer group) labeled antibodies 
were used and incubated with SuperSignal West Femto Maximum Sensitivity Substrate (Thermo 
Fisher Scientific) and detected by film.  
For coomassie-staining, first the SDS gel was washed once with H2O and then placed in coomassie-
staining Solution for at least 1-2 h. Destaining was performed as long as protein bands were clearly 
visible. 
 
Towbin blotting buffer  25mM Tris, 192mM glycine, 20 % methanol pH 8.6 
TBS-T    10mM Tris, 150mM NaCl, 0.05 % Tween pH 8 
Wet blot buffer   25mM Tris, 192mM glycine, 20 % methanol pH 8.6, 0,05 % SDS 
Blocking milk   5 % milk powder in TBS-T, 0,025 NaN3 
Coomassie stain   10 % acetic acid, 30 % ethanol, 0.25 % Coomassie R250 
Coomassie destain    10 % acetic acid, 20 % ethanol 
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4.2.4.4 RNA-pull-downs 
 
For RNA generation large amounts of DNA template were amplified in scale-up PCR reactions. In 
vitro transcriptions were performed as described in 4.2.3.1 and UREA-gel-purified. Afterwards 
80µl magnetic Dynabeads Streptavidin M270 (GE healthcare) were coupled with 2 µg biotinylated 
RNA “Hook”-oligo (Metabion) in 500 µl pull-down Puffer (PP) for 2h at 4 °C while shaking. Beads 
were washed and 10 µg of in vitro transcribed pre-miRNA was added and incubated overnight at 
4 °C while shaking.  
Meanwhile 1ml of lysate was thawed (described in 4.2.4.1.4) and precleared with 80 µl of 
magnetic Dynabeads Streptavidin M270 (GE healthcare) coupled with 2 µg biotinylated RNA 
“Hook”-oligo (Metabion) for 2-4 h at 4 °C while shaking. Afterwards precleared lysate was added 
to pre-miRNA coupled beads and incubated overnight at 4 °C. Lysate was removed and washed 
first with PPP supplemented with 0.1% Triton-X 100, second with PPP supplemented with 
additional 150 mM NaCl and third with PPP. Proteins were eluted with 25 µl of 1x LDS buffer 
(Invitrogen) and separated on a bis/tris bufferd 4-12 % gradient gel (Invitrogen) for mass 
spectrometric analysis. Alternatively pull-down was down scaled to 20-40 µl magnetic Dynabeads 
Streptavidin M270 per sample and eluted with 1,5x SDS sample buffer and separated by SDS-page 
for western blots. 
 
Pull-down buffer (PP)     50mM Tris pH 8, 150mM NaCl, 5% Glycerin 
 
Pull-down buffer for lysate preparation (PPP) 50mM Tris pH 8, 150mM NaCl, 5% Glycerin, 1 mM DTT, 1mM AEBSF 
 
5x SDS sample buffer 300 mMTris/HCl pH 6.8, 10 % SDS, 62.5 % glycerol, 0.05 % bromophenol blue, 
10 % β -mercaptoethanol 
 
4.2.5 Mass spectrometry 
 
All mass spectrometric measurements were performed at the MS facility of Biochemistry I, 
University of Regensburg under the guidance of Prof. Dr. Rainer Deutzmann and Dr. Astrid 
Bruckmann.  
 
4.2.5.1 Sample preparation 
 
After gradient-gels or SDS gels were destained, bands or gel parts were excised and transferred 
into 2ml micro tubes (Eppendorf), washed for 30 min with 500 µl 50 mM NH4HCO3, 50 mM 
NH4HCO3/ acetonitrile (3/1), 10 mM NH4HCO3/ acetonitrile (3/1), 10 mM NH4HCO3/ acetonitrile 
(1/1) and lyophilized. After reduction and alkylation of cysteines with 100 µl 1mg/ml DTT (57 °C/ 
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35 min) and 200 µl 5 mg/ml Iodoacetamide (RT/ 35 min) solved in 50 mM NH4HCO3, gel slices were 
washed again and lyophilized. Proteins were subjected to in gel tryptic digest overnight at 37 °C 
with 0,8 μg Trypsin Gold mass spectrometry grade (Promega) per sample. Peptides were first 
extracted twice with 100 mM NH4HCO3, followed by 100 mM NH4HCO3/ acetonitrile (2/1) and 
eluates were combined and lyophilized. 
Further processing was executed by Dr. Astrid Bruckmann or Eduard Hochmuth.  
 
4.2.5.2 Selected Reaction Monitoring measurements with heavy labeled 
peptides 
 
For quantification of TNRC6 proteins, IPs with different antibodies and input samples were applied 
to the QTRAP 4500 mass spectrometer combined with a SRM based method. SRM measurements 
were in general performed by Dr. Astrid Bruckmann. 
Briefly, unique synthetic peptides with a 13C15N-labeled C-terminal lysine or arginine for every 
human TNRC6 homolog were synthesized and used as standard (listed in Tab. 4.7). After samples 
were washed, 100 fmol of stable isotope-labeled peptide mix was spiked into tryptic digests and 
incubated over night at 37 °C. Afterwards peptides were extracted and applied to mass 
spectrometer 
 
4.2.5.3 MS data analysis 
 
Data obtained from samples analyzed on the MaXiS mass spectrometer were transferred to 
MASCOT 2.5.1 using the Protein-Scape software 3.1.3 (Bruker Daltonics). MASCOT aligned the 
obtained data to the annotated proteins of the NCBI protein data base or the SWISS-PROT 
database. Annotated proteins were exported as excel sheet and further analyzed depending on 
the experimental question. Therefore the expectation value, annotated peptides, protein size and 
Score served as analyses basement.  
Data obtained from relative quantification of TNRC6 protein levels was first exported to MS Office 
Excel and ratios of spike-in peptides of 100 fmol compared to measured peptides were calculated. 
Afterwards the mean value and median was calculated assuming that measured results represent 
100 % of TNRC6 proteins.  
Data obtained in the viral biogenesis screening project were combined and compared in Excel 
sheets and the selection of potential candidates was performed through the distinct parameters. 
These ones were the Score, Protein size and annotated peptides in both replicates. For 
visualization, a heatmap was designed with the candidates on the y-axis and the miRNAs on the 
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x-axis. Data sets were then for every single protein normalized to the whole score value of all 
detected single hits. Duplicates were averaged and thresholds for the different data sets were 
fixed. 
 
4.2.6 Computational methods and statistical analyses 
 
GO Term. For Go term analyses the browser programme GO.princteon.edu was used. Therefore 
selected protein lists were transformed to Uniprot nomenclature and processed.  
Sequence alignments. For Sequence and multiple Sequence alignments of annotated proteins and 
DNA/ RNA the browser programme Clustal W and TCoffee was used.  
Networks analysis. For the analysis of protein networks the programme STRING 10.0 was used.  
Kinase prediction. Kinases for selected TNRC6 phospho-sites were predicted with NETphos3.1 
(Blom et al. 2004). 
Browser based tools can be found under following www-links: 
http://www.cbs.dtu.dk/services/NetPhos-3.1/output.php 
http://www.uniprot.org 
http://pantherdb.org/ 
http://go.princeton.edu/cgi-bin/GOTermFinder 
http://www.ebi.ac.uk/Tools/services/web/toolresult.ebi?jobId=clustalo-I20170730-092917-
0605-20657726-pg&analysis=alignments 
http://string-db.org 
http://www.biovenn.nl/index.php 
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5.1 Supplementary information 
 
5.1.1 Herpesviral miRNAs and their function 
 
Table 16 Herpesviral miRNAs and their function 
hg host gene, vg viral gene, modified from (Grundhoff and Sullivan 2011; Grundhoff and Sullivan 2012; R. L. S. and B. R. Cullen 2013; 
Stern-Ginossar et al. 2009; Kang, Skalsky, and Cullen 2015; Bruscella et al. 2017; Piedade and Azevedo-Pereira 2016; Fruci, Rota, and 
Gallo 2017). 
 
mature miRNAs  target   function     publication 
 
hcmv-mir-UL22A 5p/3p 
    
hcmv-mir-UL36 5p/3p UL138 (vg), ANT3 (hg) Latent infection, cell survival (Y. Guo et al. 2015) 
 
hcmv-mir-UL112 5p/3p IE72 (vg), UL112/113 (vg), 
UL120/121 (vg) 
MICB (hg); IKKα and IKKβ (IKβ 
kinase ), IL32 (hg), type IIF sig. 
(hg), TLR3 (hg), VAMP3 
(hg),RAB5C (hg), RAB11A (hg), 
SNAP23 (hg), CDC42 (hg) 
Natural killer cell killing of virus-infected cells, 
Regulation of viral replication, latency 
Inhibition of proinflammatory cytokine 
response, tumor necrosis factor alpha, viral 
infection, immune evasion, vesicle  pathway 
(G J Seo et al. 2008; 
Stern-Ginossar et al. 
2009; Jeang 2008) 
(Hook et al. 2014) 
(Hancock et al. 2017) 
 
 
hcmv-mir-UL148D 
 
CCL5 (hg), IEX-1 (hg), CDC25B 
(hg), ACVR1B (hg) 
Immune evasion, cell survival, latent infection (Pan et al. 2016; B. 
Lau et al. 2016) 
 
hcmv-mir-US33 5p/3p Syntaxin3 Inhibition of viral DNA synthesis (X. Guo et al. 2015) 
 
hcmv-mir-US5-1 5p/3p IKKα and IKKβ (hg) (IKβ kinase ), 
US7 (vg), VAMP3 (hg),RAB5C 
(hg), RAB11A (hg), SNAP23 (hg), 
CDC42 (hg) 
Inhibition of proinflammatory cytokine 
response, tumor necrosis factor alpha, viral 
infection, vesicle pathway  
(Hancock et al. 2017) 
(Hook et al. 2014) 
 
hcmv-mir-US5-2 5p/3p US7 (vg), VAMP3 (hg),RAB5C 
(hg), RAB11A (hg), SNAP23 (hg), 
CDC42 (hg) 
viral infection, vesicle pathway (Hook et al. 2014) 
 
hcmv-mir-US25-1 5p/3p YWHAE (hg), UBB (hg), NPM1 
(hg), and HSP90AA1 (hg), ), 
VAMP3 (hg),RAB5C (hg), 
RAB11A (hg), SNAP23 (hg), 
CDC42 (hg), E2 (hg), BRCC3 (hg), 
MAPRE2 (hg), CD147 (hg)  
Inhibition of viral DNA replication, vesicle 
pathway 
(Jiang et al. 2015) 
(Hook et al. 2014) 
 
hcmv-mir-US25-2 5p/3p eIF4A1 Viral infection (M. Qi et al. 2013) 
 
hcmv-mir-US4 5p/3p ERAP1 (hg), QARS (hg) Immune evasion, cell survival 
  
hcmv-mir-UL70 5p/3p unknown Upregulation of Sox2 in CMV-mediated 
Glioblastoma multiforme cells 
(Ulasov et al. 2016) 
 
hcmv-mir-US22 5p/3p 
    
hcmv-mir-US29 5p/3p 
    
hcmv-mir-UL59 
     
hcmv-mir-UL69 
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mature miRNAs     target       function    publication 
 
ebv-mir-BHRF1-1 
    
ebv-mir-BHRF1-2 5p/3p PRDM1/Blimp1 tumor suppressor gene in B- and T-cells (Ma et al. 2016) 
ebv-mir-BHRF1-3 
 
CXCL11 (hg) Immune evasion 
 
ebv-mir-BART1 5p/3p LMP1 (vg)/Caspase-3 (hg), BIM 
(hg) 
Inhibits apoptosis/ Immune evasion (Lo et al. 2007) 
(Marquitz et al. 2011) 
(Vereide et al. 2014) 
ebv-mir-BART2 5p/3p MICB (hg) Immune evasion (Nachmani et al. 2009) 
ebv-mir-BART3 5p/3p BIM (hg), Dice1 (hg), FEM1B 
(hg), CASZ1a (hg) 
Inhibits apoptosis (Kang, Skalsky, and 
Cullen 2015), (Lei et al. 
2013) 
ebv-mir-BART4 5p/3p 
   
ebv-mir-BART5 5p/3p PUMA (hg) Inhibits apoptosis (Choy et al. 2008) 
ebv-mir-BART6 
 
Dicer (hg), OCT1 (hg) Regulation of miRNA biogenesis (Kang, Skalsky, and 
Cullen 2015; Godshalk, 
Bhaduri-McIntosh, and 
Slack 2008) 
ebv-mir-BART7 5p/3p APC (hg) Cell transformation and proliferation (Wong et al. 2012) 
ebv-mir-BART8 5p/3p ARID2 (hg) 
 
(Kang, Skalsky, and 
Cullen 2015) 
ebv-mir-BART9 5p/3p BIM (hg), E-cadherin (hg) Inhibits apoptosis, Induction of mesenchymal-
like phenotype, Migration of NPC cells 
(Hsu et al. 2014) 
(Marquitz et al. 2011) 
ebv-mir-BART10 5p/3p 
   
ebv-mir-BART11 5p/3p EBF1/BCR/BIM (hg) B-cell differentiation, Inhibits apoptosis (Ross, Gandhi, and 
Nourse 2013), 
(Marquitz et al. 2011) 
ebv-mir-BART12 
 
BIM (hg) Inhibits apoptosis (Marquitz et al. 2011) 
ebv-mir-BART13 5p/3p 
   
ebv-mir-BART14 5p/3p 
   
ebv-mir-BART15 
 
BZLF1 (vg), BRLF1 (vg), NLRP3 
(hg), LMP1 (hg) 
Immune evasion (Murphy et al. 
2008),(Haneklaus et al. 
2012) 
ebv-mir-BART16 
 
TOMM22 (hg), Caspase-3 (hg), 
CREBBP (hg), SH2B3 (hg) 
Inhibits apoptosis, Immune evasion (Kang, Skalsky, and 
Cullen 2015) 
ebv-mir-BART17 5p/3p LMP1 (vg), WIF1 (hg) Inhibits apoptosis, Proliferation (Lo et al. 2007), (Wong 
et al. 2012) 
ebv-mir-BART18 5p/3p 
   
ebv-mir-BART19 5p/3p APC (hg) Proliferation (Wong et al. 2012) 
ebv-mir-BART20 5p/3p BAD (hg) Inhibits apoptosis 
 
ebv-mir-BART21 5p/3p 
   
ebv-mir-BART22 
 
PPP3R1 (hg), PAK2 (hg), 
TP53INP1 (hg) 
Inhibits apoptosis (Kang, Skalsky, and 
Cullen 2015) 
 
 
mature miRNAs  target   function    publication 
 
hsv1-mir-H2 5p/3p ICP0 (vg) 
 
(S. Tang et al. 2008; S. 
Tang, Patel, and Krause 
2009; S. Tang et al. 
2013) 
hsv1-mir-H3 5p/3p ICP34,5 (vg) 
 
(S. Tang et al. 2008; S. 
Tang, Patel, and Krause 
2009; S. Tang et al. 
2013) 
hsv1-mir-H6 5p/3p ICP4 (vg) 
 
(S. Tang et al. 2008; S. 
Tang, Patel, and Krause 
2009; S. Tang et al. 
2013) 
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5.1.2 Virus hairpin pull-down - data sets and analysis 
 
 
Figure 39 Pull-down heat map and in silico analysis of all bound viral candidates from EBV, CMV and HSV1 and BKV, 
MCV, HPV41. 
(A), (B) Heatmap of mass spectrometric identified viral proteins. Gene symbols on the y-axis and used pre-miRNAs on 
the x-axis. Annotated protein hits were defined by score (obtained with Mascot and proteinscape). (C) Classification of 
viral candidates by subcellular localization, RBDs and Gene Ontology 
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Figure 40 Pull-down 
heat map of all bound 
viral candidates from 
EBV. 
Heatmap of mass 
spectrometric 
identified proteins. 
Gene symbols on the y-
axis and used pre-
miRNAs on the x-axis. 
Annotated protein hits 
were defined by score 
(obtained with Mascot 
and proteinscape) and 
normalized to the 
summarized counts of 
one protein. Pull-
downs were performed 
in replicates and 
averaged afterwards. 
Specific binding is 
indicated in blue 
shades (from white = 0 
to blue = 20).  
Continued on next 
page 
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Figure 41 Pull-down heat 
map of all bound viral 
candidates from HSV1. 
       Heatmap of mass 
spectrometric identified 
proteins. 
             Gene symbols on the y-axis 
and used pre-miRNAs on the x-axis. 
Annotated protein hits were defined by 
score (obtained with Mascot and 
proteinscape) and normalized to the 
summarized counts of one protein. 
Pull-downs were performed in 
replicates and averaged afterwards. 
Specific binding is indicated in blue 
shades (from white = 0 to blue = 22,5).  
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Figure 42 Combined in silico analysis of all bound candidates of the herpesviral, papilloma and polyoma virus pull-
downs. 
(A) GO term analysis classifications with high p-values and cluster frequency. (B) Subcellular localization of identified 
proteins (classified with uniprot database). (C) RNA binding domains distributed within the identified proteins. (D) 
Distribution of RNA binding domains within the identified proteins. 
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PLOD3  
hsv1-miR-H6        --------------------------CGGGGGGCCGGAG-----GGUGGAAGGCAG--GG 27 
hsv1-miR-H3        -------CCGCGGGCGCGCUCCUGACCGCGGGUUCCGAGUUGGGCGUGGAGGUUACCUGG 53 
hcmv-miR-UL70      GGUUGCGUCUCGGCCU-CGUCCAGACU--------------------GGCGAUGAGCGCC 39 
                                                                  **     *      
 
 
hsv1-miR-H6        GGGUGU-AGGAUGGGUAUCAGGACUUCCACUUCCCGUCCUUCCAUCCCCCGUUCCCCUCG 86 
hsv1-miR-H3        GACUGUGCGGUUGGG-------ACGG----CGCCCGUGG--------------------- 81 
hcmv-miR-UL70      GAGAGG-GGGAUGGG-------CUGG----CGCGCGGCC--------------------- 66 
                   *   *   ** ****                 * **                         
 
B  
hsv1-miR-H3        
          gc   ug      -      g  u   g g  
ccgcgggcgc  ucc  accgcg gguucc ag ugg c u 
||||||||||  |||  |||||| |||||| || ||| | g 
ggugcccgcg  agg  uggcgu ucaggg uc auu g g 
          gc   gu      g      -  c   g a  
 
hsv1-miR-H6   
       -c   a          ca        u   --a  g  
cgggggg  cgg ggguggaagg  ggggggug agg   ug g 
|||||||  ||| ||||||||||  |||||||| |||   || u 
gcucccc  gcc ccuaccuucc  cccuucac uuc   ac a 
       uu   c          ug        c   agg  u 
 
 
hcmv-miR-UL70 
        c      u     -aga  -    a  
gguugcgu ucggcc cgucc    cu ggcg u 
|||||||| |||||| |||||    || |||| g 
ccggcgcg ggucgg guagg    ga ccgc a 
        c      -     ggga  g    g 
 
PTBP1  
hsv1-miR-H8        ----------------GUCCCUGUAU-----AUAUAGGGUCAGGGGGUUCCGCACCCCCU 39 
hcmv-miR-UL59      ---------------------CGACGGUUCUCUCGCUCGUCAUGCCGUUCUGAGC--UCC 37 
hpv41-miR-H1       GGUAUUGUGGUGCGGUGUCCUCGACGGUCCAUG----UGUCAUCU---UAUAAUC----- 48 
                                         *               ****      *     *      
hsv1-miR-H8        AACAUG-GCGCCCCCGGUCCCUGUAUAUAU---AGUUGUC 75 
hcmv-miR-UL59      GACAUG-GCGGACGAGA-----GAAAAUGGCGUCG----- 66 
hpv41-miR-H1       -ACUUGGUCAGUCCAGG-----GUACACCACUCCAUUAUC 82 
 
  
>hcmv-miR-UL59  
    ----g        cu       c  uucu  
cgacg     uucucucg  cgucaug cg    g 
|||||     ||||||||  ||||||| ||      
gcugc     aagagagc  gcgguac gc    a 
     gguaa        ag       a  cucg  
 
 
>hsv1-miR-H8 
-gucc              u a      u   caccc  
     cuguauauauaggg c gggggu ccg     c 
     |||||||||||||| | |||||| |||       
     gauauauauguccc g cccccg ggu     c 
cuguu              u g      c   acaau  
 
 
 
Figure 43 Multiple sequence alignments from pri-miRNAs interacting with one particular candidate. 
MSA of pri-miRNA sequence of different specific RBP interacting pri-miRNAs performed with Clustal Omega from EMBL-
ebi-tools. Location of consensus sequence within the pri-miRNA hairpins marked with yellow, mature miRNAs are shown 
in yellow. Complementary base pairing is illustrated with lines between the corresponding bases. Hairpin structures 
were taken from the miRBase. 
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PURA   
hcmv-miR-UL148D      AGCAGGUGAGGU-------UGGGGCGGACAACGUGUUGCGGAUUGU----GGCGAGAACG 49 
hsv1-miR-H3          ----------CCGCGGGCGCGCUCCUGACCGCGGGUUCCGAGUUGGGCGUGGAGGUUACC 50 
hcmv-miR-UL70        ---GGUUGCGUCUCGGCCU-CGUCCAGACU--------------------GGCGAUGAGC 36 
                                             * ***                     ** *   *   
 
 
hcmv-miR-UL148D      UCGUCCUCCCCUUCUUC-A--CCGCC----- 72 
hsv1-miR-H3          UGGGACUGUGCGGUUGGGACGGCGCCCGUGG 81 
hcmv-miR-UL70        GCCGAGAGG-GGGAUGGGCUGGCGCGCGGCC 66 
                                   *       ***       
 
B  
  hsv1-miR-H3        
          gc   ug      -      g  u   g g  
ccgcgggcgc  ucc  accgcg gguucc ag ugg c u 
||||||||||  |||  |||||| |||||| || ||| | g 
ggugcccgcg  agg  uggcgu ucaggg uc auu g g 
          gc   gu      g      -  c   g a  
 
 
hcmv-miR-UL148D 
a  a       uu    c    a    -g    gga  
 gc ggugagg  gggg ggac acgu  uugc   u 
 || |||||||  |||| |||| ||||  ||||     
 cg ccacuuc  cccc ccug ugca  agcg   u 
c  -       uu    u    c    ag    gug  
 
 
hcmv-miR-UL70 
 
       c      u     -aga  -    a  
gguugcgu ucggcc cgucc    cu ggcg u 
|||||||| |||||| |||||    || |||| g 
ccggcgcg ggucgg guagg    ga ccgc a 
        c      -     ggga  g    g 
 
NOL11 
 
 
bkv-miR-B1          GGGAAUCUUCAGCAGGGGCUGAAGUAUCUGAGACUUGGGAAGAGCAUUGUGAUUGGGAUU 60 
hcmv-miR-UL112      -GAC--------------------------AGCCUCCGGA-UCACAUGGUUA------CU 26 
                     *                            ** **  ***    *** ** *       * 
 
bkv-miR-B1          CAGUGCUUG--------AUCC------AUGUCCAGAGUCUUCAGUUUCUGAAUCCU 102 
hcmv-miR-UL112      CAGCGUCUGCCAGCCUAAGUGACGGUGAGAUCCAGGCUGUC--------------- 67 
                    *** *  **        *         *  *****  * *             
 
  
bkv-miR-B1 
    aucuucag   gg       ua    a   u    aa        u   u  
ggga        cag  gcugaag  ucug gac uggg  gagcauug gau g 
||||        |||  |||||||  |||| ||| ||||  |||||||| |||   
uccu        guc  ugacuuc  agac cug accu  uucgugac uua g 
    ------aa   uu       ug    -   u    ag        -   g  
 
 
hcmv-miR-UL112 
        cc     a   g      c  c  cu  
gacagccu  ggauc cau guuacu ag gu  g 
||||||||  ||||| ||| |||||| || ||    
cugucgga  ccuag gug caguga uc cg  c 
        --     a   g      a  -  ac 
 
Figure 44 Multiple sequence alignments from pri-miRNAs interacting with one particular candidate. 
MSA of pri-miRNA sequence of different specific RBP interacting pri-miRNAs performed with Clustal Omega from EMBL-
ebi-tools. Location of consensus sequence within the pri-miRNA hairpins marked with yellow, mature miRNAs are shown 
in yellow. Complementary base pairing is illustrated with lines between the corresponding bases. Hairpin structures 
were taken from the miRBase. 
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5.1.3 MS results 
 
 
Table 17 human TNRC6 proteins 
Isoform Residue [phospho-site] p-value RP1 p-value RP2 p-value RP3 [H1] 
TNRC6A_Iso1 S[245]   1.80E-05 
 T[287] 2.40E-02 3.20E-02 8.10E-03 
 T[323]  1.30E-02  
 S[389]  4.00E-03  
 T[397]  9.20E-03  
 S[463]   6.60E-02 
 S[497], T[502]   9.50E-03 
 T[502], S[503], S[505] 7.50E-03   
 T[603], T[608]  4.30E-02  
 T[644] 1.10E-03   
 S[678] 7.20E-05   
 T[679] 6.00E-05   
 T[736] 2.00E-04   
 T[738] 2.70E-04 3.60E-04  
 S[739] 3.40E-07 2.30E-05 7.20E-08 
 S[771]   1.60E-04 
 S[781]   1.10E-03 
 S[798]  6.00E-09  
 S[942]   5.90E-04 
 S[943] 2.80E-03  1.20E-06 
 S[991] 5.30E-05 5.80E-10 1.40E-08 
 S[938]   3.40E-04 
 S[1214]   1.40E-02 
 S[1217] 1.10E-04  8.60E-05 
 S[1333] 5.00E-03   
 S[1405] 1.30E-02  1.70E-02 
 S[1448]  2.10E-02  
 S[1503]   4.10E-04 
 S[1582], S[1585]   8.70E-03 
 S[1585] 1.30E-11 1.20E-06 6.50E-14 
 S[1599] 4.00E-06 3.40E-02 4.70E-05 
 S[1605]   2.10E-02 
 Y[1631] 3.50E-05   
 S[1636] 4.40E-02   
 S[1686] 4.50E-02   
 T[1702] 1.20E-04   
 S[1704] 3.30E-06  8.40E-07 
 T[1845] 9.70E-06   
 S[1884] 2.50E-03 1.40E-06  
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Isoform Residue [phospho-site] p-value RP1 p-value RP2 p-value RP3 [H1] 
TNRC6B_Iso1 T[51]   2.00E-02 
 S[54] 1.10E-03  8.70E-03 
 S[58]   1.10E-02 
 S[59]   1.00E-04 
 S[61] 2.90E-03  1.20E-07 
 T[168]  9.80E-09  
 S[195]  1.30E-03  
 S[212]   1.00E-04 
 S[243]  6.60E-07 4.10E-02 
 S[247]  2.70E-04  
 S[250]   1.60E-02 
 S[273]  1.80E-03  
 S[309]  1.20E-03  
 S[332]   6.30E-06 
 S[333] 7.30E-03   
 S[332], S[333] 1.40E-03   
 S[343], S[348]   5.10E-03 
 S[384] 1.70E-03 2.90E-02 6.40E-04 
 S[385] 5.00E-05 9.30E-07 7.10E-11 
 T[419] 3.00E-04   
 S[421] 3.70E-06   
 T[480]   2.40E-08 
 S[483]   9.20E-06 
 S[534] 1.80E-02   
 T[535] 3.40E-02   
 T[596] 1.00E-05 7.00E-04 1.60E-04 
 T[606] 5.80E-04   
 S[609] 2.60E-03   
 T[687] 3.00E-02   
 T[782]  7.90E-03  
 S[803]   3.20E-03 
 S[879] 4.40E-09 2.50E-07 2.50E-10 
 Y[904]   2.20E-04 
 S[990], S[992] 1.30E-03   
 S[1011]   3.00E-03 
 S[1057]   2.50E-05 
 S[1067]   2.40E-05 
 S[1080], S[1081] 1.40E-03   
 S[1197] 7.30E-03   
 T[1213], S[1220], S[1221]   2.20E-03 
 S[1220], S[1221], S[1223]   2.60E-02 
 S[1221] 3.00E-03   
 S[1223] 3.00E-03  5.00E-02 
 S[1336]   1.10E-05 
 S[1338]   1.10E-04 
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 S[1401]   2.20E-02 
Isoform Residue [phospho-site] p-value RP1 p-value RP2 p-value RP3 [H1] 
TNRC6B_Iso1 T[1411]   5.00E-03 
 S[1432] 1.70E-08  7.20E-10 
 S[1432], S[1461]   3.40E-02 
 S[1461] 1.80E-03  3.30E-05 
 S[1512] 8.20E-06  6.00E-11 
 T[1517] 2.80E-05  3.40E-09 
 S[1539]   3.30E-03 
 S[1570] 2.50E-03  5.60E-04 
 T[1596]   3.60E-02 
 S[1647]   2.00E-02 
 T[1701] 1.10E-03  5.70E-02 
 T[1701], T[1711]   8.30E-03 
 T[1712] 6.50E-07   
 S[1816] 7.60E-04  1.50E-06 
 S[1830]   4.60E-02 
 S[1832] 6.80E-06  1.90E-05 
     
TNRC6C_Iso1 S[59]  2.90E-03  
 S[465] 9.70E-05 9.80E-04 6.90E-07 
 S[568] 2.00E-11 8.20E-04 2.90E-04 
 T[570] 1.60E-03   
 S[669]   4.30E-02 
 S[705]   9.00E-03 
 S[714] 3.90E-06 2.00E-07 1.60E-07 
 S[717]   6.80E-03 
 T[777] 1.90E-03 1.70E-06 7.90E-05 
 S[865]  1.10E-03  
 S[1010] 3.30E-02   
 S[1011] 6.50E-06 2.60E-02 3.50E-03 
 T[1016] 4.20E-05   
 S[1305] 6.90E-02   
 S[1358] 3.10E-03   
 T[1578] 1.80E-04   
 S[1628]  1.10E-03  
 T[1674] 2.90E-06  6.70E-04 
 T[1678]   1.20E-02 
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5.1.4 MSA, in silico and MS phospho-analysis of TNRC6 
 
 
 
Table 18 Immunoprecipitated interactors of TNRC6 (kinases and phosphatases are marked in red) 
Accession Protein MW [kDa] Scores 
AGO2_HUMAN Protein argonaute-2 OS=Homo sapiens  97.1 3216.5 
AGO1_HUMAN Protein argonaute-1 OS=Homo sapiens  97.2 2489.8 
LMNB1_HUMAN Lamin-B1 OS=Homo sapiens  66.4 2408.8 
SHIP2_HUMAN Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2 OS=Homo 
sapiens  
138.5 2159.8 
HNRPM_HUMAN Heterogeneous nuclear ribonucleoprotein M OS=Homo sapiens  77.5 2066.2 
TOP2B_HUMAN DNA topoisomerase 2-beta OS=Homo sapiens  183.2 1670.6 
AGO3_HUMAN Protein argonaute-3 OS=Homo sapiens  97.3 1647.2 
SMC1A_HUMAN Structural maintenance of chromosomes protein 1A OS=Homo sapiens  143.1 1557.5 
LMNA_HUMAN Prelamin-A/C OS=Homo sapiens  74.1 1543.2 
ENPL_HUMAN Endoplasmin OS=Homo sapiens 92.4 1483 
HSP71_HUMAN Heat shock 70 kDa protein 1A/1B OS=Homo sapiens  70.0 1238.5 
NOP56_HUMAN Nucleolar protein 56 OS=Homo sapiens  66.0 1203 
TR150_HUMAN Thyroid hormone receptor-associated protein 3 OS=Homo sapiens  108.6 1202.1 
HS90B_HUMAN Heat shock protein HSP 90-beta OS=Homo sapiens  83.2 1035.9 
SMCA5_HUMAN SWI/SNF-related matrix-associated actin-dependent regulator of 
chromatin subfamily A member 5 OS=Homo sapiens  
121.8 1003.6 
AGO4_HUMAN Protein argonaute-4 OS=Homo sapiens  97.0 946.8 
TNR6B_HUMAN Trinucleotide repeat-containing gene 6B protein OS=Homo sapiens  193.9 910.7 
SSRP1_HUMAN FACT complex subunit SSRP1 OS=Homo sapiens  81.0 896.5 
HSP72_HUMAN Heat shock-related 70 kDa protein 2 OS=Homo sapiens 70.0 885.8 
TOP2A_HUMAN DNA topoisomerase 2-alpha OS=Homo sapiens  174.3 871.5 
BAZ1B_HUMAN Tyrosine-protein kinase BAZ1B OS=Homo sapiens 170.8 810.5 
DHX9_HUMAN ATP-dependent RNA helicase A OS=Homo sapiens  140.9 805.8 
DDX27_HUMAN Probable ATP-dependent RNA helicase DDX27 OS=Homo sapiens  89.8 788.4 
KLH22_HUMAN Kelch-like protein 22 OS=Homo sapiens 71.6 777.8 
WDR36_HUMAN WD repeat-containing protein 36 OS=Homo sapiens  105.3 735.5 
RFA1_HUMAN Replication protein A 70 kDa DNA-binding subunit OS=Homo sapiens  68.1 704.8 
DDX5_HUMAN Probable ATP-dependent RNA helicase DDX5 OS=Homo sapiens  69.1 685.7 
PESC_HUMAN Pescadillo homolog OS=Homo sapiens  68.0 667 
DDX21_HUMAN Nucleolar RNA helicase 2 OS=Homo sapiens  87.3 643.8 
ZY11B_HUMAN Protein zyg-11 homolog B OS=Homo sapiens  83.9 621.4 
HS90A_HUMAN Heat shock protein HSP 90-alpha OS=Homo sapiens  84.6 607.7 
DHX30_HUMAN Putative ATP-dependent RNA helicase DHX30 OS=Homo sapiens  133.9 561.3 
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Accession Protein MW [kDa] Scores 
SP16H_HUMAN FACT complex subunit SPT16 OS=Homo sapiens  119.8 545.3 
LMNB2_HUMAN Lamin-B2 OS=Homo sapiens  67.6 543.5 
DHX15_HUMAN Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15 
OS=Homo sapiens  
90.9 529.2 
DDX18_HUMAN ATP-dependent RNA helicase DDX18 OS=Homo sapiens  75.4 523.4 
SAFB1_HUMAN Scaffold attachment factor B1 OS=Homo sapiens  102.6 502.2 
CUL5_HUMAN Cullin-5 OS=Homo sapiens  90.9 499.6 
ODP2_HUMAN Dihydrolipoyllysine-residue acetyltransferase component of pyruvate 
dehydrogenase complex, mitochondrial OS=Homo sapiens  
69.0 487.1 
UTP18_HUMAN U3 small nucleolar RNA-associated protein 18 homolog OS=Homo sapiens  62.0 485.5 
GELS_HUMAN Gelsolin OS=Homo sapiens  85.6 461.4 
K1C14_HUMAN Keratin, type I cytoskeletal 14 OS=Homo sapiens 51.5 447.9 
GRP75_HUMAN Stress-70 protein, mitochondrial OS=Homo sapiens 73.6 427.8 
GTF2I_HUMAN General transcription factor II-I OS=Homo sapiens  112.3 425.9 
NOL11_HUMAN Nucleolar protein 11 OS=Homo sapiens  81.1 407.6 
PININ_HUMAN Pinin OS=Homo sapiens  81.6 396.1 
GRP78_HUMAN 78 kDa glucose-regulated protein OS=Homo sapiens  72.3 393.3 
BCLF1_HUMAN Bcl-2-associated transcription factor 1 OS=Homo sapiens  106.1 390.2 
IMMT_HUMAN Mitochondrial inner membrane protein OS=Homo sapiens  83.6 388.5 
H90B2_HUMAN Putative heat shock protein HSP 90-beta 2 OS=Homo sapiens 44.3 382.2 
PELP1_HUMAN Proline-, glutamic acid- and leucine-rich protein 1 OS=Homo sapiens  119.6 369 
NOL10_HUMAN Nucleolar protein 10 OS=Homo sapiens  80.3 366.3 
NCOA5_HUMAN Nuclear receptor coactivator 5 OS=Homo sapiens  65.5 365.7 
CRNL1_HUMAN Crooked neck-like protein 1 OS=Homo sapiens  100.4 364.1 
RBM14_HUMAN RNA-binding protein 14 OS=Homo sapiens  69.4 360 
TBL3_HUMAN Transducin beta-like protein 3 OS=Homo sapiens  89.0 355.9 
DDX41_HUMAN Probable ATP-dependent RNA helicase DDX41 OS=Homo sapiens  69.8 352.4 
WDR43_HUMAN WD repeat-containing protein 43 OS=Homo sapiens  74.8 344.4 
TDIF2_HUMAN Deoxynucleotidyltransferase terminal-interacting protein 2 OS=Homo 
sapiens 
84.4 344.3 
ATD3B_HUMAN ATPase family AAA domain-containing protein 3B OS=Homo sapiens  72.5 332.1 
SYRC_HUMAN Arginine--tRNA ligase, cytoplasmic OS=Homo sapiens  75.3 324.6 
RAD21_HUMAN Double-strand-break repair protein rad21 homolog OS=Homo sapiens  71.6 324.1 
DDX17_HUMAN Probable ATP-dependent RNA helicase DDX17 OS=Homo sapiens  80.2 320.8 
IMB1_HUMAN Importin subunit beta-1 OS=Homo sapiens  97.1 314.1 
NOC3L_HUMAN Nucleolar complex protein 3 homolog OS=Homo sapiens  92.5 311.5 
AIFM1_HUMAN Apoptosis-inducing factor 1, mitochondrial OS=Homo sapiens 66.9 298.3 
MBB1A_HUMAN Myb-binding protein 1A OS=Homo sapiens  148.8 296.1 
XRCC6_HUMAN X-ray repair cross-complementing protein 6 OS=Homo sapiens  69.8 295.5 
SAFB2_HUMAN Scaffold attachment factor B2 OS=Homo sapiens  107.4 293.3 
IRS4_HUMAN Insulin receptor substrate 4 OS=Homo sapiens  133.7 292.2 
TIF1A_HUMAN Transcription intermediary factor 1-alpha OS=Homo sapiens  116.8 280.6 
SAS10_HUMAN Something about silencing protein 10 OS=Homo sapiens  54.5 276 
LAS1L_HUMAN Ribosomal biogenesis protein LAS1L OS=Homo sapiens  83.0 272.4 
A2MG_HUMAN Alpha-2-macroglobulin OS=Homo sapiens  163.2 264.6 
NEK9_HUMAN Serine/threonine-protein kinase Nek9 OS=Homo sapiens  107.1 263.7 
TITIN_HUMAN Titin OS=Homo sapiens  3813.7 256.5 
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HS71L_HUMAN Heat shock 70 kDa protein 1-like OS=Homo sapiens  70.3 254.9 
Accession Protein MW [kDa] Scores 
KHDR1_HUMAN KH domain-containing, RNA-binding, signal transduction-associated 
protein 1 OS=Homo sapiens  
48.2 249.4 
HSP7C_HUMAN Heat shock cognate 71 kDa protein OS=Homo sapiens  70.9 246 
PABP1_HUMAN Polyadenylate-binding protein 1 OS=Homo sapiens  70.6 245.4 
DDX3X_HUMAN ATP-dependent RNA helicase DDX3X OS=Homo sapiens  73.2 244.5 
ZN326_HUMAN DBIRD complex subunit ZNF326 OS=Homo sapiens  65.6 244.4 
VSIG8_HUMAN V-set and immunoglobulin domain-containing protein 8 OS=Homo sapiens  43.9 240.3 
CO3_HUMAN Complement C3 OS=Homo sapiens  187.0 239.3 
MTA2_HUMAN Metastasis-associated protein MTA2 OS=Homo sapiens 75.0 231.9 
SYIC_HUMAN Isoleucine--tRNA ligase, cytoplasmic OS=Homo sapiens  144.4 206.9 
ALBU_HUMAN Serum albumin OS=Homo sapiens  69.3 202 
NU160_HUMAN Nuclear pore complex protein Nup160 OS=Homo sapiens  162.0 190.6 
ADNP_HUMAN Activity-dependent neuroprotector homeobox protein OS=Homo sapiens  123.5 181 
RB12B_HUMAN RNA-binding protein 12B OS=Homo sapiens  118.0 167.8 
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Figure 45 Multiple sequence alignments from murine and human TNRC6 proteins  
(A) Conservation of TNRC6 paralogs human vs. mouse. (B) MSA of murine and human TNRC6 proteins. Known domains 
are colored. Phospho-sites are indicated in red letters. 
 
1: TNR6B_HUMAN  100.00   96.44   40.63   40.40   40.40   40.29 
2: TNR6B_MOUSE   96.44  100.00   40.44   39.62   40.20   40.28 
3: TNR6C_HUMAN   40.63   40.44  100.00   91.38   46.77   46.23 
4: TNR6C_MOUSE   40.40   39.62   91.38  100.00   46.41   45.85 
5: TNR6A_HUMAN   40.40   40.20   46.77   46.41  100.00   94.73 
6: TNR6A_MOUSE   40.29   40.28   46.23   45.85   94.73  100.00 
 
 
Paralog  Domain Position [aa] Length Function   
 
TNRC6A  ABD 1 – 932  932 Interaction with Argonaute family proteins 
RRM 1781 – 1853 73 Function unknown 
  PAM2 1604 – 1622 19 PABPC1-interacting motif-2 
  Gln – rich 93 – 127  35  
  Gln – rich 1330 – 1476 116 Function unknown, p-body localization? 
  Ser – rich 192 – 365  174 Function unknown 
  SD 1476 – 1962 486 Interaction with CNOT1 and PAN3 
 
TNRC6B  ABD 1 – 994  994 Interaction with Argonaute family proteins 
RRM 1648 – 1720 73 Function unknown 
  PAM2 1472 – 1490 19 PABPC1-interacting motif-2 
  Gln – rich 1196 – 1373 77 Function unknown, p-body localization? 
Pro – rich 825 – 880  56 Function unknown 
SD 1218 – 1723 506 Interaction with CNOT1 and PAN3 
   
 
TNRC6C  ABD 1 – 926  926 Interaction with Argonaute family proteins 
RRM 1565 – 1632 68 Function unknown 
  PAM2 1381 – 1399 19 PABPC1-interacting motif-2 
  Pro – rich 1215 – 1248 34 Function unknown, p-body localization? 
SD 1260 – 1690 431 Interaction with CNOT1 and PAN3 
n.n. 1596 – 1690 95 Interaction with the CCR4-NOT 
n.n. 1371 – 1690 320 Sufficient for translational repression when tethered to target 
UBA 933 – 978  46 Ubi interaction site 
Gly – rich 204 – 430  227 Function unknown 
  Thr – rich 756 – 777  22 Function unknown 
 
A 
B 
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Figure 46 Mass spectrometric detection of potential phosphorylation sites in endogenous TNRC6A-C proteins. 
(A) Venn diagrams depict overlapping phosphorylation sites of biological human replicates. Diagrams were conducted 
with the browser based software Biovenn. (B), (C), (D) Overview of potential phosphorylation sites according to their 
individual localization within the TNRC6 paralog. Grey bars represent TNRC6 proteins, red bars represent potential 
phosphorylation sites and black lines between the phosphor-sites indicate conservation. Hs: Homo sapiens, Mm: mus 
musculus. (E) Schematic representation of the location of phospho-sites conserved between the different paralogs. 
Unique and conserved phosphorylation sites are indicated in red. Black lines indicate conserved phospho-sites among 
the three human TNRC6 and three murine paralogues 
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A  
Phosphosite/aa seq/Probability/Kinase 
1585 S   TSPASPPGS   0.990   unsp 
1585 S   TSPASPPGS   0.590   p38MAPK    
1585 S   TSPASPPGS   0.581   cdk5 
1585 S   TSPASPPGS   0.521   GSK3 
 
 739 S   DTETSPRGE   0.974   unsp 
 739 S   DTETSPRGE   0.552   CKI  
 739 S   DTETSPRGE   0.507   cdk5 
 739 S   DTETSPRGE   0.503   p38MAPK    
 
 943 S   KPVSSPDWN   0.992   unsp 
 
 
 
771 S   IDKTSPNGN   0.903   unsp 
 771 S   IDKTSPNGN   0.536   CKI  
 771 S   IDKTSPNGN   0.504   p38MAPK    
 
1217 S   FSRDSPEEN   0.998   unsp 
 
1599 S   PRAKSPNGS   0.977   unsp 
1599 S   PRAKSPNGS   0.620   cdk5 
1599 S   PRAKSPNGS   0.603   RSK  
1599 S   PRAKSPNGS   0.522   GSK3 
 
 991 S   WEEPSPESI   0.988   unsp 
 991 S   WEEPSPESI   0.506   GSK3 
 
1704 S   KLTWSPGSV   0.562   cdk5 
1704 S   KLTWSPGSV   0.544   p38MAPK    
 
B C 
Phosphosite/aa seq/Probability/Kinase 
1512 S   GTATSPIVD   0.840   unsp 
1512 S   GTATSPIVD   0.541   cdc2 
 
 385 S   LNLSSPNPM   0.488   GSK3      
 385 S   LNLSSPNPM   0.462   p38MAPK   
 385 S   LNLSSPNPM   0.446   CaM-II    
 
 879 S   WEEPSPQSI   0.518   cdk5 
 879 S   WEEPSPQSI   0.501   GSK3 
 879 S   WEEPSPQSI   0.442   p38MAPK   
 
1432 S   TRGGSPYNQ   0.997   unsp 
1432 S   TRGGSPYNQ   0.770   PKA  
1432 S   TRGGSPYNQ   0.502   GSK3 
1432 S   TRGGSPYNQ   0.487   RSK       
 
1816 S   HRMGSPAPL   0.790   unsp 
1816 S   HRMGSPAPL   0.675   PKA  
1816 S   HRMGSPAPL   0.511   GSK3 
1816 S   HRMGSPAPL   0.507   PKG  
1816 S   HRMGSPAPL   0.505   RSK  
1816 S   HRMGSPAPL   0.484   cdk5      
 
1336 S   GMKHSPSHP   0.906   unsp 
1336 S   GMKHSPSHP   0.572   cdk5 
1336 S   GMKHSPSHP   0.507   GSK3 
1336 S   GMKHSPSHP   0.494   cdc2      
 
1832 S   GGSDSI---   0.491   CKII      
1832 S   GGSDSI---   0.476   cdc2      
1832 S   GGSDSI---   0.451   GSK3      
 
1517 T   PIVDTDHQL   0.434   CaM-II    
1517 T   PIVDTDHQL   0.420   GSK3      
1517 T   PIVDTDHQL   0.407   CKII      
1517 T   PIVDTDHQL   0.363   CKI       
 
 480 T   NNRSTGGSW   0.457   PKC       
 480 T   NNRSTGGSW   0.442   GSK3      
 480 T   NNRSTGGSW   0.436   CaM-II    
 
1461 S   LPAKSPPTN   0.550   cdk5 
1461 S   LPAKSPPTN   0.506   GSK3 
1461 S   LPAKSPPTN   0.448   CaM-II    
1461 S   LPAKSPPTN   0.395   cdc2      
 
 
Phosphosite/aa seq/Probability/Kinase 
 465 S   EFEESPRSE   0.955   unsp 
 465 S   EFEESPRSE   0.550   p38MAPK    
 465 S   EFEESPRSE   0.483   GSK3      
 
 714 S   WEEPSPPSI   0.628   unsp 
 714 S   WEEPSPPSI   0.568   cdk5 
 714 S   WEEPSPPSI   0.513   GSK3 
 714 S   WEEPSPPSI   0.495   p38MAPK   
 714 S   WEEPSPPSI   0.426   CKI       
 
 777 T   HRVETPPPH   0.959   unsp 
 777 T   HRVETPPPH   0.628   cdk5 
 777 T   HRVETPPPH   0.515   p38MAPK    
 777 T   HRVETPPPH   0.494   GSK3      
 
1674 T   IGSPTPLTT   0.546   cdk5 
1674 T   IGSPTPLTT   0.474   GSK3      
1674 T   IGSPTPLTT   0.462   p38MAPK   
 
1011 S   SKESSVDRP   0.990   unsp 
1011 S   SKESSVDRP   0.589   PKC  
1011 S   SKESSVDRP   0.526   cdc2 
1011 S   SKESSVDRP   0.450   CaM-II    
 
1016 T   VDRPTFLDK   0.449   GSK3      
1016 T   VDRPTFLDK   0.433   PKC       
1016 T   VDRPTFLDK   0.421   CKI       
 
 568 S   QEDKSPTWG   0.995   unsp 
 568 S   QEDKSPTWG   0.493   cdk5      
 568 S   QEDKSPTWG   0.489   p38MAPK   
 568 S   QEDKSPTWG   0.478   GSK3      
 
1010 S   ISKESSVDR   0.989   unsp 
1010 S   ISKESSVDR   0.514   PKG  
1010 S   ISKESSVDR   0.448   GSK3      
1010 S   ISKESSVDR   0.431   cdc2      
 
Table 19 Kinase prediction of TNRC6A-C phosphor-sites 
(A), (B), (C) Prediction of TNRC6 phospho-site specific kinases with NETphos3.1. Abbreviations: unsp = unknown;, 
ATM, CKI, CKII, CaM-II, DNAPK, EGFR, GSK3, INSR, PKA, PKB, PKC, PKG, RSK, SRC, cdc2, cdk5 and p38MAPK. 
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Table 20   De-phosphorylation of phosphorylated sites of TNRC6 proteins 
Protein 
FASTAP/ 37°C PBS/37°C PBS/4°C 
p-value position p-value position p-value position 
TN
R
C
6A
 
0,000000039 S[991] 0,000000089 S[1585] 0,000000000054 S[1585] 
0,0000011 S[739] 0,00000008 S[991] 0,000000021 S[991] 
0,000048 S[614] 0,00018 S[1589] 0,0000024 S[1884] 
0,0021 S[798] 0,0007 S[1333] 0,0000063 S[943] 
0,0097 T[1633] 0,0015 S[1503] 0,000041 S[1704] 
0,018 S[1405] 0,0017 T[1845] 0,00014 S[739] 
0,02 T[287] 0,0022 S[991] 0,00021 S[943] 
0,024 S[1603] 0,004 S[739] 0,00045 T[738] 
0,0019 S[1884] 0,0061 S[943] 0,0017 S[1333] 
    0,0056 S[1704] 0,0017 S[622] 
    0,0073 S[1224] 0,0016 T[1845] 
    0,012 S[938] 0,0023 S[388] 
    0,018 T[287] 0,0023 T[287] 
    0,041 S[1599] 0,0041 S[1599] 
        0,0047 S[1217] 
        0,0053 T[1633] 
        0,012 T[397] 
        0,012 T[287] 
        0,021 S[1869] 
        0,029 Y[1382] 
        0,041 S[938] 
        0,055 S[396] 
TN
R
C
6B
 
0,000028 T[342] 0,0000000029 S[879] 0,0000000053 S[879] 
0,00025 S[879] 0,00000005 S[879] 0,00000015 S[271] 
0,0043 S[609] 0,000000085 S[1512] 0,0000013 T[1701] 
0,02 T[596] 0,000064 S[1816] 0,0000031 S[385] 
0,041 S[1401] 0,00022 S[385] 0,0000074 S[1816] 
    0,00035 S[1401] 0,0000093 S[385] 
    0,00045 S[1432] 0,000016 S[273] 
    0,004 S[384] 0,000027 S[879] 
    0,0037 S[1816] 0,00006 S[1432] 
    0,0049 S[882] 0,00006 S[609] 
    0,014 T[596] 0,000066 S[1512] 
    0,021 S[1401] 0,00094 T[611] 
    0,046 Y[593] 0,0021 S[882] 
        0,0035 S[1401] 
        0,0057 S[882] 
        0,0088 S[1816] 
        0,017 S[61] 
        0,021 T[1517] 
        0,028 S[1832] 
        0,038 S[1432] 
        0,046 T[1676] 
TN
R
C
6
C
 
0,0014 T[777] 0,00013 S[714] 0,00001 T[777] 
    0,00015 T[1674] 0,000011 S[714] 
    0,00037 S[1011] 0,000017 S[465] 
    0,00039 T[777] 0,00071 T[1674] 
    0,042 S[714] 0,0018 S[1011] 
    0,042 S[717] 0,023 S[1038] 
        0,05 T[272] 
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5.1.5 DNA oligonucleotides for northern blot 
Sequence name Sequence 5' to 3' hsv1-mir-H3 -NB GTCCCAACCGCACAGTCCCAG 
Ebv-mir-BART1-3p NB GACATAGTGGATAGCGGTGCTA hsv1-mir-H4 -NB TGCTTGCCTGTCAAACTCTACC 
Ebv-mir-BART17-3p NB ACTAAGGGGACACCAGGCATACA hsv1-miR-H5-5p -NB GTAGAGATGCCCGAACCCCCCC 
Ebv-mir-BART6-5p NB CCTATGGATTGGACCAACCTTA hsv1-miR-H5-3p -NB CCGGAGGGTTTGGATCTCTGAC 
Ebv-mir-BART6-3p NB TCTAAGGCTAGTCCGATCCCCG hsv1-miR-H6-5p -NB TACACCCCCCTGCCTTCCACC 
Ebv-mir-BART21-5p NB GTTAGTTGCCTTCACTAGTGA hsv1-miR-H6-3p -NB GGGATGGAAGGACGGGAAGTG 
Ebv-mir-BART21-3p NB AAACACCAGTGGGCACAACTAG hsv1-mir-H11 -NB GCGTTCGCACTTTGTCCTAA 
Ebv-mir-BART18-5p NB TGTATAGGAAGTGCGAACTTGA hsv1-mir-H12 -NB AAGCGTTCGCACTTCGTCCCAA 
Ebv-mir-BART18-3p NB GACGAAGCCCAAACTTCCGATA hsv1-mir-H13 -NB CCAGTGCTCGCACTTCGCCCTAA 
Ebv-mir-BART7 NB CCCTGGACACTGGACTATGATG hsv1-miR-H14-5p -NB CCTGAGCCAGGGACGAGTGCGACT 
Ebv-mir-BART8 NB CTGTACAATCTAGGAAACCGTA hsv1-mir-H15 NB CGTGGCGGCCCGGCCCGGGGCC 
Ebv-mir-BART9 NB ACTACGGGACCCATGAAGTGTTA hsv1-mir-H16 -NB GCCTTCGATCCCAGCCTCCTGG 
Ebv-mir-BART22 NB ACTACTAGACCATGACTTTGTAA hsv1-mir-H17 -NB CCGCCTCGCGCCCCAGCGCCA 
Ebv-mir-BART10 NB ACAGCCAACTCCATGGTTATGTA hsv1-mir-H18 -NB GGTCCCGGCGTCCGGCGGGCGGG 
Ebv-mir-BART11-5p NB CAACTAGCGCACCAAACTGTCTGA hsv1-mir-H26 -NB GACCGTCGCTCACCGAGCCA 
Ebv-mir-BART11-3p NB GGCAGTCAGCCTGGTGTGCGT hsv1-miR-H27 -NB AAGAGGGGGGAGAAAGGGGTCTG 
Ebv-mir-BART12 NB AACCACACCAAACACCACAGGA 
hcmv-mir-UL22A-1-5p 
NB TCTCACGGGAAGGCTAGTTA 
Ebv-mir-BART19-5p NB CATGTCATGTTTGCGGGGAATGT 
hcmv-mir-UL22A-1-3p 
NB CTACAAACTAGCATTCTGGTGA 
Ebv-mir-BART19-3p NB AGCATTCCCAAGCAAACAAAA hcmv-mir- UL36-1 NB TCTTTCCAGGTGTCTTCAACGA 
Ebv-mir-BART20-5p NB GGAATGAAGACATGCCTGCTA 
hcmv-mir-UL112-5p 
NB TGAGTAACCATGTGATCCGGAGG 
Ebv-mir-BART20-3p NB GGTAACAGGCTGTGCCTTCATG 
hcmv-mir-UL112-3p 
NB AGCCTGGATCTCACCGTCACTT 
Ebv-mir-BART13 NB TCAGCCGTCCCTGGCAAGTTACA hcmv-mir- UL148D NB CGGTGAAGAAGGGGAGGACGA 
Ebv-mir-BART14 NB ATCCCTACTACTGCAGCATTTA hcmv-mir- US33-5p NB CGCCCACGGTCCGGGCACAATC 
Ebv-mir-BART2-5p NB GCAAGGGCGAATGCAGAAAATA hcmv-mir- US33-3p NB TTGGATGTGCTCGGACCGTGA 
Ebv-mir-BART2-3p NB TTTATTTTCTCCAAATCGCTCCTT hcmv-mir-UL5-1 NB ACGCTCTCGTCAGGCTTGTCA 
BHRF 1-1 NB loop rev 
TAATACGACTCACTATAGGGTAACCTGATCAGCCCCG
GAGTTGCCTGTTTCAT hcmv-mir- US25-1 NB GGTCCGAGCCACTGAGCGGTT 
BHRF 1-3 NB loop rev 
TAATACGACTCACTATAGGGTAACGGGAAGTGTGTA
AGCACACACGTAATTTGCA 
hcmv-mir- US25-2-5p 
NB TCATCCACCTGAACAGACCGCT 
BART 3 NB loop rev 
TAATACGACTCACTATAGGGTAAATAAGTGTCCAGC
GCACCACTAGTCACCAGGTGT 
hcmv-mir- US25-2-3p 
NB ACCGCGGGAGCTCTCCAAGTGGAT 
BART 6 5p NB loop rev 
TAATACGACTCACTATAGGG 
TAAGGTTGGTCCAATCCATAGGCTTTTTTTGT hcmv-mir- US4-5p NB CAGACATCCCCCTGCACGTCCA 
BART 6 3p NB loop rev 
TAATACGACTCACTATAGGGTTGTGAAAACCCGGGG
ATCGGACTAGCCTTAGAGT hcmv-mir- US4-3p NB AGAGGTGTAGCGGGCTGTCA 
BART 22 NB loop rev 
TAATACGACTCACTATAGGGTACCACTCGGTTACAAA
GTCATGGTCTAGTAGT hcmv-mir- UL70-5p NB TCTGGACGAGGCCGAGACGCA 
BHRF1-3 trans for 
TAATACGACTCACTATAGGGAGATCTTATCTTTTGCG
GCAGAAATTG hcmv-mir- UL70-3p NB CCGCGCGCCAGCCCATCCCC 
BHRF1-3 trans rev  GAGCTCAGTATTCCCATCTTCCCACACTCACC hcmv-mir-UL59 NB ACGGCATGACGAGCGAGAGAAC 
BART16 trans for 
TAATACGACTCACTATAGGGAGATCTGAAACCGGTG
GGCCGCTGTTC hcmv-mir-UL69 NB CGGTTTCGGCTTAGCCTCTGG 
BART16 trans rev  GAGCTCCTTGTATGCCTGCGTCCTCTTAG 
hcmv-mir-US5-2-5p 
NB CTTTCAGGATAGGTGTGGCGAAAG 
BART22 trans for 
TAATACGACTCACTATAGGGAGATCTTGACAACTATG
CTGAATATCTTG 
hcmv-mir-US5-2-3p 
NB AGACATCGTCACACCTATCATA 
BART22 trans rev  GAGCTCCCCCGGGACACTCCTCTGGGGTTCC hcmv-mir-US22-5p NB CCCGCGGACACACGCTGAAACA 
BHRF1-3 trans rev 1 CTCGAGAGTATTCCCATCTTCCCACACTCACC hcmv-mir-US22-3p NB CCTGGTTACAGCGCGGCCGGCGA 
BART16 trans rev 1  CTCGAGCTTGTATGCCTGCGTCCTCTTAG hcmv-mir-US29-5p NB CGTCACGGTCCGAGCACATCCA 
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BART22 trans rev 1 CTCGAGCCCCGGGACACTCCTCTGGGGTTCC hcmv-mir-US29-3p NB TGATTGTGCCCGGACCGTGGG 
BHRF 1-1 RNA loop  
TAATACGACTCACTATAGGGATGAAACAGGCAACTC
CGGGGCTGATCAGGTTA BART 6 5p RNA loop 
TAATACGACTCACTATAGGGACAAAAAAAGCCTATGGATTGGACCAACCTT
A 
BHRF 1-1 RNA loop g 
TAACCTGATCAGCCCCGGAGTTGCCTGTTTCATCCCT
ATAGTGAGTCGTATTA BART 6 5p RNA loop g 
TAAGGTTGGTCCAATCCATAGGCTTTTTTTGTCCCTATAGTGAGTCGTATTA 
BHRF 1-3 RNA loop 
TAATACGACTCACTATAGGGTTGCAAATTACGTGTGT
GCTTACACACTTCCCGTTA BART 6 3p 
TAATACGACTCACTATAGGGACTCTAAGGCTAGTCCGATCCCCGGGTTTTCA
CAA 
BHRF 1-3  RNA loop g 
TAACGGGAAGTGTGTAAGCACACACGTAATTTGCAA
CCCTATAGTGAGTCGTATTA BART 22 RNA loop 
TAATACGACTCACTATAGGGACTACTAGACCATGACTTTGTAACCGAGTGG
TA 
BART 3 RNA loop 
TAATACGACTCACTATAGGGACACCTGGTGACTAGT
GGTGCGCTGGACACTTATTTA BART 22 RNA loop g 
TACCACTCGGTTACAAAGTCATGGTCTAGTAGTCCCTATAGTGAGTCGTATT
A 
BART 3 RNA loop g 
TAAATAAGTGTCCAGCGCACCACTAGTCACCAGGTG
TCCCTATAGTGAGTCGTATTA 
hsv1-mir-H7 -NB CCTTTGGTTGCAGACCCCTTT 
  hsv1-mir-H8 -NB GAACCCCCTGACCCTATATA 
  hsv1-mir-H1 -NB TCCACTTCCCGTCCTTCCATC 
  hsv1-miR-H2-NB AGTCGCACTCGTCCCTGGCTCAGG 
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5.1.6 DNA Oligonucleotides 
Sequence name Sequence 5' to 3' hcmv-mir-UL5-1for TAATACGACTCACTATAGGGAGACCTAGCCTTGAACGCTTTCGTCGTG 
BHRF1-1-for 
TAATACGACTCACTATAGGGAGACCTAGCCTTATTAA
CCTGATCAGCCCCGG hcmv-mir-UL5-1-rev TGAACGCTCTCGTCAGG 
BHRF1-1-rev TTGTCAACCTCTTCAGGCC hcmv-mir- US25-1 for TAATACGACTCACTATAGGGAGACCTAGCCTTGTGAACCGCTCAGTGG 
BHRF1-2-for 
TAATACGACTCACTATAGGGAGACCTAGCCTCTTTTA
AATTCTGTTGCAGC hcmv-mir- US25-1-rev TGAGAACCGACCTAGCG 
BHRF1-2-rev CTTTCAATTTCTGCCGC hcmv-mir- US25-2-for TAATACGACTCACTATAGGGAGACCTAGCCTCGGTTAGCGGTCTGTTCAGG 
BHRF1-3-for 
TAATACGACTCACTATAGGGAGACCTAGCCTTCTAAC
GGGAAGTGTGTAAGC hcmv-mir- US25-2-rev CGGACCGCGGGAGCTCTC 
BHRF1-3-rev ATTTTAACGAAGAGCGTGAAGC hcmv-mir- US4-for TAATACGACTCACTATAGGGAGACCTAGCCTCGTGTCGCGACATGGACG 
BART3-for 
TAATACGACTCACTATAGGGAGACCTAGCCTCCTTTG
GTGGAACCTAGTGTTAG hcmv-mir- US41-rev CATGTCGCGACAGAGAGG 
BART3-rev CCTCCGGTGACACCTGGTGAC hcmv-mir- UL70-for TAATACGACTCACTATAGGGAGACCTAGCCTGGTTGCGTCTCGGCCTC 
BART4-for 
TAATACGACTCACTATAGGGAGACCTAGCCTTTTGGT
GGGACCTGATGC hcmv-mir- UL70-rev GGCCGCGCGCCAGCCCATC 
BART4-rev CCTGGTGACACCTGGTGCC hcmv-mir-UL59-for TAATACGACTCACTATAGGGAGACCTAGCCTCGACGGTTCTCTCGCTC 
BART1-for 
TAATACGACTCACTATAGGGAGACCTAGCCTGGGGG
TCTTAGTGGAAGTGACG hcmv-mir-UL59-rev CGACGCCATTTTCTCTCGTCC 
BART1-rev CGGGCGAGACATAGTGGATAGC hcmv-mir-UL69-for TAATACGACTCACTATAGGGAGACCTAGCCTAGGCCAGAGGCTAAGCC 
BART15-for 
TAATACGACTCACTATAGGGAGACCTAGCCTTGTGCC
GCTTGGAGGGAAAC hcmv-mir-UL69-rev GCACCAAAGGCTAAGTCG 
BART15-rev TGTGTCTCTATCAAGGAAACAAAACC hcmv-mir- US5-2-for TAATACGACTCACTATAGGGAGACCTAGCCTGGAGGCTTTCGCCACACC 
BART5-for 
TAATACGACTCACTATAGGGAGACCTAGCCTGCTCTG
TGGCACCTCAAGG hcmv-mir- US5-2-rev AAAGACATCGTCACACC 
BART5-rev ACCTTGCGTCACTTTAGG hcmv-mir-US22 for TAATACGACTCACTATAGGGAGACCTAGCCTGGGGACCTGTTTCAGC 
BART16-for 
TAATACGACTCACTATAGGGAGACCTAGCCTAGGCTT
TCAGGTGTGGAATTTAG hcmv-mir-US22-rev GAGGCCTGGTTACAGC 
BART16-rev AGGTTTATCAATTGTGGGATATGG hcmv-mir-US29-for TAATACGACTCACTATAGGGAGACCTAGCCTTCACGTTTGGATGTGCTCG 
BART17-for 
TAATACGACTCACTATAGGGAGACCTAGCCTGTTGA
ACAGGATGTGGCACCC hcmv-mir-US29-rev CCACGGTTGATTGTGC 
BART17-rev GCTACCTAGGCCTGCGTC hcmv-148d-g-f AGCAGGUGAGGUUGGGGCGGACAACGUGUUGCGGAUUGUGGCGAGA 
BART6-for 
TAATACGACTCACTATAGGGAGACCTAGCCTTGACCT
TGTTGGTACTTTAAGG hcmv-148d-g-r GGCGGTGAAGAAGGGGAGGACGACGTTCTCGCCACAATCCGCAAC 
BART6-rev TGGCCTTGAGTTACTCTAAGGC GST BglII fwd GATAGATCTatgtcccctatactaggttattgg 
BART21-for 
TAATACGACTCACTATAGGGAGACCTAGCCTGGGCT
GGGTATTCACTAGTG Lin28a-NotI-fwd Gat gcggccgc ATGGGCTCCGTGTCCAACC 
BART21-rev GGACCGGATAAACACCAGTGG Lin28a-BamHI-rev Atc   ggatcc  TCAATTCTGTGCCTCCGGGAG 
BART18-for 
TAATACGACTCACTATAGGGAGACCTAGCCTGGGCT
GGGTATTCACTAGTG ebv-long-BH1-1-f gtt agatct CCTTTAGGAAGCACCACGT 
BART18-rev GGACCGGATAAACACCAGTGG ebv-long-BH1-1-r aac ctcgag CACCCCGGTTCGAAATGG 
BART7-for 
TAATACGACTCACTATAGGGAGACCTAGCCTTCCAGT
GTCCTGATCCTGG ebv-long-BH1-2-f gtt agatct CCAGTAGGATATTAGGC 
BART7-rev TCCGAGTGCACTGTCCCTGG ebv-long-BH1-2-r gtt ctcgag CACTTCCCGTTAGAACAC 
BART8-for 
TAATACGACTCACTATAGGGAGACCTAGCCTTGGGTT
CACTGATTACGGTTTCC ebv-long-BH1-3-f gtt agatct GTGTTCTAACGGGAAGTG 
BART8-rev TAAGCACACTGTCTACGACC ebv-long-BH1-3-r gtt ctcgag GCAGTATAGGCTCTCACC 
BART9-for 
TAATACGACTCACTATAGGGAGACCTAGCCTCAGCT
GTTGTTTGTACTGGACC ebv-long-BART5-f gtt agatct CTGTTAACCAGGTCAGTGG 
BART9-rev CAGCATAGTTGTCACTACGGG ebv-long-BART5-r gtt ctcgag CAAGAGCACACACCCACTC 
BART22-for 
TAATACGACTCACTATAGGGAGACCTAGCCTGTCACA
GGTGCTAGACCCTGG ebv-long-BART6-f gtt agatct CCTTAGTGGGACGCAG 
BART22-rev GTCACAACTACTAGACCATGAC ebv-long-BART6-r gtt ctcgag GATCTGTGGTTACATGGtgc 
BART10-for 
TAATACGACTCACTATAGGGAGACCTAGCCTCAGAG
GAGTGTCCCGGGG ebv-long-BART9-f gtt agatct ccaGACTTCCATGGAAGATG 
BART10-rev CAGATGGAGTGCACCACAGC ebv-long-BART9-r gtt ctcgag CTATAACACTAGGACCCTC 
BART11-for 
TAATACGACTCACTATAGGGAGACCTAGCCTGGCTTC
TGTTGGGTCAGACAG ebv-long-BART11-f gtt agatct GTTTACCTGCCTTGGGTTAC 
BART11-rev GGCCACACTGCTAAGGCAG ebv-long-BART11-r gtt ctcgag GTACGTCTCAGGGCATG 
BART12-for 
TAATACGACTCACTATAGGGAGACCTAGCCTCTGGT
GACCTAACACCCGC ebv-long-BART14-f gtt agatct GACTAATGGGGGGTGTGG 
BART12-rev CTGCGTACCCCAAAACCAC ebv-long-BART14-r gtt ctcgag CAAGGGCTCACCAGGGAG 
BART19-for 
TAATACGACTCACTATAGGGAGACCTAGCCTGTATCC
GTGTCCTGACAACATTCC ebv-long-BART17-f gtt agatct cacCCTCTATCCATATCCCAc 
BART19-rev GCTTCCAGGCCCTAAGAGC ebv-long-BART17-r gtt ctcgag GGATTGGACCAACCTTAAAG 
BART20-for 
TAATACGACTCACTATAGGGAGACCTAGCCTGTATCC
GTGTCCTGACAACATTCC ebv-long-BART18-f gtt agatct GCTCAACAGCCCCACCTGG 
BART20-rev GCTTCCAGGCCCTAAGAGC ebv-long-BART18-r gtt ctcgag GTCTGGCTTAAGGGTCCCTC 
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BART13-for 
TAATACGACTCACTATAGGGAGACCTAGCCTTTGGG
CACCTCGATAACCGG ebv-long-BART19-f gtt agatct GACCCTGGTGCTAGGGTC 
BART13-rev CTAAACACATCGTCAGCCG ebv-long-BART19-r gtt ctcgag CTGCTACAATAGGCCCTACg 
BART14-for 
TAATACGACTCACTATAGGGAGACCTAGCCTCAGGG
GTGGCCGGTACCC ebv-long-BART16-f gtt agatct gtatGCTGGAAACCGGTGG 
BART14-rev CAGGTCGCGCGTCCAGATC ebv-long-BART16-r gtt ctcgag cCTGCGTCCCACTAAGG 
BART2-for 
TAATACGACTCACTATAGGGAGACCTAGCCTACTATT
TTCTGCATTCGCCCTTGC CMV-miR4-long-f gtt agatct GTCAAGAGTCACGTCAGTC 
BART2-rev TTTATTTTCTCCAAATCGCTCC CMV-miR4-long-r aac ctcgag CTGTCGCGATAGTCGAC 
BART18-for 1 
TAATACGACTCACTATAGGGAGACCTAGCCTTTGTTG
CCGTTGAAAGACGGGTG CMV-miR5-1-long-f gtt agatct gaGATCCATAGTGAAGGAGTG 
BART18-rev 1 TCGCAGCAGTCGACATTATCG CMV-miR5-1-long-r aac ctcgag GTGTGGCGAAAGCCTCC 
BART20-for 1 
TAATACGACTCACTATAGGGAGACCTAGCCTTACAG
GCGTAGGGCCTATTG CMV-miR5-2-long-f gtt agatct CTGACGAGAGCGTTCATC 
BART20-rev 1 TACATGGAAAAAAGGTGCCAATGG CMV-miR5-2-long-r aac ctcgag GGTTTACCGGAAAACCtac 
BHRF1-3 trans for 
TAATACGACTCACTATAGGGAGATCTTATCTTTTGCG
GCAGAAATTG CMV-miR22a-long-f gtt agatct GCAGACCCCAAGGGTTAACG 
BHRF1-3 trans rev  GAGCTCAGTATTCCCATCTTCCCACACTCACC CMV-miR22a-long-r aac ctcgag CGAGTCGCGTGTGTTTTGAC 
BART16 trans for 
TAATACGACTCACTATAGGGAGATCTGAAACCGGTG
GGCCGCTGTTC CMV-miR22-long-f gtt agatct CGCACACACGTGATTTGC 
BART16 trans rev  GAGCTCCTTGTATGCCTGCGTCCTCTTAG CMV-miR22-long-r aac ctcgag CTCCAGAAACCCCGTG 
BART22 trans for 
TAATACGACTCACTATAGGGAGATCTTGACAACTATG
CTGAATATCTTG CMV-miR33-long-f gtt agatct cCACGACCATTTCCGTGC 
BART22 trans rev  GAGCTCCCCCGGGACACTCCTCTGGGGTTCC CMV-miR33-long-r aac ctcgag CTGAGGTGGCAGGGGAC 
BHRF1-3 trans rev 1 CTCGAGAGTATTCCCATCTTCCCACACTCACC CMV-miR59-long-f gtt agatct CATCCGACAAAACCGTGTC 
BART16 trans rev 1  CTCGAGCTTGTATGCCTGCGTCCTCTTAG CMV-miR59-long-r aac ctcgag GTACCGAGGCGGTGC 
BART22 trans rev 1 CTCGAGCCCCGGGACACTCCTCTGGGGTTCC CMV-miR69-long-f gtt agatct CGTGTACCGACCAAAGC 
GST  XbaI fwd 
GAT   TCTAGA   TCT ATG TCC CCT ATA CTA GGT 
TAT TGG CMV-miR69-long-r aac ctcgag CGATCGTTGTGCATCATAC 
GST-Stopp-NotI rev 
TAC  GCGGCCGC  TTA   
ATCCGATTTTGGAGGATGGTCGCC CMV-miR70-long-f gtt agatct cCTGGTTGAGATGACGTAG 
QuikChange EcoRI pGex 
fwd gggagctcgaat   tc    ggcgcacgtggtctcaattc CMV-miR70-long-r aac ctcgag CCTACAGACGCAAAAGTGc 
QuikChange EcoRI pGex 
rev gaattgagaccacgtgcgcc   ga   attcgagctccc CMV-miR112-long-f gtt agatct GGTCGTTGCCCACGAAG 
BHRF1-1 trans for 
TAATACGACTCACTATAGGGAGATCTGTGCCCATGCA
TTATAATTTAACC CMV-miR112-long-r aac ctcgag GGTGGACGGGTTTCAGC 
BHRF1-1 trans rev  gta CTCGAGGTATCAGCTATCTGCTGCAACAG CMV-miR148-long-f gtt agatct CGTTAATGCAGCCGTTGatg 
BHRF1-2 trans for 
TAATACGACTCACTATAGGGAGATCTGGCCCCCACTT
TTAAATTCTG CMV-miR148-long-r aac ctcgag cttGCACACCGGTGATTATG 
BHRF1-2 trans rev  gta CTCGAGGCAAATTACGTGTGTGCTTAC UL97-HCMVT-f Agt gctagc ATGTCCTCCGCACTTCGGTC 
BART3 trans for 
TAATACGACTCACTATAGGGAGATCTCCTATAGGTCC
TACCGGAGCTCC UL97-HCMVT-r Agt gaattc TTACTCGGGGAACAGTTGGc 
BART3 trans rev  gtaCTCGAG CCCACCAAATGTTACAGAGC RFOX2_HUMAN-f Agt gcggccgc ATGGAGAAAAAGAAAATGGTAACTC 
BART4 trans for 
TAATACGACTCACTATAGGGAGATCTTCACCGGAGG
CTACTTGCC RFOX2_HUMAN-r Agt ggatcc TCAGTAGGGGGCAAATCGG 
BART4 trans rev  gtaCTCGAGAGCACGTCACTTCCACTAAG UNG_HCMVM-f Agt gctagc  ATGGCCCTCAAGCAGTGGATG 
BART1 trans for 
TAATACGACTCACTATAGGGAGATCTTCACCAGGGCT
ACTTGCC UNG_HCMVM-r Agt gaattc  TCACCCACAGAGTCGCCAG 
BART1 trans rev gtaCTCGAGCCTGGTTAACAGACTTCAGGTGG UL77_HCMVA-f Agt gctagc ATGAGTCTGTTGCACACCTTTTGG 
BART15 trans for 
TAATACGACTCACTATAGGGAGATCTATATGTCGCCT
TACCTCCC UL77_HCMVA-r Agt gaattc TTACAACACCGCCACGCTCG 
BART15 trans rev  gtaCTCGAGGAGGTGCCACAGAGCATCAG PORTL_HCMVA-f Agt gctagc ATGGAGCGAAACCACTGGaac 
BART5 trans for 
TAATACGACTCACTATAGGGAGATCTATAGAGACAC
AAGGACTGCC PORTL_HCMVA-r Agt gaattc CTAGTGAAATCCGTATGGACCTC 
BART5 trans rev  gtaCTCGAGTTAAACAAGAGCACACACCC K0020_HUMAN-f Agt gctagc ATGGAAGTTAAAGGGAAAAAGCAATTC 
BART17 trans for 
TAATACGACTCACTATAGGGAGATCTTTACACCAAGA
TCACCACC K0020_HUMAN-r Agt gaattc CTATGTGCTCAGTTTTTCAAGTAG 
BART17 trans rev  gtaCTCGAGCCTATGGATTGGACCAACC PP65_HCMVM-f Agt gctagc  ATGGAGTCGCGCGGTCGC 
BART6 trans for 
TAATACGACTCACTATAGGGAGATCTTGTATGCCTGG
TGTCCCCTTAG PP65_HCMVM-r Agt gaattc  TCAACCTCGGTGCTTTTTGGg 
BART6 trans rev  gtaCTCGAGTGAAACCCAAGTTTCCTTGCC PURB_HUMAN-f Agt gctagc ATGGCGGACGGCGACAG 
BART21 trans for 
TAATACGACTCACTATAGGGAGATCTTGTTAGCTTTT
TTGGTGGG PURB_HUMAN-r Agt ggatcc TCAATCCTCATCCACCTCCTC 
BART21 trans rev gtaCTCGAGAGCATCCCCCACTCTGATAC PURA_HUMAN-f Agt gctagc ATGGCGGACCGAGACAGC 
BART18 trans for 
TAATACGACTCACTATAGGGAGATCTGTTGTAGGGT
AACGAAGACC PURA_HUMAN-r Agt ggatcc  TCAATCTTCTTCCCCTTCTTCC 
BART18 trans rev  gtaCTCGAGAGCCAAGTGCACCTGCCTAAC CPSF6_HUMAN-f Agt gctagc ATGGCGGACGGCGTGG 
BART7 trans for 
TAATACGACTCACTATAGGGAGATCTGCCAAACCTCC
AGAATATC CPSF6_HUMAN-r Agt ggatcc CTAACGATGACGATATTCGCG 
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BART7 trans rev  gtaCTCGAGCAGATGTCAGCAGCATGCCAG CPSF5_HUMAN-f Agt gctagc ATGTCTGTGGTACCGCCC 
BART8 trans for 
TAATACGACTCACTATAGGGAGATCTACCTGACTGGC
CGGTGCAATTAG CPSF5_HUMAN-r Agt ggatcc  TCAGTTGTAAATAAAATTGAACCTGCTC 
BART8 trans rev  gtaCTCGAGTCACAAAGCCCCACTACATG CPSF7_HUMAN-f Agt gctagc  ATGTCAGAAGGAGTGGACTTG 
BART9 trans for 
TAATACGACTCACTATAGGGAGATCTTGTGAATTTGC
TGCTAGCTATATGG CPSF7_HUMAN-r Agt ggatcc  TCAGTGGTGCCGGTCCc 
BART9 trans rev 1 gtaCTCGAGCGCCCTATAACACTAGGACCCTC 
A-TSS736/8/9AAA-QC-
f 
CAGAATACTGCCTGGGATgctGAAGCTGCTCCTAGAGGGGAACGAAAGACT
GAC 
BART10 trans for 
TAATACGACTCACTATAGGGAGATCTGTAGTTGTGAC
CCTGCAAAG 
A-TSS736/8/9AAA-QC-
r 
GTCAGTCTTTCGTTCCCCTCTAGGAGCAGCTTCagcATCCCAGGCAGTATTCT
G 
BART10 trans rev  gtaCTCGAGAAAGGTGTGGTCGTTTGGAATAG A-T1844A-QC-fwd GTGTGTACTGGGGAACGCTACTATTCTTGCTGAG 
BART11 trans for 
TAATACGACTCACTATAGGGAGATCTGTTTACCTGCC
TTGGGTTAC A-T1844A-QC-rev CTCAGCAAGAATAGTAGCGTTCCCCAGTACACAC 
BART11 trans rev  gtaCTCGAGCGATTAAGTCCTAACTCGAG A-T1844E-QC-fwd CACATGTGTGTACTGGGGAACGAGACTATTCTTGCTGAGTTTGC 
BART12 trans for 
TAATACGACTCACTATAGGGAGATCTATGTAAGAGA
GGTTGCCTAG A-T1844E-QC-rev GCAAACTCAGCAAGAATAGTCTCGTTCCCCAGTACACACATGTG 
BART12 trans rev  gtaCTCGAG GTTATTGGCACCGTGTAAC A-Y1631A-QC-fwd 
CAAACATTGACCCTGAAACTGACCCTGCCGTCACTCCTGGCAGTGTCATAAA
C 
BART9 trans rev gtaCTCGAGACATGCCTGCTACAATAGG A-Y1631A-QC-rev 
GTTTATGACACTGCCAGGAGTGACGGCAGGGTCAGTTTCAGGGTCAATGTT
TG 
BART20 trans for 
TAATACGACTCACTATAGGGAGATCTAAACATGTTTT
GTTTGCTTGGG A-Y1631E-QC-fwd GACCCTGAAACTGACCCTGAGGTCACTCCTGGCAGTGTC 
BART20 trans rev  gtaCTCGAGAACGTCGAGATACCCTGGC A-Y1631E-QC-rev GACACTGCCAGGAGTGACCTCAGGGTCAGTTTCAGGGTC 
BART13 trans for 
TAATACGACTCACTATAGGGAGATCTTGATCCTGGGT
CCTTTGG A-SSS1582/5/9AAA-Qf 
GACTTTATGAACAGCAGTACGTCACCAGCCgcTCCTCCAGGTGCAATAGGA
GATGGCTGG 
BART13 trans rev  gtaCTCGAGGACATCCCCAGACTCACC A-SSS1582/5/9AAA-Qr 
CCAGCCATCTCCTATTGCACCTGGAGGAgcGGCTGGTGACGTACTGCTGTTC
ATAAAGTC 
BART14 trans for 
TAATACGACTCACTATAGGGAGATCTGTGTGGTATG
GCACAGG A-SSS1582/5/9EEE-Qf 
CTATGACTTTATGAACAGCAGTACTGAACCAGCCgaaCCTCCAGGTgaAATA
GGAGATGGCTGGCC 
BART14 trans rev  gtaCTCGAG CGAGCAGTCGCATGGCG A-SSS1582/5/9EEE-Qr 
GGCCAGCCATCTCCTATTtcACCTGGAGGttcGGCTGGTTCAGTACTGCTGTT
CATAAAGTCATAG 
BART2 trans for 
TAATACGACTCACTATAGGGAGATCTTGGTCAGAGC
CAGACTG T6A S1884A f AGCCGGCTGGGCGCCCTCGACTGTT 
BART2 trans rev  gtaCTCGAG TTCAGACAGCCGCGGTTGTC T6A S1884A r AACAGTCGAGGGCGCCCAGCCGGCT 
hsv1-mir-H7 -for 
TAATACGACTCACTATAGGGAGACCTAGCCTGAAGA
GGGGGGAGAAAGG T6A S1884E f AGAGCCGGCTGGGCGAACTCGACTGTTCCCACTCATTCT 
hsv1-mir-H7 -rev GAGAAGAGGGAAGAAGAG T6A S1884E r AGAATGAGTGGGAACAGTCGAGTTCGCCCAGCCGGCTCT 
hsv1-mir-H8 -for 
TAATACGACTCACTATAGGGAGACCTAGCCTGTCCCT
GTATATATAGG PCIneo-FseIAscI-in-f atctctagactgaggcgcgccatatggccggccatagcggccgcttat 
hsv1-mir-H8 -rev GACAACTATATATACAGG PCIneo-FseIAscI-in-r ataagcggccgctatggccggccatatggcgcgcctcagtctagagat 
hsv1-mir-H1 -for 
TAATACGACTCACTATAGGGAGACCTAGCCTCGAGG
GGAACGGGGGATG TC6A-3-EcoRI-rev1 cgact gaattc ttacatggactctccacc 
hsv1-mir-H1 -rev CGGGGGGCCGGAGGGTG pGEM-QC-XbaI-fwd  GTGAATTGTAATACGACTCTAGATAGGGCGAATTGGGCCCG 
hsv1-miR-H2-for 
TAATACGACTCACTATAGGGAGACCTAGCCTGCCACC
GTCGCACGCG pGEM-QC-XbaI-rev CGGGCCCAATTCGCCCTATCTAGAGTCGTATTACAATTCAC 
hsv1-miR-H2-rev GCCCCAGTCGCACTCGTC TC6A-1-XbaI-fwd atg    tctaga atggatgctgattctgcc 
hsv1-mir-H3 -for 
TAATACGACTCACTATAGGGAGACCTAGCCTCCGCG
GGCGCGCTCCTGAC TC6A-1-SacII-rev ggt ccgcgg atctaagtcagttctgtttac 
hsv1-mir-H3 -rev CCACGGGCGCCGTCCCAAC TC6A-2-SacII-fwd  tac ccgcgg gtcctgtccaactctggttg 
hsv1-mir-H4 -for 
TAATACGACTCACTATAGGGAGACCTAGCCTGCCGG
GGTGGTAGAGTTTG TC6A-3-NotI-rev cgact gcggccgc ttacatggactctccacc 
hsv1-mir-H4 -rev GCCGAGACTAGCGAGTTAG TC6A_T736A_QC-f CAGAATACTGCCTGGGATGCAGAAACATCACCTAGAG 
hsv1-mir-H5 -for 
TAATACGACTCACTATAGGGAGACCTAGCCTGCGCTC
CCTCGGGGGGGTTC TC6A_T736A_QC-r CTCTAGGTGATGTTTCTGCATCCCAGGCAGTATTCTG 
hsv1-mir-H5 -rev GCGCCCCCGGAGGGTTTG TC6A_T736E_QC-f GAATACTGCCTGGGATGAAGAAACATCACCTAGAG 
hsv1-mir-H6 -for 
TAATACGACTCACTATAGGGAGACCTAGCCTCGGGG
GGCCGGAGGGTGGAAG TC6A_T736E_QC-r CTCTAGGTGATGTTTCTTCATCCCAGGCAGTATTC 
hsv1-mir-H6 -rev CGAGGGGAACGGGGGATG TC6A_T738A_QC-f GCCTGGGATACAGAAGCATCACCTAGAGGGG 
hsv1-mir-H11 -for 
TAATACGACTCACTATAGGGAGACCTAGCCTGGGCG
TGGCCGCTATTATAAAAAAAG TC6A_T738A_QC-r CCCCTCTAGGTGATGCTTCTGTATCCCAGGC 
hsv1-mir-H11 -rev GGGCGTGGCCGCTATTATAAAAAAAG TC6A_T738E_QC-f CTGCCTGGGATACAGAAGAATCACCTAGAGGGGAAC 
hsv1-mir-H12 -for 
TAATACGACTCACTATAGGGAGACCTAGCCTGGAGT
CGGGCACGGCGCC TC6A_T738E_QC-r GTTCCCCTCTAGGTGATTCTTCTGTATCCCAGGCAG 
hsv1-mir-H12 -rev GAAGTGAGAACGCGAAGCG TC6A_T739A_QC-f GGGATACAGAAACAGCACCTAGAGGGGAAC 
hsv1-mir-H13 -for 
TAATACGACTCACTATAGGGAGACCTAGCCTGCGAA
GCGTTCGCACTTCG TC6A_T739A_QC-r GTTCCCCTCTAGGTGCTGTTTCTGTATCCC 
hsv1-mir-H13 -rev GCGCCAGTGCTCGCACTTC TC6A_T739E_QC-f GGGATACAGAAACAGAACCTAGAGGGGAACG 
hsv1-mir-H14 -for 
TAATACGACTCACTATAGGGAGACCTAGCCTGCCGT
GTGCCCCAGTCGCAC TC6A_T739E_QC-r CGTTCCCCTCTAGGTTCTGTTTCTGTATCCC 
hsv1-mir-H14 -rev GCCGCGCGCCACCGTCGC TC6B-part1-XbaI-f  gat tctaga atgagagagaaggagcaagaaagg 
hsv1-mir-H15 -for 
TAATACGACTCACTATAGGGAGACCTAGCCTACCACA
GCGCATGCG TC6B-part2-NotI-r GATGCGGCCGCtcagattgaatccgaccctc 
hsv1-mir-H15 -rev ACCGCCAACGGCCGGCCCCCGTG TC6B-part2-SacII-f ctaccgcgggaaccaaacctgcccacc 
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hsv1-mir-H16 -for 
TAATACGACTCACTATAGGGAGACCTAGCCTGCGCA
GAGAGCCTCGTTAAG TC6B-part1-SacII-r gttccgcggtgctgggcccccttgggaattc 
hsv1-mir-H16 -rev GCGAAGAGTCCCCCGGCAG VP5-SacIIexit-QC-f GATATTCACCTGGCCCACGGTGATGCCTTTGAG 
hsv1-mir-H17 -for 
TAATACGACTCACTATAGGGAGACCTAGCCTGGCCC
ACTCGCACGCCGCCTG VP5-SacIIexit-QC-r CTCAAAGGCATCACCGTGGGCCAGGTGAATATC 
hsv1-mir-H17 -rev GGCCGGCGCGCACCGCCTC pGEMTe-NotIexit-Q-f CGGCCGCCATGATGGCCGCGGGAATTCGATTATCACTAG  
hsv1-mir-H18 -for 
TAATACGACTCACTATAGGGAGACCTAGCCTCGGTCC
CGCCCGCCGGAC pGEMTe-NotIexit-Q-r CTAGTGATAATCGAATTCCCGCGGCCATCATGGCGGCCG 
hsv1-mir-H18 -rev CGGTCCCGCCCGCCGGCCAATG TC6B-S879A-QC-f GTGGTTGGGAAGAGCCAGCCCCACAGTCAATTAGTC 
hsv1-mir-H26 -for 
TAATACGACTCACTATAGGGAGACCTAGCCTTCAGG
CTAGCGCGGCGGGCCTG TC6B-S879A-QC-r GACTAATTGACTGTGGGGCTGGCTCTTCCCAACCAC 
hsv1-mir-H26 -rev CCAAGCAACCGGACCGTC TC6B-S879E-QC-f 
GAACCCAGTGGTTGGGAAGAGCCAGAGCCACAGTCAATTAGTCGGAAAAT
G 
hsv1-miR-H27 -for 
TAATACGACTCACTATAGGGAGACCTAGCCTAGAAG
AGGGAAGAAGAGG TC6B-S879E-QC-r CATTTTCCGACTAATTGACTGTGGCTCTGGCTCTTCCCAACCACTGGGTTC 
hsv1-miR-H27 -rev GGAAGAGGGGGGAGAAAG TC6B-S1711E-QC-f CACATGTGTGTGTTGGGAAACGAGACCATCCTTGCTGAGTTTGCC 
hsv1-mir-H15-g-for 
ACCACAGCGCATGCGCCGGGCCGTTGTGGGGCCCCG
GGCCGGGGCCCCTTGGGTCCG TC6B-S1711E-QC-r GGCAAACTCAGCAAGGATGGTCTCGTTTCCCAACACACACATGTG 
hsv1-mir-H15-g-rev 
TTGGGTCCGCCGGGGCCCCGGGCCGGGCCGCCACG
GGGGCCGGCCGTTGGCGGT TC6B-S1711A-QC-f GTGTGTGTTGGGAAACGCTACCATCCTTGCTGAG 
hsv1-mir-H17-g-for 
GGCCCACTCGCACGCCGCCTGCGCGCGCTGGGGCCT
GGGCGCGCCGCTGCG TC6B-S1711A-QC-r CTCAGCAAGGATGGTAGCGTTTCCCAACACACAC 
hsv1-mir-H17-g-rev 
CGCCGCTGCGGCCCGTGTACGTGGCGCTGGGGCGC
GAGGCGGTGCGCGCCGGCC TC6B-S1400E-QC-f GTCTCGCTTTAAACAGTGGGAGTCCATGATGGAGGGGCTGC 
hsv1-mir-H18-g-for 
CGGTCCCGCCCGCCGGACGCCGGGACCAACGGGAC
GGCGGGCGGCCCAAGGGC TC6B-S1400E-QC-r GCAGCCCCTCCATCATGGACTCCCACTGTTTAAAGCGAGAC 
hsv1-mir-H18-g-rev 
GCCCAAGGGCCGCCCGCCTTGCCGCCCCCCCATTGG
CCGGCGGGCGGGACCG TC6B-S1400A-QC-f CGCTTTAAACAGTGGGCCTCCATGATGGAGGG 
hsv1-mir-H8-g-for 
GTCCCTGTATATATAGGGTCAGGGGGTTCCGCACCC
CCTA TC6B-S1400A-QC-r CCCTCCATCATGGAGGCCCACTGTTTAAAGCG  
hsv1-mir-H8-g-rev 
GACAACTATATATACAGGGACCGGGGGCGCCATGTT
AGGGGGTG TC6A-S991E-QC-f CACAGGCTGGGAGGAACCAGAGCCAGAATCTATACGTCGC 
hsv1-mir-H11-g-for 
GGGCGTGGCCGCTATTATAAAAAAAGTGAGAACGC
GAAGCGTTCGCACTTTGTCCTAATAATATATATA TC6A-S991E-QC-r GCGACGTATAGATTCTGGCTCTGGTTCCTCCCAGCCTGTG 
hsv1-mir-H11-g-rev 
GGGCGTGGCCGCTATTATAAAAAAAGTGAGAACGC
GAAGCGTTCGCACTTTGTCCTAATAATATATAT TC6A-S991A-QC-f GGCTGGGAGGAACCAGCCCCAGAATCTATACG 
hsv1-mir-H12-g-for 
GGAGTCGGGCACGGCGCCAGTGCTCGCACTTCGCCC
TAATAATATATATAT TC6A-S991A-QC-r CGTATAGATTCTGGGGCTGGTTCCTCCCAGCC 
hsv1-mir-H12-g-rev 
GAAGTGAGAACGCGAAGCGTTCGCACTTCGTCCCAA
TATATATAT TC6A-T1844E-QC-f GCACATGTGTGTACTGGGGAACGAGACTATTCTTGCTGAGTTTGCC 
hsv1-mir-H15-g-r1 
ACCGCCAACGGCCGGCCCCCGTGGCGGCCCGGCCCG
GGGCCCCGGCGGACCCAA TC6A-T1844E-QC-r GGCAAACTCAGCAAGAATAGTCTCGTTCCCCAGTACACACATGTGC 
hsv1-mir-H17-g-r1 
GGCCGGCGCGCACCGCCTCGCGCCCCAGCGCCACGT
ACACGGGCCGCAGCGGCG TC6A-T1844A-QC-f CATGTGTGTACTGGGGAACGCTACTATTCTTGCTGAG 
hsv1-mir-H18-g-r1 
CGGTCCCGCCCGCCGGCCAATGGGGGGGCGGCAAG
GCGGGCGGCCCTTGGGC TC6A-T1844A-QC-r CTCAGCAAGAATAGTAGCGTTCCCCAGTACACACATG 
QC-THSV1miR3C-for AACTCGGAACCCGCGGTCAGGAGCG TC6A-T1548E-QC-f CAAGACTAAGGAAGTGGGAGACAGTGGACAGCATTTC 
QC-THSV1miR3C-rev CGCTCCTGACCGCGGGTTCCGAGTT TC6A-T1548E-QC-r GAAATGCTGTCCACTGTCTCCCACTTCCTTAGTCTTG 
HSV1-miR18mid-rev 
GCAAGGCGGGCGGCCCTTGGGCCGCCCGCCGTCCCG
TTGGTCCCGGCGTCCGGCGGGCGGGACCG TC6A-T1548A-QC-f GTCAAGACTAAGGAAGTGGGCGACAGTGGACAGCATTTC 
HSV1-miR11mid-for 
TATTATAAAAAAAGTGAGAACGCGAAGCGTTCGCAC
TTTGTCCTAATAATATATATATTATTAGG TC6A-T1548A-QC-r GAAATGCTGTCCACTGTCGCCCACTTCCTTAGTCTTGAC 
HSV1-miR11t7-l-rev 
CGCGTTCTCACTTTTTTTATAATAGCGGCCACGCCCA
GGCTAGGTCTCCCTATAGTGAGTCGTATTA TC6A-T1549E-QC-f CAAGACTAAGGAAGTGGACGGAGGTGGACAGCATTTCTGTGAAC 
HSV1-miR12mid-for 
CACGGCGCCAGTGCTCGCACTTCGCCCTAATAATATA
TATATATTGGGACGAAGTGCG TC6A-T1549E-QC-r GTTCACAGAAATGCTGTCCACCTCCGTCCACTTCCTTAGTCTTG 
HSV1-miR12t7-l-rev 
GAGCACTGGCGCCGTGCCCGACTCCAGGCTAGGTCT
CCCTATAGTGAGTCGTATTA TC6A-T1549A-QC-f GACTAAGGAAGTGGACGGCAGTGGACAGCATTTC 
hcmv-mir-UL22A-1for 
TAATACGACTCACTATAGGGAGACCTAGCCTCCTGTC
TAACTAGCCTTCC TC6A-T1549A-QC-r GAAATGCTGTCCACTGCCGTCCACTTCCTTAGTC 
hcmv-mir-UL22A-1-rev CCTCTACAAACTAGCATTC TC6C-part1-FseI-f gatggccggccatggctacagggag 
hcmv-mir- UL36-1 for 
TAATACGACTCACTATAGGGAGACCTAGCCTCCACGT
CGTTGAAGACACC TC6C-part2-AscI-r gatggcgcgggctacagggactccc 
hcmv-mir- UL36-1-rev CCACGCACGTTGAAAACACC TC6C-part1-XbaI-r gtatctagaagaattcaagttttgcatgccc 
hcmv-mir-UL112 for 
TAATACGACTCACTATAGGGAGACCTAGCCTGACAG
CCTCCGGATCACATG TC6C-part2-XbaI-f gtatctagacagataccgagtggcaatctg 
hcmv-mir-UL112 rev GACAGCCTGGATCTCAC TC6C-S714E-QC-f CTGGGAAGAACCCGAGCCACCGTCCATTCGCCGCAAAATG 
hcmv-mir- UL148D -for 
TAATACGACTCACTATAGGGAGACCTAGCCTAGCAG
GTGAGGTTGGG TC6C-S714E-QC-r CATTTTGCGGCGAATGGACGGTGGCTCGGGTTCTTCCCAG 
hcmv-mir- UL148D -rev GGCGGTGAAGAAGGGGAG TC6C-S714A-QC-f CTGGGAAGAACCCGCTCCACCGTCCATTCGCCGCAAAATG 
hcmv-mir- US33-1for 
TAATACGACTCACTATAGGGAGACCTAGCCTCACGG
TTGATTGTGCCCGGAC TC6C-S714A-QC-r CATTTTGCGGCGAATGGACGGTGGAGCGGGTTCTTCCCAG 
hcmv-mir- US33-1-rev CACGTTTGGATGTGCTCG TC6C-T1301E-QC-f CTCCCCCAGTGGGAGCACCCCAACTCCATGGATAACTTG 
TNRC6B-seq-1f -new ccaattcacatctgggacaagg TC6C-T1301E-QC-r CAAGTTATCCATGGAGTTGGGGTGCTCCCACTGGGGGAG 
TNRC6B-seq-4f -new ggtaatggtggcaatgcaagc TC6C-T1301A-QC-f CTCCCCCAGTGGGCGCACCCCAACTCCATG 
TNRC6C-seq-1f -new gcacaacctcagaaccttaac TC6C-T1301A-QC-r CATGGAGTTGGGGTGCGCCCACTGGGGGAG 
TNRC6C-seq-2f -new GAA CGG GAG AAG GCC GAA G TC6C-T1577E-QC-f CATGTGCGTCCTGGGAAACGAGACCATCCTGGCCGAGTTC 
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TNRC6C-seq-3f -new CCA ACA GAA CTG GGC TAG C TC6C-T1577E-QC-r GAACTCGGCCAGGATGGTCTCGTTTCCCAGGACGCACATG  
TNRC6C-seq-4f -new CCA GTG GGA GGA TGA AGA AGG TC6C-T1577A-QC-f CATGTGCGTCCTGGGAAACGCTACCATCCTGG 
TNRC6C-seq-5f -new GGT CTC AAC CCT GCA CTA TTA ACC TC6C-T1577A-QC-r CCAGGATGGTAGCGTTTCCCAGGACGCACATG 
VP5-NheI_XbaI-NotI-f acggctagccgtaactctagaatgctcgcggccgcacg pGEMtE-FseIAscI+-f gacgtcgcatgcggccggccgccatggcgcgcccgggaattcg 
VP5-NheI_XbaI-NotI-r cgtgcggccgcgagcattctagagttacggctagccgt pGEMtE-FseIAscI+-r cgaattcccgggcgcgccatggcggccggccgcatgcgacgtc 
VP5-QC-XbaI-exit-f GGGATCAATTCTCTCAAGCTCGCTGATCAGC PAN3-ISO4-f Gat gctagc ATGGATGGAGGTGCTTTAACTGATAC 
VP5-QC-XbaI-exit-r GCTGATCAGCGAGCTTGAGAGAATTGATCCC PAN3-ISO4-r Gat  ggccggcc CTACAACTGACCATTTGCAGCTGC 
VP5-NheIXbaIEcoRI-f acggctagctagatctagaacttcggcggccgcactggaattctag NOT9-ISO1-F Gat gctagc  ATGCACAGCCTGGCGACGGCTG 
VP5-NheIXbaIEcoRIr ctagaattccagtgcggccgccgaagttctagatctagctagccgt NOT9-ISO1-R Gat  ggccggcc  TCACTGAGGGGGCAGGGGGATAC 
VP5-TNRC6A-REs-for 
acggctagctaggactctagaactgagagctcgttcggcggccgcac
tggaattctag A-TSS736/8/9EEE-QC-r GTCAGTCTTTCGTTCCCCTCTAGGttcctcTTCctcATCCCAGGCAGTATTCTG 
VP5-TC6A-REs-rev 
ctagaattccagtgcggccgccgaacgagctctcagttctagagtcct
agctagccgt TC6B-S1432-A-fwd GTAAAACCCGGGGAGGGgcACCGTACAAC 
PAN3-hs-f Gat gctagc ATGAACAGTGGCGGCGGC TC6B-S1432-A-rev GTTGTACGGTgcCCCTCCCCGGGTTTTAC 
PAN3-hs-r Gat  ggccggcc CTACAACTGACCATTTGCAGC TC6B-S385-A-fwd CTTGAACTTAAGTgCACCAAACC 
VP5-TC6A-Res-r-f 
acggctagcaaggactctagaactgaccgcgggttcggcggccgca
ctggaattctag TC6B-S385-A-rev GGTTTGGTGcACTTAAGTTCAAG 
VP5-TC6A-Res-r-r 
ctagaattccagtgcggccgccgaacccgcggtcagttctagagtcct
tgctagccgt TC6B-S609-A-fwd CAGACTCTTTTGgcCCGAACTGATTTG 
A-TSS736/8/9EEE-QC-f 
CAGAATACTGCCTGGGATgagGAAgaggaaCCTAGAG
GGGAACGAAAGACTGAC TC6B-S609-A-rev CAAATCAGTTCGGgcCAAAAGAGTCTG 
ebv-long-BART4-f gtt agatct GGAGCTCCTTGTCTTGATAATC TC6B-S744-A-fwd CAAGGATGGTCTgCTGGAAAGAATG 
ebv-long-BART4-r gtt ctcgag CAGCACACCAGCAGCATCAG TC6B-S744-A-rev CATTCTTTCCAGcAGACCATCCTTG 
HCMV-miR148-l-pgem-f gtt agatct GAATTGTAATACGACTCACTATAG TC6B-T596-A-fwd CGTACAGGCCCgCACATCCTGATTG 
HCMV-miR148-l-pgem-r gtt ctcgag CGCCAAGCTATTTAGGTGAC TC6B-T596-A-rev CAATCAGGATGTGcGGGCCTGTACG 
pGem NotI exit 2 f GCCGCCATGCAGGCCGCGGGAATTCGAT TC6B-T626-A-fwd GCTGGGGCCAAgCTCAAATTAAGC 
pGem NotI exit 2 r ATCGAATTCCCGCGGCCTGCATGGCGGCC TC6B-T626-A-rev GCTTAATTTGAGcTTGGCCCCAGC 
BKV-long-M1sup-f gtt agatctGCTTTTGTATAAGCCACTTTTAAGC TC6B-S1432-E-fwd GTAAAACCCGGGGAGGGgaACCGTACAAC 
BKV-long-M1sup-r aac ctcgagCAAAGTGGAATGACCTTGTTGC TC6B-S1432-E-rev GTTGTACGGTtcCCCTCCCCGGGTTTTAC 
MCV-long-M1sup-f gtt agatctCTCCTCGGCAGAGGAAGAC TC6B-S385-E-fwd CTTGAACTTAAGTgaACCAAACC 
MCV-long-M1sup-r aac ctcgagGTATGGGTCCTTCTCAGCGTC TC6B-S385-E-rev GGTTTGGTtcACTTAAGTTCAAG 
HPV41-long-M1sup-f gtt agatct CTGGTATCACTCAGTCATCATC TC6B-S609-E-fwd CAGACTCTTTTGgagCGAACTGATTTG 
HPV41-long-M1sup-r aac ctcgag GTGCCAAATCATGAGACATGAAC TC6B-S609-E-rev CAAATCAGTTCGctcCAAAAGAGTCTG 
Bkv-miR-B1-f 
TAATACGACTCACTATAGGGAGACCTAGCCTGGGAA
TCTTCAGCAGGGGCTG TC6B-S744-E-fwd CAAGGATGGTCTgaaGGAAAGAATG 
Bkv-miR-B1-r AGGATTCAGAAACTGAAGACTCTGGAC TC6B-S744-E-rev CATTCTTTCCttcAGACCATCCTTG 
mcv-miR-M1-f 
TTAATACGACTCACTATAGGGAGACCTAGCCTAGGT
GCCATACGTTCTGGAAG TC6B-T596-E-fwd CGTACAGGCCCgaACATCCTGATTG 
mcv-miR-M1-r AGGAGACCACCAATTCAGGAAG TC6B-T596-E-rev CTTGAACTTAAGTgaACCAAACC 
hpv41-miR-f 
TAATACGACTCACTATAGGGAGACCTAGCCTGGTATT
GTGGTGCGGTGTCC TC6B-T626-E-fwd GCTGGGGCCAAgagCAAATTAAGC 
hpv41-miR-r GATAATGGAGTGGTGTACCCTGG TC6B-T626-E-rev GCTTAATTTGctcTTGGCCCCAGC 
CRRM1-NotI-for cat gcggccgc agcagctggctcgttcttcg TC6C-T777-A-fwd CACCACACACAGGGTCGAGgCGCCGCCCCCGCAC 
CRRM1-BamHI-rev cat ggatcc tca aggcccatgttgcaaacacaatg TC6C-T777-A-rev GTGCGGGGGCGGCGcCTCGACCCTGTGTGTGGTG 
CRRM2-NotI-for cat gcggccgc catgggcctcttatcacattcc TC6C-S1628-A-fwd CATGGCCTGGTACGCgcCGACGCTGGCCAC 
CRRM2-BamHI-rev gcccagaagtctctgcacatg tga ggatcc atg TC6C-S1628-A-rev GTGGCCAGCGTCGgcGCGTACCAGGCCATG 
CRRM3-NotI-for cat gcggccgc cacatgtgcgtcctgggaaac TC6C-S1011-A-fwd CTCCAAAGAGTCTgCCGTGGACC 
CRRM3-BamHI-rev cat ggatcc tcattgggctaagaagcgattcacttc TC6C-S1011-A-rev GGTCCACGGcAGACTCTTTGGAG 
pGEX-QC-NotI-F 
GGATCTGGAAGTTCTGTTCCAGCGGCCGCTGTGATC
CCCGGAATTCGATTGTC TC6C-T1016-A-fwd GTGGACCGCCCCgcCTTTCTTGACAAG 
pGEX-QC-NotI-R 
GACAATCGAATTCCGGGGATCACAGCGGCCGCTGGA
ACAGAACTTCCAGATCC TC6C-T1016-A-rev CTTGTCAAGAAAGgcGGGGCGGTCCAC 
pGEX-QC-BamHI-F 
GATGGGGGGAGCTCTGAGCGGATCCATCGTGACTG
ACTGACGATC TC6C-S714-A-fwd GGAAGAACCCgCTCCACCGTCC 
pGEX-QC-BamHI-R 
GATCGTCAGTCAGTCACGATGGATCCGCTCAGAGCT
CCCCCCATC TC6C-S714-A-rev GGACGGTGGAGcGGGTTCTTCC 
CRRM2r-BamHI-rev cat ggatcc tca catgtgcagagacttctgggc TC6C-S465-A-fwd GAATTTGAAGAAgCCCCTAGGTCTG 
RFOX2-g1-f cacc GCGTACTTCCGTAGAGTGTCAGG TC6C-S465-A-rev CAGACCTAGGGGcTTCTTCAAATTC 
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RFOX2-g1-r caaa CCTGACACTCTACGGAAGTACGC TC6C-S1358-A-fwd GAGTCACCAGCCgcTCCTCCCGTAGC 
RFOX2-g2-f cacc CGGAAGTACGCAAGCCCACGGGG TC6C-S1358-A-rev GCTACGGGAGGAgcGGCTGGTGACTC 
RFOX2-g2-r  caaa CCCCGTGGGCTTGCGTACTTCCG TC6C-S568-A-fwd CAGGAGGACAAGgCACCCACCTGG 
CRIPPCR_FOX_for CGCAGAATGGAATTCCCACAGAG TC6C-S568-A-rev CCAGGTGGGTGcCTTGTCCTCCTG 
CRIPPCR_FOX_rev cCGTAAGAGATCCATTTTGTGTGC TC6C-T484-A-fwd GGTTGTGCAGCTgCTCAGGCTTC 
SYNC_hs_nhei-f Agt gctagcATGGTGCTAGCAGAGCTGTAC TC6C-T484-A-rev GAAGCCTGAGcAGCTGCACAACC 
NONO_hs_fsei-f Agt  ggccggccatgcagagtaataaaacttttaacttg TC6C-T777-E-fwd CACCACACACAGGGTCGAGgaaCCGCCCCCGCAC 
NCOA5_hs_noti-f Agt gcggccgc atgaatacggctccatcaagac  TC6C-T777-E-rev GTGCGGGGGCGGttcCTCGACCCTGTGTGTGGTG 
TIAR_hs_nhei-f Agt gctagc atgatggaagacgacgggcag TC6C-S1628-E-fwd CATGGCCTGGTACGCgaaGACGCTGGCCAC 
PTCD3_hs_nhei-f Agt gctagc atggcggttgtatctgctgttc TC6C-S1628-E-rev GTGGCCAGCGTCttcGCGTACCAGGCCATG 
KRI1_hs_nhei-f Agt gctagc atgggccacagaaccgccatg TC6C-S1011-E-fwd CTCCAAAGAGTCTgaaGTGGACC 
ZCHC3_hs_fsei-f Agt  ggccggcc atggccaccggcggcggc TC6C-S1011-E-rev GGTCCACttcAGACTCTTTGGAG 
SYNC_hs_bamhi-r Agt ggatcc TTATGGCGTGCAACGCTGGAC TC6C-T1016-E-fwd GTGGACCGCCCCgaaTTTCTTGACAAG 
NONO_hs_asci-r Agt ggcgcgcc ttagtatcggcgacgtttgtttg TC6C-T1016-E-rev CTTGTCAAGAAAttcGGGGCGGTCCAC 
NCOA5_hs_ecori-r Agt gaattc tcagtaatgcctctggtaagatc TC6C-S714-E-fwd GGAAGAACCCgaaCCACCGTCC 
TIAR_hs_bamhi-r Agt ggatcc tcactgtgtttggtaacttgccatac TC6C-S714-E-rev GGACGGTGGttcGGGTTCTTCC 
PTCD3_hs_bamhi-r Agt ggatcc tcatttgccttcactggtgtcac TC6C-S465-E-fwd GAATTTGAAGAAgaaCCTAGGTCTG 
KRI1_hs_bamhi-r Agt ggatcc tcaggagctgttcttgggcccctg TC6C-S465-E-rev CAGACCTAGGttcTTCTTCAAATTC 
ZCHC3_hs_asci-r Agt ggcgcgcc ttagtgcccggccacgccgg TC6C-S1358-E-fwd GAGTCACCAGCCgaaCCTCCCGTAGC 
pGEM-QC-NheI-fwd GAATTGGGCCCGACGTCGCtaGCTCCCGGCCGCCATG TC6C-S1358-E-rev GCTACGGGAGGttcGGCTGGTGACTC 
pGEM-QC-NheI-rev 
CATGGCGGCCGGGAGCtaGCGACGTCGGGCCCAATT
C TC6C-S568-E-fwd CAGGAGGACAAGgaaCCCACCTGG 
TC6A-1-NheI-fwd atg    gctagc atggatgctgattctgcc TC6C-S568-E-rev CCAGGTGGGttcCTTGTCCTCCTG 
TC6A-1-SpeI-rev gtg actagt atcattaccattagggctag TC6C-T484-E-fwd GGTTGTGCAGCTgaaCAGGCTTC 
TC6A-2-SpeI-fwd cac actagt tctgtatcagggtggggcgatc TC6C-T484-E-rev GAAGCCTGttcAGCTGCACAACC 
TC6A-2-SacI-rev gtg gagctc aggtgtagtgtggggcatg 
  
TC6A-3-SacI-fwd  aag gagctc caaaaagggccatcacc 
  
TC6A-3-EcoRI-rev ggtggagagtccatgtaa gaattc agtcg 
  
A-TSS736/8/9AAA-fwd gctgct cctagaggggaacgaaagac 
  
A-TSS736/8/9AAA-rev ttccgc atcccaggcagtattctgc 
  
A-TSS736/8/9EEE-fwd gaggaa cctagaggggaacgaaagac 
  
A-TSS736/8/9EEE-rev ttcttc atcccaggcagtattctgc 
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5.4 List of abbreviations 
_  Deletion min  minute 
aa  amino acid Mio  million, 106 
AEBSF  
4-(2-aminoethyl) benzenesulfonyl .uoride 
hydrochloride 
miRISC  miRNA induced silencing complex 
Ago  Argonaute miRNA  microRNA 
Ago-APP Ago a•nity puri€cation by peptides miRNP  micro-ribonucleoprotein 
Amp  ampicillin MKK  MAPK kinase 
APS ammonium persulphate mRNA  messenger RNA 
ATP adenosine triphosphate MS  mass spectrometry, mass spectrometric 
bp  base pair(s) Neo  neomycine 
BSA  bovine serum albumin NES  nuclear localization signal 
C. elegans  Caenorhabditis elegans NLS  nuclear export signal 
cDNA  complementary DNA NMR  nuclear magnetic resonance 
CDS  coding sequence NSC  neural stem cell 
Ci  Curie nt  nucleotides(s) 
CoIP  co-immunoprecipitation o/n  over night 
CSC  cancer stem cell OD  optical density 
CTD C-Terminal domain ORF  open reading frame 
cv  column volume PABP  poly(A)-binding protein 
D. 
melanogaster  
Drosophila melanogaster PACT  protein activator of the interferon-induced protein kinase 
Da  Dalton PAGE  polyacrylamide gel electrophoresis 
DCL -3 Dicer-like 3 PAM2  PABP interacting motif 2 
DMEM  Dulbecco’s Modi€ed Eagle’s Medium PAN2/3  PAB-dependent poly(A)-speci€c ribonuclease subunit 2/3 
DNA  deoxyribonucleic acid PAR-CLIP  Photoactivatable-Ribonucleoside-Enhanced Crosslinking and IP 
dNTP  deoxynucleoside triphosphate PAZ  PIWI-Argonaute-Zwille 
ds double-stranded P-bodies  processing bodies 
dsRBD  double-stranded RNA binding domain PBS  Phosphate buffered saline 
dT  desoxythymidine PBS(-T)  phosphate-buffered saline (containing Tween 20) 
DTT dithiothreitol PCR  polymerase chain reaction 
DUF  domain of unknown function piRNA  Piwi-interacting RNA 
EDC  
1-ethyl-3-(3-dimethyl-aminopropyl)-
carbodiimid 
  
EDTA  ethylenediaminetetraacetic acid   
EGFR epithelial growth factor receptor piRNA  PIWI-interacting RNA 
eIF  eukaryotic initiation factor PIWI  P-element-induced wimpy testes 
ERK  extracellular signal–regulated protein kinases PNK  polynucleotide kinase 
EtBr ethidium bromide pre-miRNA  precursor miRNA 
Exp  Exportin pri-miRNA  primary miRNA 
FBS  fetal bovie serum PTGS  post-transcriptional gene silencing 
FDR  false discovery rate PTM  post-translational modification 
g  gram PTP1B  protein tyrosine phosphatase 1B 
GAPDH  glyceraldehyde 3-phosphate dehydrogenase qRT-PCR  quantitative real-time polymerase chain reaction 
GDP  guanosine diphosphate RAS  rat sarcoma 
GFP  green fluorescent protein RdDM  RNA-dependent DNA methylation 
GSH  glutathione RdRP  RNA-dependent RNA polymerase 
GSK3 glycogen synthase kinase 3_ RIPA  radioimmunoprecipitation assay 
GST glutahione-S-transferase RISC  RNA-induced silencing complex 
GTP  guanosine triphosphate RNA  ribonucleic acid 
h  hour RNAi  RNA interference 
H. sapiens  Homo sapiens RNP  ribonucleoprotein 
HA  hemagglutinin ROS  reactive oxygen species 
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HEK 293T  human embryonic kidney 293T rpm  revolutions per minute 
HEPES  
4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid 
RRM  RNA recognition motif 
HMGA2  high mobility group AT hook 2 RT  room temperature 
HSP90  heat shock protein 90 S. cerevisiae  Saccharomyces cerevisiae 
IDA  iminodiacetate sDMA  symmetric dimethyl arginine 
Imp  Importin SDS  sodium dodecyl sulfate 
IP  immunoprecipitation sec  second 
IPTG  isopropyl _-D-1-thiogalactopyranoside shRNA  short hairpin RNA 
IRES  internal ribosome entry site siRNA  small interfering RNA 
k  kilo snoRNA  small nucleolar RNA 
Kana kanamycin SRM  selected reaction monitoring 
kb  kilobase ss  single-stranded 
l  liter SSC  saline-sodium citrate bu.er 
LB  lysogeny broth TBE T Tris/Borate/EDTA buffer 
M  molar TBS  Tris buffered saline 
MAPK  MAP (mitogen-activated protein) kinase TBS(-T)  Tris-bu.ered saline (containing Tween 20) 
MAPKAPK2  MAP-activated protein kinase 2 TEMED  tetramethylethylenediamine 
MCS  multiple cloning site TRBP  transactivating response RNA binding protein 
mHESM  
miRNAs regulated by hypoxia-dependent 
EGFR-suppressed maturation 
TRIM71  tripartite motif-containing protein 71 
  tRNA  transfer RNA 
  UBA  ubiquitin-associated 
  UTP  uridine triphosphate 
  UTR  untranslated region 
  W  tryptophan 
  w/v  weight per volume 
  wt  wild type 
  YAP  Yes-associated protein 
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